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ABSTRACT 
Promotion of intestinal health in preruminant dairy calves is essential for growth and 
overall health.  Yet, a large proportion of dairy calves in the United States is affected by enteric 
challenges in the preweaning period.  Maintenance of intestinal integrity is associated with an 
intestinal peptide, glucagon-like peptide-2 (GLP-2), which stimulates proliferation, decreases 
apoptosis, enhances intestinal barrier function, and decreases intestinal inflammation.  During 
diarrheic episodes and at weaning, feed intake is reduced, potentially decreasing gut release of 
trophic hormones such as GLP-2.  Stressors to the small intestine can induce inflammation and 
increase permeability to pathogens.  A dataset was created to quantify the impact of diarrhea on 
dairy calves in the first 21 d after arrival to the research facility, which was within several days 
after birth.  These data were analyzed to evaluate feed and water intakes, growth, and efficiency 
in diarrheic calves versus their healthy counterparts in the early preweaning period.  Overall, 
calves that were classified as diarrheic in the first 21 d after arrival had reduced intake of milk 
replacer and starter dry matter intake, as well as increased consumption of electrolytes to 
counteract water and electrolytes lost in the feces.  Growth and efficiency were also decreased in 
diarrheic calves compared with healthy calves in the first 21 d after arrival.  Additionally, four 
experiments were conducted to identify methods to stimulate secretion of GLP-2 which, through 
its associated effects in the small intestine, might maintain intestinal permeability and decrease 
intestinal inflammation to improve health and growth in young dairy calves.  The first 
experiment sought to characterize the GLP-2 response to four amounts of feed intake and the 
effect of metabolizable and non-metabolizable glucose supplementation in a 4 × 3 factorial 
arrangement with 12 treatments.  Results indicated that at feed intakes of 75% or greater of 
control intake (1.75% of BW as DM) GLP-2 secretion was maximized and at intakes <50% 
GLP-2 secretion became suboptimal.  Effect of glucose supplement type on GLP-2 secretion was 
limited.  The second experiment evaluated effects of increasing doses (0, 30, or 60 mg/kg of BW 
per day) of an Olea europaea extract (OBE) on GLP-2 secretion, intestinal permeability, and 
diarrhea incidence in pre-weaning dairy calves.  The ability to enhance endogenous GLP-2 
secretion via the feeding of plant-derived GLP-2 agonists is an attractive and yet unexplored 
approach for promoting intestinal adaptation and function in newborn calves.  If this prediction 
was met, then the incidence of intestinal disorders and associated preweaning growth limitation 
should be reduced.  Secretion of GLP-2 tended to increase for OBE treatments, and was 
iii 
significantly greater for the higher inclusion rate than for the non-supplemented control.  
Intestinal permeability in the small intestine was not affected by treatment but there was a 
significant time effect, with increases in permeability during wk 2, and then permeability 
decreased with age.  Enteric challenges in this experiment were high and the control calves were 
less likely to have diarrhea than those supplemented with OBE.  A third experiment sought to 
identify the optimal dose of OBE with treatments of 60, 90, 120, or 180 mg/kg of BW per day 
supplementation.  The maximal response of GLP-1 (co-secreted with GLP-2) secretion to each 
dose was determined in a 5 × 5 Latin square design with 5 calves.  A dose of 60 mg/kg of BW 
per day stimulated the greatest increase in GLP-1 secretion relative to the baseline secretion.  A 
fourth experiment evaluated the effect of OBE (0 and 60 mg/kg of BW per day) on intake, 
growth, intestinal permeability, intestinal inflammation, and health.  Feeding OBE tended to 
increase prefeeding levels of GLP-1 however, this did not elicit improvements in permeability, 
intake, or growth in calves that were relatively healthy in the preweaning period.  Furthermore, 
there were no differences in intake, growth, or efficiency during the weaning and immediate 
postweaning period.  Through analysis of mRNA for inflammatory markers isolated from feces, 
there was some indication that calves supplemented with OBE had a less pronounced 
inflammatory status relative to control calves.  Together, data from these experiments indicate 
that secretion of gut trophic hormones such as GLP-2 is influenced by feed intake and a bioactive 
extract targeted at improving intestinal barrier function and health. 
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CHAPTER 1. INTRODUCTION 
Several phases challenge the gastrointestinal function and economic profitability of 
young ruminants, including preweaning and weaning (Steele et al., 2016).  In the United States 
the most recent estimate was reported in a survey conducted in 2011, which showed 
approximately 25.3% of preweaned heifers had diarrhea and that diarrhea or other digestive 
problems accounted for 31% of the preweaning heifer mortality (NAHMS, 2011).  Furthermore, 
of the preweaning heifers that had digestive disorders 71.8% were treated with an antibiotic 
during this period (NAHMS, 2011).   
Not only is there risk to young calves for illness and antibiotic treatment with enteric 
illnesses, diarrhea is one of the leading causes of death during this life phase.  Health of calves 
has been connected to longevity, with calves that have been treated with antibiotics having 
decreased lifetime milk production (Soberon et al., 2012).  Moreover, the number of days that 
calves are sick in the first 4 mo of life has been shown to have negative effects on first-lactation 
305-d ME and actual milk, protein, and fat production (Heinrichs and Heinrichs, 2011).  In the 
beginning of 2017 the Food and Drug Administration implemented the amended drug regulations 
related to the Veterinary Feed Directive (VFD; 2015) in order to protect human and animal 
health.  Specifically, this directive has targeted medically important antimicrobial drugs in food 
producing animals’ feed and water by controlling the distribution and use of VFD drugs.   
The preruminant gastrointestinal tract can be described as a dynamic and complex 
ecosystem (Niewold, 2015).  Feed, microbiota, and the host mucosa interact with each other and 
play important roles in supporting the health and growth of the animal (Niewold, 2015). The role 
of the intestine is to be a selective barrier between the luminal contents and the body.  The 
function of the small intestine is dual purpose.  The first function is to provide selective 
absorption of nutrients, while the second function is to provide a protective barrier against 
harmful antigens and pathogens within the luminal contents (Groschwitz and Hogan, 2009). Gut 
growth is regulated by several factors, including metabolic and trophic hormones, and chemical 
and physical properties of the diet (Baldwin et al., 2004).   
A number of hormones and peptides are secreted by cells within the gastrointestinal tract 
that serve to signal maintenance, growth, and repair of epithelial tissue (Drucker et al., 1994; 
Burrin et al., 2003).  Among the most important of these are glucagon-like peptides 1 (GLP-1) 
2 
and -2 (Estall and Drucker, 2006).  Treatment with GLP-2 has been shown to increase intestinal 
cell proliferation, reduce apoptosis, increase nutrient absorption and gut integrity, and reduce 
inflammation in nonruminants (Lovshin and Drucker, 2000; Burrin et al., 2003; Drucker, 2005).  
Furthermore, bile acids stimulate activation of TGR5 receptors, which results in release of GLP-
1 and co-secreted GLP-2 (Thomas et al., 2009; Katsuma et al., 2005; Kidd et al., 2008; Parker et 
al., 2012).   
Intestinal barrier dysfunction allows foreign antigens, including harmful bacteria, access 
to the underlying mucosal immune system, which may lead to intestinal inflammation (Cameron 
and Perdue, 2005).  However, if we can manipulate secretion of GLP-2 through nutrients or 
additives, there is potential to promote intestinal function in production animals through 
stimulation of GLP-2.  Potentially, specific feed additives could be used that would manipulate 
the gastrointestinal environment to be advantageous to that ecosystem and promote health and 
growth, especially during times where that environment could be compromised (Niewold, 2015).   
Evaluation of non-antibiotic additives to help with growth and health is needed (Windish 
et al., 2008).  Implementation of changes in the VFD also increases the pressure to find non-
antibiotic additives that may be included in feed and water for food producing animals.  
Phytogenic feed additives are plant-based products used in animal feeding (Windish et al., 2008).  
Phytogenic feed additives have been indicated to have antioxidative and antimicrobial properties, 
influence palatability and gut function, and ultimately affect growth depending on the additive 
and its observed properties (Windish et al., 2008).  Olive-derived plant bioactives have anti-
inflammatory, antioxidant, and antimicrobial properties that have positive effects under 
pathological conditions (Sanchez-Quesada et al., 2013; Pereira et al., 2007), which make them 
potential feed additives (Liehr et al., 2017).  Use of the plant-derived TGR5 agonist from Olea 
europaea is a relatively new approach to promote intestinal adaptation and has yet to be explored 
in newborn calves.   
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CHAPTER 2. LITERATURE REVIEW 
INTRODUCTION 
In dairy calf development, a major focus of research has been the maturation of the 
rumen (Baldwin et al., 2004).  In preruminants, however, there is a critical period before the 
consumption of solid feed in which there is rapid and extensive change, as well as heightened 
susceptibility to disease, in the small intestine prior to the complete development and maturation 
of the rumen (Morisset, 1993; Steele et al., 2016).  Several phases challenge the gastrointestinal 
function and economic profitability of young ruminants, including preweaning and weaning 
(Steele et al., 2016).  Understanding these changes and how they can be manipulated might 
improve health and productivity of dairy replacement animals. 
RELEVANCE OF ANIMAL PRODUCTION AND HEALTH 
Whole Animal Health and Enteric Problems 
Intestinal disorders are common in newborn calves.  Several reports have estimated 
morbidity and treatment on dairy farms over the last several decades.  Curtis et al. (1988) 
estimated the incidence rate of diarrhea in New York Holstein herds to be 9.9 per 100 calves 
during the first 14 d and 5.2 per 100 calves from 15 to 90 d.  The median age of diarrhea was 6 d 
for the first 14 d of life and 30 d for 15 to 90 d of age period.  One report from Norway indicated 
a relatively low diarrheic incidence with only 4.7% of the samples being classified at diarrheic 
over the two-year study (Gulliksen et al., 2009).  Meanwhile, a Dutch study observed a 
prevalence of diarrhea of 19.1% in calves under 22 d (Bartels et al., 2010).  In this study the 
percentage of calves (51.6%) with non-normal feces, which was classified as ‘custard-like’ feces 
or diarrhea, was highest in the second week compared to the first and third weeks of life (Bartels 
et al., 2010).  In Ontario herds the greatest risk for treatment for diarrhea was observed at 10 d of 
age (Waltner-Towes et al., 1986; Windeyer et al., 2014) with 23% of calves treated for diarrhea 
(Windeyer et al., 2014).  In the United States the most recent estimate was reported in a survey 
conducted in 2011, which showed approximately 25.3% of preweaned heifers had diarrhea and 
that diarrhea or other digestive problems accounted for 31% of the preweaning heifer mortality 
(NAHMS, 2011).  Furthermore, of the preweaning heifers that did had digestive disorders 71.8% 
were treated with an antibiotic during this period (NAHMS, 2011).   
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Not only is there risk to young calves for illness and antibiotic treatment with enteric 
illnesses, diarrhea is one of the leading causes of death during this life phase.  Curtis et al. (1988) 
estimated calf morality in the first 90 d as 3.5 per 100 calves in New York Holstein herds and 
calves were most likely to die between 1 to 3 wk of age.  In a Swedish study a mortality of 3.1% 
was observed before 90 d of age with enteritis the prevailing cause of death before 31 d 
(Svensson et al., 2006).  Most recently it was estimated that 1.4% of preweaning heifer calves in 
the United States died from diarrhea and other digestive disorders (NAHMS, 2011).   
These estimates show that neonatal diarrhea is a very prevalent and reoccurring issue 
within calf management systems in the United States and the world.  Neonatal diarrhea is 
frequently observed from 3 to 21 d of age, but its onset and duration is determined by the number 
of pathogens involved and the immune condition of the animal (Butler and Clark, 1994). The 
major pathogens that have been identified as contributing to enteric challenge in calves during 
the preweaning period include Escherichia coli K99 (E. coli), Rotavirus, Coronavirus, 
Salmonella spp., and Cryptosporidium parvum (C. parvum; Izzo et al., 2011; Cho and Yoon, 
2014). In a Spanish study the detection rate of E. coli, Rotavirus, Coronavirus and C. parvum 
was 11.9, 41.9, 7.3, and 52.3% of samples (García et al., 2000) while a Swiss study estimated 
prevalence in diarrheic calves of 6, 59, 8, and 55% (Uhde et al., 2008), respectively.  The 
presence of enteric pathogens in feces does not directly indicate the cause of diarrhea; however, 
there has been evidence to show a strong association between the two (De Rycke et al., 1986; 
García et al., 2000).  Additionally, it is often observed that two or more enteropathogens can be 
detected at the same time, with C. parvum and Rotavirus being the most prevalent combination 
(de la Fuente et al., 1999; García et al., 2000)  
Animal Growth and Future Production 
 Health of calves has been connected to longevity, with calves that have been treated with 
antibiotics having decreased lifetime milk production (Soberon et al., 2012).  Moreover, the 
number of days that calves are sick in the first 4 mo of life has been shown to have negative 
effects on first-lactation 305-d ME and actual milk, protein, and fat production (Heinrichs and 
Heinrichs, 2011).  Additionally, increased plane of nutrition during the preweaning period is 
linked to improved potential lifetime production (Soberon et al., 2012; Soberon and Van 
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Amburgh, 2013).  As a result, strategies that can improve health and maximize growth in the 
preweaning period should improve production potential and longevity of replacement animals.    
Veterinary Feed Directive and Antibiotic Use  
In 2011, the NAHMS reported that 62.8% of dairy farm operations in the United States 
fed medicated milk replacers.  The survey also detailed that 35% of all operations fed preweaned 
heifers with a combination of oxytetracycline/neomycin, 5.5% fed oxytetracycline, and 7.1% fed 
chlortetracycline (NAHMS, 2011).  In the beginning of 2017 the Food and Drug Administration 
implemented the amended drug regulations related to the Veterinary Feed Directive (VFD; 2015) 
in order to protect human and animal health.  Specifically, this directive has targeted medically 
important antimicrobial drugs in food producing animals’ feed and water by controlling the 
distribution and use of VFD drugs.  This transition included chloratetracycline, oxytetracycline 
and oxytetracycline/neomycin.  As a result of the VFD the use of medicated feeds fed to calves 
requires a VFD issued by a licensed veterinarian that has an established veterinarian-client-
patient-relationship (Veterinary Feed Directive, 2015).   
THE SMALL INTESTINE: NORMAL FUNCTION AND INFLAMMATORY 
RESPONSE 
 The gastrointestinal tract has been described as a dynamic and complex ecosystem 
(Niewold, 2015).  Feed, microbiota, and the host mucosa interact with each other and play 
important roles in supporting the health and growth of the animal (Niewold, 2015). The role of 
the intestine is to be a selective barrier between the luminal contents and the body.  The function 
of the small intestine is dual purpose.  The first function is to provide selective absorption of 
nutrients, while the second function it to provide a protective barrier against harmful antigens 
and pathogens within the luminal contents (Groschwitz and Hogan, 2009). Gut growth is 
regulated by several factors, including metabolic and trophic hormones, and chemical and 
physical properties of the diet (Baldwin et al., 2004).   
Intestinal Structure, Cells, and Immune System 
 The mucosa of the gastrointestinal tract is composed of a mixture of many different types 
of cells that come together to form an extensive system that works in concert to support optimal 
function (Peterson and Artis, 2014; Niewold, 2015).  The lining of the intestine is the largest 
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mucosal surface in the body.  Small intestinal cells are columnar epithelial cells (Liévin-Le Moal 
and Servin, 2006; Steele et al., 2016), which form crypts and villi to increase surface area for 
absorption (Peterson and Artis, 2014).  The intestinal epithelium includes absorptive epithelial 
cells (enterocytes), nerve cells, mucin secreting goblet cells, immune cells, and enteroendocrine 
cells (Niewold, 2015; Peterson and Artis, 2014). The density of specialized cells that make up 
the gastrointestinal tract is location dependent (Niewold, 2015).  The intestine has a range of 
sensory receptors that activate four main effector systems: the enteroendocrine, nervous, gut 
immune, and the nonimmune defense systems of the gut (Furness et al., 2013).   
Coexistence with commensal bacterial is maintained through segregation between the 
host and microorganisms.  Epithelial cells form a physical and biochemical barrier between 
microorganisms in the lumen and the mucosal immune system. The physical barrier is primarily 
composed of absorptive epithelial cells.  The biochemical barrier is composed of epithelial cells 
that secrete components into the lumen of the intestine, including enteroendocrine cells, goblet 
cells, and Paneth cells (Peterson and Artis, 2014).   
The intestinal enterocytes are immature at birth, as indicated by the large empty vacuoles 
present along the upper part and tip of the villi (Baintner, 2002).  Absorptive type enterocytes 
mature within the first week after birth as indicated by the loss of vacuoles along the proximal-
distal axis, which contributes to intestinal barrier closure (Asari et al., 1987).  Mature enterocytes 
are responsible for absorption of nutrients through active and passive transport and brush border 
enzyme activity (McOrist and Corona-Barrera, 2015). 
The enteric nervous system is very important in gastrointestinal functions, including 
motility, secretion, blood flow, and the immune system (Hansen, 2003).  Intrinsic and extrinsic 
nerves are involved in normal gut motility (Hansen, 2003), including control of the mixing and 
propulsion of contents through the small intestine (Kunze and Furness, 1999).  Furthermore, 
absorption, secretion, integrity, proliferation, barrier function, and defense alarm system are 
affected by the enteric nervous system (Hansen, 2003).   
The mucosal surfaces in the intestines are crucial sites for innate and adaptive immunity 
(Turner, 2009).  A physical barrier is created by production of mucus, antimicrobial proteins, and 
immunoglobulin A (IgA; Hooper and Macpherson, 2010).  Goblet cells secrete mucus, primarily 
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in the form of MUC2.  Mucus is the first defense against bacterial infiltration (Kim and Ho, 
2010).  The role of mucus is to provide a physical barrier between the harmful luminal contents 
and the epithelial cells, while also allowing transport of nutrients (Atuma et al., 2001; Kim and 
Ho, 2010).  Intestinal epithelial cells are covered with two layers of mucus, the firmly adherent 
layer that is closest to the epithelium and the loosely adherent layer that is the outer layer.  
Microbial populations are associated with the outer, loosely adherent mucin layer (Kim and Ho, 
2010).  The thickness of the mucosal layers is location dependent along the gastrointestinal tract.  
In rats, there is a higher proportion of mucus in the stomach, the ileum, and colon relative to the 
duodenum and jejunum.  In the duodenum and jejunum the mucosal layer is primarily composed 
of loosely adherent mucus (Atuma et al., 2001).   
Antimicrobial proteins (AMPs) are secreted from Paneth cells (Gallo and Hooper, 2012).  
The modes of action of AMPs are varied but many target the cell membrane or wall, while others 
enzymatically attack cell structures (Gallo and Hooper, 2012; Hooper and Macpherson, 2010).   
Intestinal epithelial cells also secrete IgA antibodies to regulate commensal bacterial 
populations and maintain homeostasis (Peterson and Artis, 2014).  Dendritic cells help in 
producing IgA that is specific to intestinal bacteria by sampling the contents, which results in B 
cell differentiation into plasma cells that produce IgA (Hooper and Macpherson, 2010).  The IgA 
originate from Peyer’s patches and travel to the intestinal lamina propria where the antibodies are 
secreted into the mucus (Husband, 1987).   Once secreted, IgA limit bacterial association with 
the intestinal epithelial surface (Hooper and Macpherson, 2010).   
Enteroendocrine cells link central and enteric neuroeoendocrine systems through 
hormone regulators of digestive function (Peterson and Artis, 2014).  They represent around 1% 
of the epithelial cells in the intestine.  Multiple biological functions are physiologically regulated 
by the gut peptides that are secreted from enteroendocrine cells including food intake, gastric 
emptying, gut motility, gut barrier formation, and glucose metabolism.  Enteroendocrine cells 
play an important role in gut homeostasis because they promote absorption of nutrients while 
also maintaining intestinal barrier function (Cani et al., 2013).   
Intestinal Permeability 
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The epithelial cell membrane is impermeable to hydrophilic solutes unless specific 
transporters are present.  Transcellular permeability is the transport of solutes through epithelial 
cells by selective transporters.  Amino acids, electrolytes, short-chain fatty acids, and sugars are 
the primary solutes that are regulated by selective transporters (Groschwitz and Hogan, 2009).  
Transepithelial transport relies on fully functioning tight junctions (TJ) to maintain a 
concentration gradient to drive passive paracellular transport of ions and water (Turner, 2009). 
Paracellular permeability is the transport of molecules through the space between 
epithelial cells through complexes on the apical-lateral membrane junction and the lateral 
membrane (Van Itallie and Anderson, 2006).  In intact epithelial cell layers, the paracellular 
pathway between cells is sealed through the apical junctional complex, which has three contact 
points composed of adherens junctions, desmosomes, and tight junctions (Groschwitz and 
Hogan, 2009).  Adherens junctions and desmosomes are the cement for cell adhesion and also 
serve as communication between cells (Groschwitz and Hogan, 2009; Turner, 2009).  Adherens 
are composed of cadherins, which are transmembrane proteins (Turner, 2009).  Tight junctions 
(TJ) are located at the most apical-lateral membrane in order to seal the intercellular space and 
regulate passage of solutes (Förster, 2008).  Tight junctions determine mucosal permeability 
because they are the bottleneck for solute flux and are more permeable than transcellular 
pathways (Turner, 2009).  The ability of tight junctions to discriminate between and restrict 
passage of solutes is based on size (Fihn et al., 2000) and charge selectivity (Turner, 2009). 
There are two pathways that allow transport across TJ: the first is the leak pathway that allows 
large particles, with no charge selectivity, and the second pathway is through formation of pores 
of claudin proteins that are primarily associated with charge selectivity (Turner, 2009).   
Expression of junctional proteins is dependent on the location within the intestine, the 
location on the microvilli, and the location between epithelial cell membranes (Groschwitz and 
Hogan, 2009).  Permeability to large solutes decreases from the crypt to the villus (Fihn et al., 
2000).  
Intestinal Permeability throughout the Intestinal Tract  
The permeability along the gastrointestinal tract is location dependent.  However, there 
seems to be some consistency among species, with the exception of the rat.  In humans and pigs 
intestinal permeability decreases from the small intestine to the colon, while the rat has greater 
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permeability in the ileum compared to the jejunum and colon (Nejdfors et al., 2000). In 
ruminants, passive ion permeability was greatest in the jejunum and least for rumen and omasum 
(Penner et al., 2014).  Similarly, small pore permeability, measured across intestinal segments, 
increased from the rumen and omasum to the jejunum followed by a sharp decline in the ileum 
(Penner et al., 2014).  Overall, the highest paracellular permeability was observed in the jejunum, 
indicating the lowest barrier function.  The differences observed in intestinal permeability and 
endocytotic potential throughout the gastrointestinal tract are thought to be related to nutrient 
availability and microbial fermentation (Penner et al., 2014).  Permeability of the GIT decreases 
with age during the preweaning period (Wood et al., 2015). 
Measuring Small Intestinal Permeability  
Small intestinal mucosal integrity can be evaluated non-invasively by measuring how 
permeable the intestine is to two different sized non-digestible probe molecules (Hall, 1999; 
Menzies et al., 1979; Uil et al., 1997).  The two probes are dosed orally, then the probes are 
quantified by collecting urine for 5 or 6 h after dosing (Menzies et al., 1979).  Of the two probes 
that are paired together, one should be a monosaccharide, like L-rhamnose or mannitol, while the 
second molecule is an oligosaccharide, like lactulose or raffinose (Bjarnason et al., 1995; Hall, 
1999). The sugars used are divided into different categories based on their chemical structure.  
Monosaccharides, such as D-mannitol, are generally < 0.4 nm with a molecular weight <200 Da, 
while disaccharides, such as lactulose, are generally > 0.5 to 6 nm with a molecular weight > 300 
Da (Jenkins and Bell, 1987; Travis and Menzies, 1992; Uil, et al., 1997).   The larger molecular 
mass of the oligosaccharides correlate with paracellular permeability while the monosaccharides 
indicate transcellular permeability (Bjarnason et al., 1995).  Translocation is assumed to be 
through passive diffusion, indicating nonspecific transport of inert molecules (Hall, 1999; Uil et 
a., 1997).  The reduction of small probe passage usually indicates a reduction in the mucosal 
surface area and villous atrophy (Hall, 1999).  An increase in larger probes indicates a disruption 
in tight junction function most often associated with intestinal inflammation or damage 
(Bjarnason et al., 1995; Hall and Batt, 1991).    
Dosing the two molecules at the same time and calculating the excretion ratio eliminates 
other nonmucosal factors because the two probes are affected equally (Hall, 1999).  Nonmucosal 
factors include ingestion, gastric emptying, intestinal dilution and transit, systemic distribution, 
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metabolism, and renal clearance (Hall, 1999).  The amount of known marker that permeates the 
small intestine is inversely related to mucosal integrity and any increase or change in the ratio 
between the two markers indicates damage (Hall, 1999).   
A common combination of markers in animals is the lactulose-D-mannitol method (Uil et 
al., 1997; Hall, 1999).  This method has been tested and validated in many species (Hall, 1999; 
Hall and Batt, 1991; Papasouliotis et al., 1993; Branco Pardal et al., 1995; Klein et al., 2007, 
2008).  Intestinal permeability has been measured in preruminant calves (Branco Pardal et al., 
1995; Klein et al., 2007, 2008; Araujo et al., 2015).  The excretion of the two markers has been 
observed to be tightly correlated in urine (Klein et al., 2007) and has been tested at varying ages 
in preruminant calves.  In the intestine of preruminant calves there is a higher proportion of 
permeability to disaccharides and lower permeability to monosaccharides compared to other 
species (Branco Pardal et al., 1995).   
An increased ratio of lactulose to rhamnose or to mannitol indicates an increased 
permeability to lactulose and a decreased permeability to rhamnose or mannitol (Gilani et al., 
2017; Araujo et al., 2015; Shaikh et al., 2015).   
Inflammatory Response 
The mucosal immune system is designed for tolerance rather than activation of the 
systemic immune system, but an active defense can be induced if necessary (Niewold, 2015).  
When foreign antigens translocate through the TJ barrier in the small intestine they are identified 
by antigen presenting cells and T-lymphocytes, which activate an inflammatory response.  
Consequentially, there is an increased production and secretion of pro-inflammatory cytokines 
and their mediators through recruitment of circulating inflammatory cells (Al-Sadi et al., 2009).  
The innate immune system results in recruitment of immune cells and production of acute phase 
proteins in the liver (Niewold, 2015).   
Inflammatory cytokines are considered to be the mediators of immunological and 
pathological responses to stress and infection (Kim et al., 2011).  However, pro-inflammatory 
cytokines [tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-6 (IL-6)] and anti-
inflammatory cytokines (IL-10, transforming growth factor (TGF-β)) regulate intestinal barrier 
function differently (Al-Sadi et al., 2009).  Pro-inflammatory cytokines result in an increased 
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disruption in the TJ barrier and worsen the inflammatory response in the intestine to further 
increase permeation to intestinal antigens (Al-Sadi et al., 2009; Ma and Anderson, 2006; Nusrat 
et al., 2000; Bruewer et al., 2006; Shen and Turner, 2006).  Anti-inflammatory cytokines, like 
IL-10 and TGF-β, may counteract some of this inflammation in order to maintain TJ function 
(Madsen et al., 1997; Forsyth et al., 2007). 
Pro-inflammatory IFN-γ causes an increase in epithelial TJ permeability (Madara and 
Stafford, 1989) and specifically increases permeability to larger-sized molecules (Watson et al., 
2005).  This is thought to be through activation of PI3-kinase pathway (Roy et al., 2006), which 
causes a delayed activation of NF-kB (Al-Sadi et al., 2009). Total parenteral nutrition (TPN) 
models have been shown to increase IFN-γ expression (Yang et al., 2002).  Increased TNF-α 
causes an increase in TJ permeability in intestinal monolayers, which is mediated through NF-κB 
and myosin light-chain kinase (MLCK) opening of the TJ barrier (Al-Sadi et al., 2009).  
Increased concentration of IL-1β closely correlates with intestinal inflammation (Reinecker et 
al., 1991) and is associated with increases in TJ permeability (Al-Sadi et al., 2009).  Several cell 
types produce IL-6, which is involved with inducing the acute-phase response (Barton, 1997).  
Other pro-inflammatory stimuli, including TNF-α and IL-1β, result in IL-6 secretion (Song and 
Kellum, 2005) and cause a drop in transepithelial electrical resistance (TEER) and increased 
permeability to mannitol (Tazuke et al., 2003).  Furthermore, IL-6 has been identified as a 
prognostic indicator in calf diarrhea and is a marker of early inflammation (Fischer et al., 2016; 
Rincon, 2012).  Increases in IL-6, above 38.7 pg/mL, at the initiation of a bout of diarrhea 
increase the likelihood of a prolonged episode (Fischer et al., 2016).  
Interleukin-10 is thought to be protective against TJ barrier disturbance and prevents 
IFN-γ induced paracelluar permeability to mannitol and inulin (Schroder et al., 2004).  In a total 
parenteral nutrition (TPN)-induced intestinal barrier dysfunction model in mice, TPN caused an 
increase in intestinal permeability to mannitol and bacterial translocation.  This was associated 
with decreased epithelial cell production of IL-10 but was reversed with IL-10 treatment (Sun et 
al., 2008).  Epithelial barrier disruption in TPN models is further associated with loss of ZO-1, E-
cadherin, and occludin which is also prevented by IL-10 treatment (Sun et al., 2008).  This 
indicates that IL-10 has an important role in protecting from epithelial barrier damage (Al-Sadi et 
al., 2009).   
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Direct evaluation of intestinal health can be challenging because of its relative 
inaccessibility.  However, there are specific indirect intestinal biomarkers that can be used to 
help assess intestinal health status in vivo (Niewold, 2015).  Myeloperoxidase (MPO) is an 
enzyme in inflammatory cells, mainly neutrophils, and has been used to indicate the degree of 
inflammation as a reflection of the number of inflammatory cells (Niewold, 2015).  Fecal MPO 
can be used to determine intestinal inflammation, which has been done in humans (Kosek et al., 
2012).  Additionally, fecal MPO can be used in pigs and ruminants, but is not a viable option in 
poultry (Niewold, 2015).  A recent experiment by Rosa et al. (2018) evaluated a method of 
extracting RNA from fecal samples of calves that had incidences of diarrhea in the preweaning 
period.  Inflammatory changes were evaluated at a transcriptomic level in the gastrointestinal 
tract by looking at several genes related to the inflammatory response (i.e., TLR2, TLR4, NFKB1, 
TNFA, IL1B, IL8, and IFNG) and cell membrane transporters (i.e., SLC5A1, AQP3, and SLC2A2; 
Rosa et al., 2018).  These methods provide promise for less invasive ways to evaluate changes in 
the gastrointestinal tract.   
Trophic Hormones and Peptides 
A number of hormones and peptides are secreted by cells within the gastrointestinal tract 
that serve to signal maintenance, growth, and repair of epithelial tissue (Drucker et al., 1994; 
Burrin et al., 2003).  Among the most important of these are glucagon-like peptides 1 (GLP-1) 
and -2 (Estall and Drucker, 2006).  The proglucagon gene is mainly expressed in the pancreas 
and in the mucosa of the gastrointestinal tract (Drucker et al., 1994; Mojsov et al., 1986; Novak 
et al., 1987).  In the intestine, cleavage of proglucagon by the enzyme, prohormone convertase 
(PC) 1/3, results in the release of GLP-1 and GLP-2 (Rothenberg et al., 1995; Rouille et al., 
1995; Dhanvantari et al., 1996).  The PC1/3 enzyme is synthesized as an 87 kDa protein that 
undergoes autocatalytic processing in the endoplasmic reticulum, is transported to the Golgi 
complex, and then undergoes further processing to go to secretatory granules that are important 
for the liberation of proglucagon-derived peptides (Dhanvantari et al., 1996).  Glucagon-like 
peptide-1 and -2 are released in equal ratio from the enteroendocrine cells in the intestines 
(Ørskov et al., 1986). Both GLP-1 and GLP-2 have an alanine residue in the number 2 position, 
which allows dipeptidyl peptidase 4 (DPP-IV) to inactivate both peptides (Drucker, 1999; Inoue 
et al., 2012).  As a result, the half-life of these peptides in blood is relatively short, with ~1 to 2 
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min for GLP-1 and ~7 min for GLP-2 in humans due to cleavage by DPP-IV and renal clearance 
(Hartmann et al., 2000; Tavares et al., 2000; Holst, 2007).   
Glucagon-like peptide-1 helps regulate glucose-dependent insulin secretion, gastric 
emptying, food and water intake, glucagon secretion, and stimulation of insulin gene expression 
(Drucker, 1999, Holst, 2007).  Glucagon-like peptide-2 is a 33 amino acid peptide that has 
trophic and regenerative properties for the intestinal epithelium (Burrin et al., 2000).  Secretion 
from the intestinal L-cells is stimulated by nutrient ingestion, primarily in response to 
carbohydrates and lipids (Estall and Drucker, 2006).  The L cells account for only 1 to 5% of 
mucosal cells along the intestinal tract in humans (Sjolund et al., 1983), but are most densely 
found in the distal part of the jejunum, ileum, and colon (Larsson et al., 1975; Eissele et al., 
1992).   
A group of G-protein coupled receptors have been identified that influence GLP-2 
secretion in nonruminants by “tasting” the luminal contents and regulating absorption of 
nutrients, hormone release, and overall metabolism (Akiba and Kaunitz, 2014; Connor et al., 
2015).  These receptors are expressed on the apical membrane of the L cells.  The group includes 
the umami taste receptor (T1R1-T1R3), the bile acid receptor (TGR5), free fatty acid receptors 
(GPR40, GPR41, GPR43, and GPR120), and sweet taste receptor (T1R2-T1R3; Connor et al., 
2015). 
Different nutrients in the intestinal lumen interact with these receptors to initiate release 
of various enteroendocrine hormones.  Carbohydrates and nonnutritive sweeteners stimulate the 
sweet taste receptor T1R2-T1R3 in the L cells, which results in increased expression of glucose 
transporters and GLP release (Furness et al., 2013; Shirazi-Beechey et al., 2014).  A sweet taste 
receptor on L cells in the distal small intestine, T1R3, results in release of L-cell hormones, 
including GLP-1 in response to glucose (Margolskee et al., 2007). Fats initiate the release of 
peptide YY (PYY) and GLP-1 from L cells.  Peptide YY inhibits motility in the proximal 
intestine (Furness et al., 2013), while GLP-1 inhibits gastric emptying and gastric acid secretion 
in the proximal regions in the intestine (Holst, 2007).  Digested proteins also stimulate release of 
GLP-1 from the L cells (Cordier-Bussat et al., 1998).    
The secretion of GLP-1 and GLP-2 is biphasic, with an early peak approximately 30 min 
after nutrient ingestion and a second, more prolonged peak at 60 to 120 min (Morgan et al. 1993; 
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Xiao et al., 1999; Rask et al., 2001).  The first wave is initiated through indirect stimulation from 
the subepithelial vagal afferent nerves, through glucose-dependent insulinotropic peptide (GIP) 
secretion from the enteroendocrine K cells in the proximal small intestine (Connor et al., 2015).  
The second wave is initiated when nutrients arrive in the distal small intestine, which directly 
stimulates L cells to secrete GLP-1 and GLP-2 (Xiao et al., 1999; Brubaker and Anini, 2003; 
Akiba and Kaunitz, 2014).   
Release of GLP-2 indirectly initiates its intestinotrophic actions in the gut via 
downstream mediators from GLP-2 receptor (GLP-2R) expressing cells (Yusta et al., 2000).  The 
GLP-2R is a G-protein-coupled, transmembrane receptor that is primarily expressed in the gut 
(Munroe et al., 1999).  The GLP-2R is located on enteric neurons, endocrine cells, and 
subepithelial myofibroblasts (Bjerknes and Cheng, 2001; Connor et al., 2015; Rowland and 
Brubaker, 2011), but not epithelial cells.  The effects of GLP-2, therefore, are indirectly 
mediated through paracrine-acting effector molecules (Rowland and Brubaker, 2011).   
Genes involved in the GLP-2 pathway are expressed along the gastrointestinal tract of 
ruminants (Taylor-Edwards et al., 2008; Connor et al., 2010), and the GLP2R and DPP4 had 
highest expression in the small intestine (Connor et al., 2010).  Proglucagon and GLP-2R mRNA 
transcription has been observed in the ruminant intestinal tract in the duodenum, jejunum, ileum, 
and cecum (Connor et al., 2010; Taylor-Edwards et al., 2010).  The expression of GLP-2R in the 
ileum is also increased in response to increased energy intake (Taylor-Edwards et al., 2010).  
Expression of DPP4 was dependent on stage of development and lactation (Connor et al., 2010).   
The concentration of GLP-2 in plasma changes throughout development from fetus to 
post weaning in piglets (Petersen et al., 2003).  The concentration is very low in the fetus, 
increases significantly right before birth, and peaks in the day after birth.  Moreover, the 
concentration decreases during weaning, correlating with decreased feed intake, and then 
concentrations return to preweaning levels when intake of nutrients increases again (Petersen et 
al., 2003).  In pigs there are low concentrations of GLP-2 in amniotic fluid, colostrum, and milk 
so there is limited absorption from these sources, indicating that circulating GLP-2 arises from 
GLP-2 synthesis stimulated by the nutrients from these sources in newborns, rather from 
absorption of the peptides (Petersen et al., 2003).    
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Various studies have elucidated the role of keratinocyte growth factor (KGF), endothelial 
nitric oxide synthase (eNOS), vasoactive intestinal polypeptide (VIP), insulin-like growth factors 
(IGFs), and the ErbB network in the trophic actions of GLP-2 in the intestine (Rowland and 
Brubaker, 2011).  Kerotinocyte growth factor mediates the GLP-2 effect for growth, particularly 
with goblet cell stimulation, so its effects are mainly observed in the colon, and to a lesser extent 
in the intestine because of lower goblet cell numbers (Iwakiri and Podolsky, 2001; Ørskov et al., 
2005).  Endothelial nitric oxide synthase (eNOS) is involved in intestinal blood flow, and 
increases in response to GLP-2 administration (Guan et al., 2003, 2006).  The GLP-2R is also co-
localized with VIP-positive enteric neurons (Guan et al., 2006).  Vasoactive intestinal 
polypeptide similarly induces increases in intestinal blood flow, secretion, motility, and smooth 
muscle relaxation (Furness et al., 2003; Guan et al., 2006).  Insulin-like growth factors are 
mitogenic peptides whose functions include cellular proliferation, survival, and differentiation 
and have many shared effects with GLP-2 in the gut (Lund, 1999; Rowland and Brubaker, 2011).  
The effects of GLP-2 primarily require the actions of IGF-1 to exhibit trophic effects in the 
intestine (Dube et al., 2006).  The effect of GLP-2 on IGF-1 mRNA transcript levels is 
dependent on phosphatidylinositol-3-kinase (PI3K)/Akt (Leen et al., 2011) in intestinal 
subepithelial myofibroblasts (ISEMF) cells.  The PI3K/Akt signaling pathway has been shown to 
be activated in vivo (Burrin et al., 2007; Cheesman, 1997; Dube et al., 2008).  Binding of GLP-
2R on ISEMF cells leads to release of IGF-1, which binds to IGF-1 receptors on crypt epithelial 
cells, and may transactivate ErbB receptors that in turn activate cell proliferation via PI3/Akt and 
β-catenin signaling (Rowland and Brubaker, 2011).  Ligand binding in cells transfected with 
GLP-2R results in a dose-dependent increase in cAMP and activation of PKA (Munroe et al., 
1999; Yusta et al., 1999; Anini et al., 2007, Dube et al., 2006, Shin et al., 2005, Walsh et al., 
2003).  Additionally, GLP-2 has a small PKA-independent proliferative effect that decreases 
apoptosis through inhibition of glycogen synthase kinase-3β and Bc1-2-associated death 
promoter (Yusta et al., 2002).  The ErbB ligands help maintain intestinal mucosal growth and 
function with its proliferative system (Helmrath et al., 1997), which is increased in murine small 
intestine after GLP-2 treatment (Yusta et al., 2009).  Proliferation is regulated by Wnt signaling 
in the intestinal crypt cells (Dube et al., 2008).  As a result, GLP-2 increases crypt cell 
proliferation and decreases apoptotic cell numbers in the tips of the villi, subsequently increasing 
small intestinal mass (Tsai et al., 1997; Drucker et al., 1997).   
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Furthermore, GLP-2 has been implicated in reducing intestinal inflammation and damage 
through GLP-2R on submucosal enteric neurons by activating VIP producing neurons (Furness 
et al., 2013; Sigalet et al., 2007).  In rat and mouse models, GLP-2 treatment reduces 
inflammatory cytokines (IFN-γ, TNF-α, IL-1β) while also increasing the anti-inflammatory 
cytokine IL-10 in association with increased VIP expressing neurons (Rowland and Brubaker, 
2011; Sigalet et al., 2007).  Actions of GLP-2 also include upregulation of sodium-dependent 
glucose transporter 1 (SGLT-1), which increases glucose and galactose transport across the 
intestinal epithelium (Cheesman, 1997).  Moreover, action of GLP-2 has been shown to increase 
absorption of amino acids and digestion of triglycerides, as well as to increase activity of 
digestive enzymes in enterocytes (Brubaker et al., 1997; Hsieh et al., 2009; Shirazi-Beechey et 
al., 2011). Glucagon-like peptide-2 inhibits gastric emptying, similar to GLP-1 (Drucker, 1999).   
Bile Acids and TGR5 Agonists 
Bile acids act as signaling molecules and can exert endocrine and metabolic actions in 
addition to their primary function of cholesterol homeostasis and facilitation of fat digestion 
(Burrin et al., 2013).  Bile acids act as signaling molecules through activation of TGR5, a 
membrane G protein-coupled receptor, and farnesoid X receptor (FXR), a nuclear hormone 
receptor (Kawamata et al., 2003; Maruyama et al., 2002; Burrin et al., 2013).   
Expression of the G-protein coupled receptor, TGR5, has been found on enteroendocrine 
L cells in the small intestine (Lavoie et al., 2010; Alemi et al., 2013).  Bile acids stimulate 
activation of TGR5 receptors, which results in release of GLP-1 and co-secreted GLP-2 (Thomas 
et al., 2009; Katsuma et al., 2005; Kidd et al., 2008; Parker et al., 2012).  Chenodeoxycholic acid 
(CDCA) activates both FXR and TGR5 (Jain et al., 2012).  Stimulation of GLP-1 can be 
achieved through TGR5-mediated pathways by initiating cAMP formation (Katsuma et al., 2005; 
Parker et al., 2012) in the Gs/cAMP/PLC/Ca2+ pathway (Bala et al., 2014).  Inhibition of the 
TGR5 mediated effects is thought to be through H2S inhibition of PI hydrolysis (Bala et al., 
2014).  Secretion of GLP-2 in response to bile acids is likely the link to trophic actions of 
luminal bile acids (Burrin et al., 2013).  Trophic effects likely occur through control of intestinal 
barrier function by regulation of expression of TJ proteins via GLP-2 linked mechanisms 
(Inagaki et al., 2006; Cipriani et al., 2011).  Induction of TGR5, through bile acids, helps 
regulate intestinal homeostasis by regulating genes that have established antimicrobial actions, 
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while also attenuating inflammation and decreasing intestinal permeability (Inagaki et al., 2006; 
Cipriani et al., 2011). 
The FXR receptors are located in enterocytes and are most potently activated by CDCA 
(Burrin et al., 2013) but also by cholic acid (Edwards et al., 2002).  In the ileum, sodium-
dependent bile acid transporter (ASBT) aids in absorption of bile acids into the cell and then 
FXR is activated by binding the bile acids, which results in transcriptional and hormonal control 
of bile acid clearance (Hylemon et al., 2009).  Activation of FXR results in the secretion of 
fibroblast growth factor 19 (FGF19; Inagaki et al., 2005; Burrin et al., 2013). Activation of FXR 
has two negative feedback mechanisms that suppress synthesis of bile acids through cholesterol 
7α-hydroxylase (CYP7A1), the rate limiting enzyme of bile acid synthesis, and through FGF19 
(Burrin et al., 2013).  In the intestine FXR helps regulate genes like ileal bile acid binding protein 
and fibroblast growth factor 15 (Makishima et al., 1999; Grober et al., 1999; Li et al., 2005; 
Inagaki et al., 2005).  Furthermore, FXR helps protect against bacterial over-proliferation and 
disruption of epithelial barrier function in the small intestine (Inagaki et al., 2006).     
INTESTINAL DYSFUNCTION AND STRESS 
As discussed above, the host mucosa plays an important role in maintaining the balance 
among the animal, feed, and microbiota (Niewold, 2015).  Disruption of this balance among the 
three components can lead to gastrointestinal dysfunction.  Specifically, in the calf there are 
several situations where pathogenic or nutritional insults can affect feed intake, growth and 
efficiency and in turn can disrupt the balance of the host mucosa, feed, and microbiota (Steele et 
al., 2016; Meale et al., 2017).  Gastrointestinal dysfunction has been classified into three 
categories: mucosal barrier disruption, altered motility, and atrophy of the mucosa (Martindale et 
al., 2013).  These effects all have been indicated in enteric diseases associated with pathogenic 
invasion resulting in diarrhea (Connor et al., 2013, 2017; Walker et al., 2015) and in distress 
associated with weaning (Malmuthuge et al., 2013; Eckert et al., 2015; Wood et al., 2015), two 
very important hurdles in a young calf’s life.   
Intestinal barrier dysfunction has been considered as an early or initiating event to 
intestinal inflammation (Cameron and Perdue, 2005).  Activation of the adaptive part of the 
immune system reallocates resources from growth to production of cytotoxic immune cells and 
antibodies (Iseri and Klasing, 2013).  Inflammation leads to reduced appetence and catabolism of 
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muscle resulting in a reduction in growth, while also enhancing susceptibility to intestinal 
pathogens (Niewold, 2015).   
Previous studies in pig models of intestinal dysfunction suggest that a key element of 
intestinal adaptation during the neonatal and early postweaning phases is the nutrient-induced 
secretion of GLP-2 and its associated effects on mucosal cell proliferation, barrier function, and 
inflammatory response (Burrin et al., 2003; Cameron and Perdue, 2005; Sigalet et al., 2007; 
Ipharraguerre et al., 2013).  Promotion of the secretion of GLP-2 or GLP-2 therapy might help 
improve production in animals that are compromised in situations like reduced feed intake, 
diarrhea, and weaning (Connor et al., 2016).  Additionally, activation of signals in the intestine 
related to bile acids can stimulate the release of endogenous GLP-2 and its trophic effects related 
to gut integrity in models of intestinal atrophy and dysfunction (de Diego-Cabero et al., 2015).   
Reduced Feed Intake 
Reduced feed intake or lack of enteral nutrition can lead to reduced growth and functional 
development of the intestinal mucosa (Buchman et al., 1995; Groos et al., 1996).  Reduced feed 
intake and intestinal atrophy can be modeled through varying levels of enteral intake in animals 
maintained via total parenteral nutrition (TPN; McCauley et al., 1996; Burrin et al., 2000).  In a 
piglet model, varying levels of enteral intake were provided to determine the level to either 
stimulate or normalize intestinal growth (Burrin et al., 2000).  The researchers observed that the 
proximal segments of the intestine were the most sensitive.  In the jejunum, 40% of total nutrient 
intake provided enterally was required to increase wet weight and protein content, while the 
ileum required 60% enteral intake.  Both intestinal segments were returned to normal wet weight 
and protein content when enteral nutrients provided 80% of total intake.  Morphological changes 
also were evaluated.  Villus height was stimulated at 40% enteral intake and normalized at 60% 
in both the jejunum and ileum.  Crypt depth was normalized at 60% enteral intake relative to the 
control.  Furthermore, two indices of proliferation were evaluated and were normalized when 
enteral intake was 60% of total intake or above.  Circulating concentrations of GLP-2, PYY, GIP 
and IGF-1 were correlated with increasing enteral intake and the resulting increases in wet 
weight, protein content, villus height, and crypt depth above 60% enteral intake (Burrin et al., 
2000).    
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In nonruminants, treatment with GLP-2 has been shown to increase intestinal cell 
proliferation, reduce apoptosis, increase nutrient absorption and gut integrity, and reduce 
inflammation (Lovshin and Drucker, 2000; Burrin et al., 2003; Drucker, 2005).  As a result, the 
use of GLP-2 as a therapy for improving nutrient absorption and production efficiency has been 
reported in poultry and livestock species (Hu et al., 2010; Burrin et al., 2003; Sigalet, 2012). In 
rats maintained on TPN for 10 d, GLP-2 infusion prevented mucosal atrophy and maintained 
small intestinal weight, indicating that trophic effects are at least in part responsible for 
maintaining mucosal integrity and permeability (Drucker, 1999).  Similarly, TPN-maintained 
pigs treated with exogenous GLP-2 had increased intestinal mucosal mass and villus height 
relative to untreated control (Petersen et al., 2001).   
Short term feed restriction results in decreased nutrient provision and has been associated 
with reduced total tract function in cattle (Gäbel et al., 2002; Zhang et al., 2013).  Furthermore, 
similar findings of GLP-2 trophic effects have been reported in ruminants (Taylor-Edwards et 
al., 2011, 2012; Connor et al., 2013).  In ruminating dairy calves GLP-2 was infused for 10 d, 
which increased small intestinal mass and tended to increase DNA, protein, villus height, crypt 
cell proliferation, and crypt depth in the duodenum.  Similarly, GLP-2 infusion increased section 
mass in the jejunum through increased epithelium, DNA content, and crypt cell proliferation 
(Taylor-Edwards et al., 2011).  Blood flow in the superior mesenteric artery is most responsive to 
GLP-2 infusion in ruminating calves (Taylor-Edwards et al., 2011) and there is limited effect on 
portal and hepatic plasma flow (Taylor-Edwards et al., 2012).  Nutrient uptake in the portal 
drained viscera is also influenced by GLP-2 infusion, particularly amino acids (Taylor-Edwards 
et al., 2012).   
Similar to the decreased concentration of GLP-1 and GLP-2 in TPN-fed piglets, 
abundance of bile acids and FGF19 also are reduced (Jain et al., 2012).  Treatment with CDCA 
significantly increases concentrations of FGF19, GLP-1, and GLP-2.  Furthermore, CDCA 
stimulates intestinal growth and reverses mucosal atrophy (Jain et al., 2012).  These findings 
indicate that CDCA can restore some of the metabolic and trophic effects in TPN fed animals 
(Jain et al., 2012).  
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Effect of Enteric Pathogens 
Pathogens in the intestine develop different traits to circumvent the barriers used by the 
animal, as described above, to translocate to the epithelial layer, adhere to, and invade the cells 
(Kim and Ho, 2010).  These pathogen traits include motility, mucolytic activity, and other 
virulence factors that can degrade and penetrate the mucosal layers allowing for adhesion to the 
villi and upper crypts of the intestine (Kim and Ho, 2010).  Intestinal barrier dysfunction allows 
foreign antigens, including harmful bacteria, access to the underlying mucosal immune system 
which may lead to intestinal inflammation (Cameron and Perdue, 2005).   
As noted in earlier sections, several enteric pathogens are implicated in calf diarrhea (Cho 
and Yoon, 2014).  The timing of infection ranges from a few days after birth to 1 to 2 wk old or 
beyond, but several pathogens affect calves around 1 to 2 wk old (Cho and Yoon, 2014; Foster 
and Smith, 2009).  Actions of viruses, bacteria, and protozoa vary with species type and location 
in the intestine that is infected, but include: destruction of enterocytes in the villi causing villus 
atrophy, activation of enteric nervous system by vasoactive components from damaged cells, 
secretion of enterotoxins, colonic crypt atrophy, necrosis of the lamina propria, and disruption of 
epithelial tight junction integrity (Cho and Yoon, 2014; Foster and Smith, 2009).  Damaged 
intestinal epithelium can cause prolonged malnutrition and reduced growth rates in affected 
calves due to malabsorption and fermentation of undigested milk in the intestinal lumen (Cho 
and Yoon, 2014).  Several enteric pathogens (various strains of E. coli, Rotavirus, and 
Salmonella typhimurium) and virulence factors (Clostridum perfringens and E. coli) have been 
implicated specifically in modifying epithelial barrier function or TJ proteins (Sears, 2000).  
Limited research demonstrates that decreased permeability leads to an increase in the numbers of 
bacteria that cross the intestinal mucosa (Chen et al., 2015).   
Increased intestinal permeability after birth may predispose calves to diarrhea in the first 
21 d of life (Araujo et al., 2015).  Calves that had increased paracellular permeability at birth 
were more likely to develop diarrhea.  Furthermore, calves that received colostrum late appeared 
to have greater lactulose/mannitol ratio, which could indicate slower gut closure and 
predisposition to allow pathogenic bacteria and their antigens to disturb intestinal permeability 
and induce diarrhea in calves (Araujo et al., 2015).  In calves, episodes of diarrhea are associated 
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with decreases in intake, and the concentration of circulating GLP-2 decreases markedly when 
milk ingestion drops below 0.875% of the calf BW (Castro et al., 2016).   
Administration of GLP-2 in pigs with diarrhea and maintained in low-sanitary conditions 
increased small intestinal weight, reduced severity of diarrhea, increased villus height and crypt 
depth, and enhanced peptidase activities (Thymann et al., 2014).   In neonatal calves challenged 
with C. parvum, infection resulted in a severe deviation of paracellular permeability and 
absorptive capacity for 2 wk post infection (Klein et al., 2008).  On d 7 post infection there was 
almost a 100% increase in paracellular permeability, as evaluated by the lactulose/mannitol test.  
Administration of GLP-2 could help alleviate some effects of C. parvum including increasing 
mucin production, villus length, and tight junction expression (Connor et al., 2016).  Treatment 
with GLP-2 in infected calves improved villus height and tended to reduce crypt cell 
proliferation.  Treatment also increased mRNA expression of TJ proteins in the jejunum (Connor 
et al., 2017).  Challenge with Eimeria bovis is associated with oxidative tissue damage and 
decreased epithelial integrity in calves but these effects can be alleviated with subcutaneous 
injections of GLP-2 (Connor et al., 2013).  The decreased intestinal integrity is likely associated 
with the negative effects of E. bovis on genes associated with the TJ complex, but GLP-2 therapy 
has been shown to restore intestinal integrity if supplemented in sufficient amounts (Walker et 
al., 2015).   
Weaning 
In piglets, weaning is associated with adverse changes to intestinal morphology, intestinal 
permeability, absorptive capacity, disaccharidase activity, and inflammation (Hampson, 1986; Le 
Huerou-Luron et al., 2002; Kelly et al., 1991; Pié et al., 2004; Hu et al., 2013).  Changes in 
intestinal morphology, absorptive capacity, and disaccharidase activity are associated with 
reduction in nutrient intake (Hampson, 1986; Le Huerou-Luron et al., 2002; Kelly et al., 1991).  
Piglet intestinal morphology and permeability are negatively affected by weaning through the 
decreased villus height, decreased ratio of villus height to crypt depth, and increased paracellular 
permeability (Hu et al., 2013).  Although almost 14 d are required to recover intestinal 
morphology relative to preweaning values, it takes longer than 14 d to recover mucosal barrier 
function (Hu et al., 2013).  Weaning piglets results in transient inflammation of the gut, with 
upregulation of mRNA for IL-1β, IL-6, and TNF-α (Pié et al., 2004).  These cytokines likely 
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mediate the decreased TJ protein expression in the first week after weaning (Hu et al., 2013).  
Early weaning in piglets has been associated with a reduction in barrier function in the mid-
jejunum and ascending colon (Moeser et al., 2007). Furthermore, stress in weaning pigs (changes 
in feed, environment, or enteric challenges) reduces expression of intestine TJ proteins and 
increases intestinal permeability (Bruewer et al., 2003). 
Observed reductions in circulating GLP-2 during weaning are likely the result of 
interruptions in gut-signaling cascades because of reduced intake (Petersen et al., 2003). 
Administering GLP-2 to piglets around weaning increases villus height and crypt depth in the 
jejunum and ileum, and increases crypt depth in the colon due to an increase in crypt cell 
proliferation and decreases in apoptosis (Sigalet et al., 2014).  Administration of GLP-2 increases 
TJ mRNA and protein expression in piglet jejunal sections through the MAPK signaling pathway 
(Yu et al., 2014).  Some of the effects of GLP-2 seem to be related to sanitary conditions with a 
greater effect observed in weaning piglets under unsanitary conditions that increase the 
prevalence of diarrhea compared with more sanitary conditions (Thymann et al., 2014).   
A few research studies have evaluated administration of bile acids to help activate the 
TGR5 pathway in weanling piglets.  Administration of CDCA in early weaned piglets resulted in 
an increased secretion of GLP-2 but this did not translate into improved intestinal growth, 
morphology, or inflammation postweaning (Ipharraguerre et al., 2013).  In a different study, 
supplementation of CDCA to piglets around weaning increased the expression of genes related to 
protection and barrier function of the distal small intestine (de Diego-Cabero et al., 2015).    
  Weaning elicits one of the most extensive modifications in digestive physiology in 
domestic animals (Steele et al., 2016; Guilloteau et al., 2009) and is a major part of the 
transformation of the preruminant calf into a ruminant.  Weaning is associated with altered GIT 
health, stress, and reduced growth (Khan et al., 2011; 2016).  Rumen development is often the 
metric used to assess weaning programs but there is very limited information about the response 
of the intestine to weaning (Baldwin et al., 2004).  However, recent research indicates that rumen 
development might be linked to developmental changes in the small intestine (Meale et al., 2017; 
Górka et al., 2011).   
During weaning there is a major shift in the site of nutrient digestion from the small 
intestine to the reticulo-rumen (Wood et al., 2015).  There is a shift in the energy and protein 
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sources from glucose, galactose, milk fat, and protein to short-chain fatty acids and microbial 
protein (Wood et al., 2015).  This shift in site of digestion and substrate supply could 
compromise GIT barrier function (Wijtten et al., 2011).  Depending on weaning strategy and 
functionality of the gastrointestinal tract, utilization of nutrients (e.g., SCFA from ruminal 
fermentation) may not be completely developed and could lead to increased fecal starch (Eckert 
et al., 2015).   Increased fecal starch could be associated with an increase in hindgut 
fermentation, which potentially could lead to gut inflammation (Steele et al., 2016; Eckert et al., 
2015).  Subsequently, increased inflammatory markers in peripheral blood have been observed in 
dairy calves around weaning (Kim et al., 2011).  Furthermore, in response to weaning, the 
rumen, duodenum, and jejunum have increased permeability and lowered barrier function (Wood 
et al., 2015).  During weaning in calves, villus height is increased in the jejunum but is decreased 
in the ileum (Guilloteau et al., 2009).  In the lamb, villus height in the ileum shows a similar 
trend; however, there is a reduction in the jejunum villus height, which decreases the absorptive 
capacity because of a reduction in absorptive area.  Additionally, the epithelial renewal time 
during weaning is shorter (Attaix and Meslin, 1991). 
  There is very limited information about the changes in intestinal morphology and 
permeability around weaning in dairy calves (Baldwin et al., 2004).  Additionally, there is even 
less information that integrates inflammation and inflammatory cytokines over the weaning 
period and how they would affect morphology and permeability changes.  While there is a large 
pool of information related to early weaning in piglets, it remains unclear how this might 
compare with weaning strategies in dairy calves.  More information is needed in this area to be 
able to speculate on how the severity of small intestinal morphological, integrity, and 
inflammation changes around weaning could impact reticulo-rumen development and overall 
gastrointestinal health and function.   
Implications 
While the effects observed in the small intestine are positive there are some limitations to 
treating calves with GLP-2 because of public concern about administration of hormones in food-
producing animals (Clemens, 2015; Johnson and Hanrahan, 2010; Refsdal, 2000).  However, if 
we can manipulate secretion of GLP-2 through nutrients or additives, there is potential to 
promote intestinal function in production animals through stimulation of GLP-2.  Moreover, 
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there are little to no data on stimulation of TGR5 in dairy calves in any production settings so at 
this time it is unclear what potential benefits this might provide to calf health and growth.  
BIOACTIVE FEED ADDITIVES 
Feed additives and their impact on intestinal health 
The three components of the gastrointestinal environment, feed (and additives), microbial 
populations, and the host mucosa, influence each other.  Ideally, they all work together to 
support optimal health and growth, but if there is a dysfunctional state this balance can be 
compromised.  Potentially, specific feed additives could be used that would manipulate the 
gastrointestinal environment to be advantageous to the ecosystem and promote health and 
growth, especially during times where the gastrointestinal environment could be compromised 
(Niewold, 2015).  Phytogenic feed additives are plant-based products used in animal feeding 
(Windish et al., 2008).  Evaluation of non-antibiotic additives to help with growth and health is 
needed (Windish et al., 2008).  Implementation of changes in the VFD also increases the 
pressure to find non-antibiotic additives that may be included in feed and water for food 
producing animals.  Phytogenic feed additives have been indicated to have antioxidative and 
antimicrobial properties, influence palatability and gut function, and ultimately affect growth 
depending on the additive and its observed properties (Windish et al., 2008).    
Sterols and Plant Additives 
Activating TGR5 with natural or synthetic agonists allows for an augmentation of the 
release of GLP in vitro and in vivo (Katsuma et al., 2005, Thomas et al., 2009).  Phytosterols 
have been shown to antagonize FXR and alter circulation of bile acids in TPN-fed-neonates 
(Carter et al., 2007; Iyer et al., 1998).  This has been proposed as a method that might modify 
activation of TGR5 and subsequent secretion of GLP (Ipharraguerre et al., 2013).  However, in 
early weaned piglets supplemented with phytoesterol β-sitoesterol, an antagonist of FXR (Carter 
et al., 2007), no response of plasma concentration of GLP-1 was observed (Ipharraguerre et al., 
2013).   
Olea europaea  
Different parts of the olive (Olea europaea) contain significant amounts of hydrophilic 
and lipophilic bioactives including flavones, phenolic acids, phenolic alcohols, secoiridoids, and 
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hydroxycinnamic acid derivatives (Ghanbari et al., 2012; Bayram et al., 2012; Visioli and Galli, 
2002).  Olive-derived plant bioactives have anti-inflammatory, antioxidant, and antimicrobial 
properties that have positive effects under pathological conditions (Sanchez-Quesada et al., 
2013; Pereira et al., 2007), which make them potential feed additives (Liehr et al., 2017).  
Bioactive molecules extracted from O. europaea have been shown to induce the secretion of 
GLP-1, which is co-secreted with GLP-2, in model enteroendocrine cells via activation of the 
bile acid receptor TGR5 (Bala et al., 2014). Additionally, O. europaea in vivo and in vitro 
significantly increased the secretion of GLP-1 in mice (Rafferty et al., 2011).   
Subclinical chronic inflammation (SCI) in weaned pigs can be induced by intraperitoneal 
injections of lipopolysaccharide (LPS).  Olive-oil extract enriched with olive bioactives (OBE) 
can be made by filtering pomace olive oil and extraction and purification of bioactive 
compounds in the solid fraction.  The resulting product is standardized to 10% maslinic acid, 4% 
oleanolic acid, and 2% hydroxytyrosol (Liehr et al., 2017).  Treatment with hydroxytyrosol 
results in decreased TEER (increased permeability) in cell cultures (Piegholdt et al., 2014).  
Oleanoic acid is an activator of TGR5 receptors and is presumed to stimulate secretion of GLP-1 
(Sato et al., 2007).  
Supplementation of OBE to SCI pigs resulted in an increased abundance of mRNA forTJ 
proteins (OCLN, CDH1), which led to an increased functionality of the TJ as observed by the 
improved TEER and dual marker permeability test.  Taken together these findings indicated 
improved intestinal integrity.  Furthermore, OBE attenuated the inflammatory response, possibly 
through NF-κB, which has negative effects on feed intake and subsequent growth performance.  
These changes ameliorated the reductions in feed intake compared to the SCI pigs, which 
potentially can translate to improved growth (Liehr et al., 2017). 
Use of the plant-derived TGR5 agonist from O. europaea is a relatively new approach to 
promote intestinal adaptation and has yet to be explored in newborn calves.   
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DISSERTATION OBJECTIVES 
 Based on this review of literature, it seems clear that the trophic effects of nutrient- or 
agonist-induced secretion of GLP-2, possibly mediated through stimulation of the bile acid 
receptor TGR5, may be important to maintaining gut integrity and overall health in young calves.  
Therefore, the objectives of this dissertation were to answer the following questions: 
1. How does diarrhea in calves in the first 21 d after arrival affect intake, growth, and 
efficiency? 
2. How does feeding rate affect GLP-2 secretion in young calves? 
3. What is the effect of metabolizable and nonmetabolizable glucose on GLP-2 secretion at 
different feeding rates? 
4. Is O. europaea a natural TGR5 agonist in preruminant dairy calves that leads to increased 
GLP-2 secretion? 
5. How does O. europaea: 
I. Affect growth of preruminant calves? 
II. Affect overall health of preruminant calves? 
III. Affect permeability of the small intestine of preruminant calves? 
IV. Affect the secretion of gut trophic hormones in preruminant calves? 
 
 
29 
 
REFERENCES 
Akiba, Y., and J. D. Kaunitz.  2014.  Duodenal luminal chemosensing: Acid, ATP, and nutrients.  
Curr. Pharm. Des.  20:2760-2765.   
Alemi, F., Poole, D., Chium, J., Schoonjans, K., Cattaruzza, F., Grider, J. F., N. W. Bunnett, C. 
U. Corvera.  2013. The receptor TGR5 mediates the prokinetic actions of intestinal bile 
acids and is required for normal defecation in mice. J. Gastroenterol. 144:145-154. 
Al-Sadi, R., M. Boivin, and T. Ma. 2009. Mechanism of cytokine modulation of epithelial tight 
junction barrier. Frontiers Biosci. 14:2765. 
Anini, Y., A. Izzo, G. Y. Oudit, P. H. Backx, and P. L. Brubaker.  2007.  Role of 
phosphatidylinositol-3 kinase-γ in the actions of glucagon-like peptide-2 on the murine 
small intestine.  Am. J. Phsiol. Endocrinol. Metab.  292:E1599-E1606.   
Araujo, G., C. Yunta, M. Terré, A. Mereu, I. Ipharraguerre, and A. Bach.  2015.  Intestinal 
permeability and incidence of diarrhea in newborn calves. J. Dairy Sci.  98:7309-7317. 
Asari, M., N. Kawaguchi, S. Wakui, K. Fukaya, and Y. Kano. 1987. Development of the bovine 
ileal mucosa. Cells Tissues Organs 129:315-324. 
Attaix, D., and J. C. Meslin.  1991.  Changes in small intestinal mucosa morphology and cell 
renewal in suckling, prolonged-suckling, and weaned lambs. Am. J. Physiol. 4:R811-
R818.   
Atuma, C., V. Strugala, A. Allen, and L. Holm. 2001. The adherent gastrointestinal mucus gel 
layer: thickness and physical state in vivo. Am. J.  Physiol.-Gastrointest. Liver Physiol. 
280:G922-G929. 
Baintner, K. 2002. Vacuolation in the young. Biology of Growing Animals 1:55-110. 
Bala, V., S. Rajogopal, D. P. Kumar, A. D. Nalli, S. Mahavadi, A. J. Sanyal, J. R. Grider, and K. 
S. Murthy.  2014.  Release of GLP-1 and PYY in response to the activation of G protein-
coupled bile acid receptor TGR5 is mediated by Epac/PLC-Ɛ pathway and modulated by 
endogenous H2S.  Front. Physiol. 5:420.  
Baldwin, R. L. VI, K. R. McLeod, J. L. Klotz, and R. N. Heitmann.  2004. Rumen development, 
intestinal growth and hepatic metabolism in the pre- and postweaning ruminant. J. Dairy 
Sci. 87:E55-E65. 
Bartels, C. J. M., M. Holzhauer, R. Jorritsma, W. A. J. M. Swart, and T. J. G. M. Lam. 2010. 
Prevalence, prediction and risk factors of enteropathogens in normal and non-normal 
faeces of young Dutch dairy calves. Prev. Vet. Med. 93:162-169. 
Barton, B. E. 1997.  IL-6: Insights into novel biological activities.  Clin. Immunol. 
Immunopathol. 85:16-20. 
30 
 
Bayram B., T. Esatbeyoglu, N. Schulze, B. Ozcelik, J. Frank, and G. Rimbach. 2012. 
Comprehensive analysis of polyphenols in 55 extra virgin olive oils by HPLC-ECD and 
their correlation with antioxidant activities. Plant Foods Hum. Nutr. 67: 326-336. 
Bjerknes, M., and H. Cheng. 2001. Modulation of specific intestinalepithelial progenitors by 
enteric neurons. Proc. Natl. Acad. Sci. U.S.A. 98:12497-12502. 
Bjarnason, I., A. Macpherson, and D. Hollander.  1995.  Intestinal permeability: An overview.  J. 
Gastroenterol.  108:1566-1581. 
Branco Pardal, P., J. P. Lallès, F. André, E. Delval, and R. Toullec.  1995.  Assessment of 
gastrointestinal permeability to small marker probes in the preruminant calf.  Reprod. 
Nutr. Dev. 35:189-200.   
Brubaker, P. L., and Y. Anini. 2003. Direct and indirect mechanisms regulating secretion of 
glucagon-like peptide-1 and glucagon-like peptide-2. Can. J. Physiol. Pharmacol. 
81:1005-1012. 
Brubaker, P. L., A. Izzo, M. Hill, and D. J. Drucker. 1997. Intestinal function in mice with small 
bowel growth induced by glucagon-like peptide-2. Am. J. Physiol.-Endocrinol. Metab. 
272:E1050-E1058. 
Bruewer, M., A. Luegering, T. Kucharzik, C. A. Parkos, J. L. Madara, A. M. Hopkins, and A. 
Nusrat. 2003. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-
independent mechanisms. J. Immunol. 171:6164-6172. 
Bruewer M., S. Samarin, and A. Nusrat. 2006.  Inflammatory bowel disease and the apical 
junctional complex. Ann. N.Y. Acad. Sci. 1072:242-252. 
Buchman, A. L., A. A. Moukarzel, S. Bhuta, M. Belle, M. E. Ament, C. D. Eckhert, D. 
Hollander, J. Gornbeln, J. D. Kopple, and S. R. Vijayaroghavan. 1995. Parenteral 
nutrition is associated with intestinal morphologic and functional changes in humans. J. 
Parent. Enteral Nutr. 19:453-460. 
Burrin, D. G., B. Stoll, R. Jiang, X. Chang, B. Hartmann, J. J. Holst, G. H. Greeley, and P. J. 
Reeds. 2000. Minimal enteral nutrient requirements for intestinal growth in neonatal 
piglets: how much is enough? Am. J. Clin. Nutr. 71:1603-1610. 
Burrin, D. G., B. Stoll, and X. Guan. 2003. Glucagon-like peptide-2 function in domestic 
animals. Domest. Anim. Endocrin. 24:103-122. 
Burrin, D. G., B. Stoll, X. Guan, L. Cui, X. Chang, and D. Hadsell.  2007.  GLP-2 rapidly 
activates divergent intracellular signaling pathways involved in intestinal cell survival 
and proliferation in neonatal piglets.  Am. J. Physiol. Endocrin. Metab. 292:E281-E291.   
Burrin, D., B. Stoll, and D. Moore. 2013. Digestive physiology of the pig symposium: Intestinal 
bile acid sensing is linked to key endocrine and metabolic signaling pathways. J. Anim. 
Sci. 91:1991-2000. 
31 
 
Butler, D. G., and R. C. Clark.  1994.  Diarrhoea and dysentery in calves.  Pages 91-116 in 
Escherchia coli in domestic animals and humans.  C. L. Gyles, ed. CAB International, 
Wallingford, UK.  
Cameron, H. L., and M. H. Perdue. 2005. Stress impairs murine intestinal barrier function: 
Improvement by glucagon-like peptide-2. J. Pharmacol. Exp. Therap. 314:214-220. 
Cani, P. D., A. Everard, and T. Duparc.  2013.  Gut microbiota, enteroendocrine functions and 
metabolism.  Curr. Opinions Pharmacol.  13:935-940.   
Carter, B. A., O. A. Taylor, D. R. Prendergast, T. L. Zimmerman, R. Von Furstenberg, D. D. 
Moore, and S. J. Karpen. 2007.   Stigmasterol, a soy lipid-derived phytosterol, is an 
antagonist of the bile acid nuclear receptor FXR.  Pediatr. Res. 62:301-306.   
Castro, J. J., S. Y. Morrison, A. Hosseinni, J. J. Loor, J. K. Drackley, and I. R. Ipharraguerre. 
2016. Secretion of glucagon-like peptide-2 responds to nutrient intake but not glucose 
provision in milk-fed calves. J. Dairy Sci. 99:5793-5807. 
Cheesman, C. I. 1997. Upregulation of SGLT-1 transport activity in rat jejunum induced by 
GLP-2 infusion in vivo. Am. J. Physiol. 273:R1965-R1971. 
Chen, P., P. Stärkel, J. R. Turner, S. B. Ho, and B. Schnabl. 2015. Dysbiosis-induced intestinal 
inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver 
disease in mice. Hepatology 61:883-894. 
Cho, Y.-i., and K.-J. Yoon. 2014. An overview of calf diarrhea - infectious etiology, diagnosis, 
and intervention. J. Vet. Sci. 15:1-17. 
Cipriani, S., A. Mencarelli, M. G. Chini, E. Distrutti, B. Renga, G. Bifulco, F. Baldelli, A. 
Donini, and S. Fiorucci. 2011. The bile acid receptor GPBAR-1 (TGR5) modulates 
integrity of intestinal barrier and immune response to experimental colitis. PloS One 
6:e25637. 
Clemens, R. L. B.  2015.  The EU-U.S. hormone dispute: The negotiations continue. Iowa Ag 
Rev.  Vol. 8: Iss. 2, Article 5. 
Connor, E. E., R. L. Baldwin Vi, A. V. Capuco, C. M. Evock-Clover, S. E. Ellis, and K. S. 
Sciabica. 2010. Characterization of glucagon-like peptide-2 pathway member expression 
in bovine gastrointestinal tract. J. Dairy Sci. 93:5167-5178. 
Connor, E. E., S. Kahl, T. H. Elsasser, R. L. Baldwin VI, R. Fayer, M. Santin-Duran, G. L. 
Sample, and C. M. Evock-Clover. 2013. Glucagon-like peptide-2 therapy reduces 
negative effects of diarrhea on calf gut. J. Dairy Sci. 96:1793-1802. 
Connor, E. E., C. M. Evock-Clover, M. P. Walker, T. H. Elsasser, and S. Kahl. 2015. 
Comparative gut physiology symposium: Comparative physiology of glucagon-like 
peptide-2: Implications and applications for production and health of ruminants. J. Anim. 
Sci. 93:492-501. 
32 
 
Connor, E. E., C. M. Evock-Clover, E. H. Wall, R. L. Baldwin Vi, M. Santin-Duran, T. H. 
Elsasser, and D. M. Bravo. 2016. Glucagon-like peptide-2 and its beneficial effects on 
gut function and health in production animals. Dom. Anim. Endocrinol. 56(Supp):S56-
S65. 
Connor, E. E., E. H. Wall, D. M. Bravo, C. M. Evock-Clover, T. H. Elsasser, R. L. V. Baldwin, 
M. Santín, B. T. Vinyard, S. Kahl, and M. P. Walker. 2017. Reducing gut effects from 
Cryptosporidium parvum infection in dairy calves through prophylactic glucagon-like 
peptide-2 therapy or feeding of an artificial sweetener. J. Dairy Sci. 100:3004-3018. 
Cordier-Bussat, M., C. Bernard, F. Levenez, N. Klages, B. Laser-Ritz, J. Philippe, J.-A. 
Chayvialle, and J.-C. Cuber. 1998. Peptones stimulate both the secretion of the incretin 
hormone glucagon-like peptide-1 and the transcription of the proglucagon gene. Diabetes 
47:1038-1045. 
Curtis, C. R., H. N. Erb, and M. E. White.  1988.  Descriptive epidemiology of calfhood 
morbidity and mortality in New York Holstein herds.  Prev. Vet. Med.  5:293-307.   
de Diego-Cabero, N., A. Mereu, D. Menoyo, J. J. Holst, and I. R. Ipharraguerre. 2015. Bile acid 
mediated effects on gut integrity and performance of early-weaned piglets. BMC Vet. 
Res. 11:111. 
de la Fuente, R., M. Luzón, J. A. Ruiz-Santa-Quiteria, A. Garcı́a, D. Cid, J. A. Orden, S. Garcı́a, 
R. Sanz, and M. Gómez-Bautista. 1999. Cryptosporidium and concurrent infections with 
other major enterophatogens in 1 to 30-day-old diarrheic dairy calves in central Spain. 
Vet. Parasitol. 80:179-185. 
De Rycke, J., S. Bernard, J. Laporte, M. Naciri, M. Popoff, and A. Rodolakis. 1986. Prevalence 
of various enteropathogens in the feces of diarrheic and healthy calves. Pages 159-168 in 
Proc. Ann. Rech. Vét. 
Dhanvantari, S., N. G. Seidah, and P. L. Brubaker.  1996.  Role of prohormone convertases in 
the tissue-specific processing of proglucagon.  Mol. Endocrinol.  10:342-355.   
Drucker, D. J. 1999. Glucagon-like peptide-2. Trends Endocrinol. Metab. 10:153-156. 
Drucker, D. J. 2005. Biological actions and therapeutic potential of the proglucagon-derived 
peptides. Nat. Clin. Pract. Endocrinol. Metab. 1:22-31. 
Drucker, D. J., T. Jin, S. L. Asa, T. A. Young, and P. L. Brubaker.  1994.  Activation of 
proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine 
cell line.  Mol. Endocrinol. 8:1646-1655. 
Drucker, D. J., Q. Shi, A. Crivic, M. Sumner-Smith, W. Tavares, M. Hill, L. DeForest, S. 
Cooper, and P. L. Brubaker. 1997. Regulation of the biological activity of glucagon-like 
peptide-2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol. 15:673-677. 
33 
 
Dube, P. E., C. L. Forse, J. Bahrami, and P. L. Brubaker.  2006.  The essential role of insulin-like 
growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.  J. 
Gastroenterol.   131:589-605.   
Dube, P. E., K. J. Rowland, P. L. Brubaker.  2008. Glucagon-like peptide-2 activates beta-
catenin signaling in the mouse intestinal crypt: role of insulin-like peptide-2 in mice.  J. 
Gastroenterol.   131:589-605.   
Eckert, E., H. E. Brown, K. E. Leslie, T. J. DeVries, and M. A. Steele. 2015. Weaning age 
affects growth, feed intake, gastrointestinal development, and behavior in Holstein calves 
fed an elevated plane of nutrition during the preweaning stage. J. Dairy Sci. 98:6315-
6326. 
Edwards, P. A., H. R. Kast, and A. M. Anisfeld. 2002. BAREing it all: the adoption of LXR and 
FXR and their roles in lipid homeostasis. J. Lipid Res. 43:2-12. 
Eissele, R., R. Goke, S. Willemer, H. P. Harthus, H. Vermeer, R. Arnold, and B. Goke.1992.  
Glucagon-like peptide-1 cells in the gastroninetestinal tract and pancreas of the rat, pig 
and man.  Eur. J. Clin. Invest.  22:283-291. 
Estall, J. L., and D. J. Drucker. 2006. Glucagon-like peptide-2. Annu. Rev. Nutr. 26:391-411. 
Fihn, B. M., A. Sjoqvist, and M. Jodal.  2000.  Permeability of the rat small intestinal epithelium 
along the villus-crypt axis: effects of glucose transport.  J. Gastroenterol. 119:1029-1036.   
Fischer, S., R. Bauerfeind, C.-P. Czerny, and S. Neumann. 2016. Serum interleukin-6 as a 
prognostic marker in neonatal calf diarrhea. J. Dairy Sci. 99:6563-6571.  
Fihn, B. M., A. Sjoqvist, and M. Jodal. 2000. Permeability of the rat small intestinal epithelium 
along the villus–crypt axis: effects of glucose transport. J. Gastroenterol.  119: 1029-
1036. 
Förster, C. 2008. Tight junctions and the modulation of barrier function in disease. Histochem. 
Cell Biol. 130:55-70. 
Foster, D. M. and G. W. Smith. 2009. Pathophysiology of diarrhea in calves. Vet. Clinics N. 
Amer.: Food Anim. Pract. 25:13-36. 
Forsyth C., A. Banan, A. Farhadi, J. Z. Fields, Y. Tang, M. Shaikh, L. J. Zhang, P. A. Engen, and 
A. Keshavarzian.  2007.  Regulation of oxidant-induced intestinal permeability by 
metalloprotease-dependent epidermal growth factor receptor signaling. J. Pharmacol. 
Exp. Ther. 321:84-97.   
Furness, J. B., G. Alex, M. J. Clark, V. V. Lal.  2003.  Morphologies and projections of defined 
classes of neurons in the submucosa of the guinea-pig small intestine.  Anat. Rec. 
272A:475-483.   
34 
 
Furness, J. B., L. R. Rivera, H. J. Cho, D. M. Bravo, and B. Callaghan. 2013. The gut as a 
sensory organ. Nat. Rev. Gastroenterol. Hepatol. 10:729-740. 
Gäbel, G., and J. R. Aschenbach. 2002. Influence of food deprivation on the transport of 3-O-
methyl-alpha-d-glucose across the isolated ruminal epithelium of sheep. J. Anim. Sci. 
80:2740-2746. 
Gallo, R. L., and L. V. Hooper. 2012. Epithelial antimicrobial defence of the skin and intestine. 
Nat. Rev. Immun. 12:503-516. 
Garcı́a, A., J. A. Ruiz-Santa-Quiteria, J. A. Orden, D. Cid, R. Sanz, M. Gómez-Bautista, and R. 
de la Fuente. 2000. Rotavirus and concurrent infections with other enteropathogens in 
neonatal diarrheic dairy calves in Spain. Comp. Immun., Microbiol. Infec. Dis. 23:175-
183. 
Ghanbari R., F. Anwar, K. M. Alkharfy, A.-H. Gilani, and N. Saari. 2012. Valuable nutrients and 
functional bioactives in different parts of olive (Olea europaea L.)-a review. Int. J. Mol. 
Sci. 13: 3291-3340. 
Gilani, S., G. S. Howarth, S. M. Kitessa, C. D. Tran, R. E. A. Forder, and R. J. Hughes. 2017. 
Intestinal permeability induced by lipopolysaccharide and measured by lactulose, 
rhamnose and mannitol sugars in chickens. Animal 11:1147-1179. 
Grober, J., I. Zaghini, H. Fujii, S. A. Jones, S. A. Kliewer, T. M. Willson, T. Ono, and P. 
Besnard. 1999. Identification of a bile acid-responsive element in the human ileal bile 
acid-binding protein gene Involvement of the farnesoid X receptor/9-cis-retinoic acid 
receptor heterodimer. J. Biol. Chem. 274:29749-29754. 
Groos, S., G. Hünefeld, and L. Luciano.  1996.  Parenteral versus enteral nutrition: 
morphological changes in human adult intestinal mucosa.  J. Submicrosc. Cytol. Pathol.  
28:61-74.  
Górka, P., Z. M. Kowalski, P. Pietrzak, A. Kotunia, W. Jagusiak, and R. Zabielski. 2011. Is 
rumen development in newborn calves affected by different liquid feeds and small 
intestine development? J. Dairy Sci. 94:3002-3013. 
Groschwitz, K. R., and S. P. Hogan. 2009. Intestinal barrier function: molecular regulation and 
disease pathogenesis. J. Allergy Clin. Immunol. 124:3-20. 
Guan, X. H. E. Karpen, J. Stephens, J. T. Bukowski, S. Niu, G. Zhang, B. Stoll, M. J. Finegold, 
J. J. Holst, D. Hadsell, B. L. Nichols, D. G. Burrin.  2006.  GLP-2 receptor localizes to 
enteric neurons and endocrine cells expressing vasoactive peptides and mediates 
increased blood flow.  J. Gastroenterol.  130:150-164. 
Guan, X., B. Stoll, X. Lu, K. A. Tappenden, J. J. Holst, B. Hartmann, D. G. Burrin.  2003.  GLP-
2-mediated up-regulation of intestinal blood flow and glucose uptake in nitric oxide-
dependent in TPN-fed piglets 1.  J. Gastroenterol.  125:136-147.   
35 
 
Guilloteau, P., R. Zabielski, and J. W. Blum. 2009. Gastrointestinal tract and digestion in the 
young ruminant: ontogenesis, adaptations, consequences and manipulations. J. Physiol. 
Pharmacol. 60:37-46. 
Gulliksen, S. M., E. Jor, K. I. Lie, I. S. Hamnes, T. Løken, J. Åkerstedt, and O. Østerås. 2009. 
Enteropathogens and risk factors for diarrhea in Norwegian dairy calves. J. Dairy Sci. 
92:5057-5066. 
Hall, E. J. 1999.  Clinical laboratory evaluation of small intestinal function.  Vet. Clin. N. Am.: 
Sm. Ani. Pract. 29: 441-469.   
Hall, E., and R. Batt. 1991. Abnormal permeability precedes the development of a gluten 
sensitive enteropathy in Irish setter dogs. Gut 32:749-753. 
Hampson, D. J. 1986.  Alterations in piglet small intestinal structure at weaning.  Res. Vet. Sci.  
40:32-40. 
Hansen, M. B. 2003. The enteric nervous system II: gastrointestinal functions. Basic Clin. 
Pharmacol. 92:249-257. 
Hartmann, B., M. B. Harr, P. B. Jeppesen, M. Wojdemann, C. F. Deacon, P. B. Mortensen, and 
J. J. Holst.  2000.  In vivo and in vitro degradation of glucagon-like peptide-2 in humans. 
J. Clin. Endocrinol. Metab.  85:2884-2888.   
Heinrichs, A. J., and B. S. Heinrichs. 2011. A prospective study of calf factors affecting first-
lactation and lifetime milk production and age of cows when removed from the herd. J. 
Dairy Sci. 94:336-341. 
Helmrath, M. A., C. R. Erwin, and B. W. Warner.  1997.  A defective EGF-receptor in waved-2 
mice attenuates intestinal adaptation.  J. Surg. Res.  69:76-80. 
Holst, J. J. 2007.  The physiology of glucagon-like peptide 1.  Physiol. Rev.  87:1409-1439.  
Hooper, L. V., and A. J. Macpherson.  2010.  Immune adaptations that maintain homeostasis 
with the intestinal microbiota.  Nat. Rev. Immunol.  10:159-169. 
Hsieh, J., C. Longuet, A. Maida, J. Bahrami, E. Xu, C. L. Baker, P. L. Brubaker, D. J. Drucker, 
and K. Adeli. 2009. Glucagon-like peptide-2 increases intestinal lipid absorption and 
chylomicron production via CD36.  J. Gastroenterol. 137:997-1005.  
Hu, X. F., Y. M. Guo, B. Y. Huang, S. Bun, L. B. Zhang, J. H. Li, D. Liu, F. Y. Long, X. Yang, 
and P. Jiao. 2010. The effect of glucagon-like peptide 2 injection on performance, small 
intestinal morphology, and nutrient transporter expression of stressed broiler chickens. 
Poult. Sci. 89:1967-1974. 
Hu, C. H., K. Xiao, Z. S. Luan, and J. Song. 2013. Early weaning increases intestinal 
permeability, alters expression of cytokine and tight junction proteins, and activates 
mitogen-activated protein kinases in pigs. J. Anim. Sci. 91:1094-1101. 
36 
 
Husband, A. J. 1987. Perspectives in mucosal immunity: A ruminant model. Vet. Immunol. 
Immunopath. 17:357-365. 
Hylemon, P. B., H. Zhou, W. M. Pandak, S. Ren, G. Gil, and P. Dent. 2009. Bile acids as 
regulatory molecules. J. Lipid Res. 50:1509-1520. 
Inagaki, T., M. Choi, A. Moschetta, L. Peng, C. L. Cummins, J. G. McDonald, G. Luo, S. A. 
Jones, B. Goodwin, and J. A. Richardson. 2005. Fibroblast growth factor 15 functions as 
an enterohepatic signal to regulate bile acid homeostasis. Cell Metabol. 2:217-225. 
Inagaki, T., A. Moschetta, Y. K. Lee, L. Peng, G. Zhao, M. Downes, R. T. Yu, J. M. Shelton, J. 
A. Richardson, J. J. Repa, D. J. Mangelsdorf, and S. A. Kliewer. 2006. Regulation of 
antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Nat. 
Acad. Sci. USA 103:3920-3925. 
Inoue, T., J. H. Wang, M. Higashiyama, S. Rudenkyy, K. Higuchi, P. H. Guth, E. Engel, J. D. 
Kaunitz, and Y. Akiba. 2012. Dipeptidyl peptidase IV inhibition potentiates amino acid 
and bile acid-induced bicarbonate secretion in rat duodenum. Am. J. Physiol. 
Gastrointest. Liver Physiol. 303:G810-G816. 
Ipharraguerre, I. R., G. Ted, D. Menoyo, N. de Diego Cabero, J. J. Holst, M. Nofrarías, A. 
Mereu, and D. G. Burrin. 2013. Bile acids induce glucagon-like peptide-2 secretion with 
limited effects on intestinal adaptation in early weaned pigs. J. Nutr. 143:1899-1905. 
Iseri, V. J., and K. C. Klasing.  2013.  Dynamics of the systemic components of the chicken 
(Gallus gallus domesticcus) immune system following activation by Escherichia coli; 
implications for the costs of immunity.  Dev. Comp. Immunol.  40:248-257.   
Iwakiri, D., and D. K. Podolsky. 2001. Keratinocyte growth factor promotes goblet cell 
differentiation through regulation of goblet cell silencer inhibitor. J. Gastroenterol. 
120:1372-1380. 
Iyer, K. R., L. Spitz, and P. Clayton. 1998. New insight into mechanisms of parenteral 
nutrition—Associated cholestasis: Role of plant sterols. J. Ped. Surg. 33:1-6. 
Izzo, M., P. Kirkland, V. Mohler, N. Perkins, A. Gunn, and J. House. 2011. Prevalence of major 
enteric pathogens in Australian dairy calves with diarrhoea. Aust. Vet J. 89:167-173. 
Jain, A. K., B. Stoll, D. G. Burrin, J. J. Holst, and D. D. Moore. 2012. Enteral bile acid treatment 
improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in 
neonatal pigs. Am. J. Physiol. – Gastrointest. Liver Physiol. 302:G218-G224. 
Jenkins, R., and R. Bell. 1987. Molecular radii of probes used in studies of intestinal 
permeability. Gut 28:110-111. 
Johnson, R. and C. E. Hanrahan, 2010. The U.S.-EU beef hormone dispute.  CRS Rep. No. 
R40449.  Accessed Jan 9, 2018.  http://www.fas.org/sgp/crs/row/R40449.pdf.  
37 
 
Katsuma, S., A. Hirasawa, and G. Tsujimoto. 2005. Bile acids promote glucagon-like peptide-1 
secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. 
Res. Commun. 329:386-390. 
Kawamata, Y., R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, S. Fukusumi, Y. Habata, 
T. Itoh, Y. Shintani, S. Hinuma, Y. Fujisawa, and M. Fujino. 2003. A G protein-coupled 
receptor responsive to bile acids. J. Biol. Chem. 278:9435-9440. 
Kelly, D., J. A. Smyth, and K. J. McCracken.  1991.  Digestive development of the early-weaned 
pig. 2. Effect of level of food intake on digestive enzyme activity during the immediate 
post- weaning period.  Br. J. Nutr.  65:181-188. 
Khan, M. A., A. Bach, D. M. Weary, and M. A. G. von Keyserlingk. 2016. Invited review: 
Transitioning from milk to solid feed in dairy heifers. J. Dairy Sci. 99:885-902. 
Khan, M. A., D. M. Weary, and M. A. G. von Keyserlingk. 2011. Invited review: Effects of milk 
ration on solid feed intake, weaning, and performance in dairy heifers. J. Dairy Sci. 
94:1071-1081. 
Kidd, M., I. M. Modlin, B. I. Gustafsson, I. Drozdov, O. Hauso, and R. Pfragner. 2008. Luminal 
regulation of normal and neoplastic human EC cell serotonin release is mediated by bile 
salts, amines, tastants, and olfactants. Am. J. Physiol. – Gastrointest. Liver Physiol. 
295:G260-G272. 
Kim, M. H., J. Yang, S. D. Upadhaya, H. Lee, C. Yun, and J. K. Ha. 2011. The stress of weaning 
influences serum levels of acute-phase proteins, iron-binding proteins, inflammatory 
cytokines, cortisol, and leukocyte subsets in Holstein calves. J. Vet. Sci. 12:151-157. 
Kim, Y. S., and S. B. Ho. 2010. Intestinal goblet cells and mucins in health and disease: recent 
insights and progress. Curr. Gastroenterol. Reports 12:319-330. 
Klein, P., J. Moravcová, T. Kleinová, Z. Volek, and V. Skřivanová.  2007.  Assessment of 
intestinal permeability in preruminant calves by lactulose/mannitol test.  J. Anim. 
Physiol. Anim. Nutr.  16:43-52.   
Klein, P., T. Kleinová, Z. Volek, J. Šimůnek.  2008.  Effect of Cryptosporidium parvum 
infection on the absorptive capacity and paracellular permeability of the small intestine in 
neonatal calves.  Vet. Parasit. 152:53-59. 
Kosek, M., Haque, R., Lima, A., Babji, S., Shrestha, S., Qureshi, S., Amidou, S., Mduma, E., 
Lee, G., Yori, P. P., Guerrant, R. L., Bhutta, Z., Mason, C., Kang, G., Kabir, M., Amour, 
C., Bessong, P., Turab, A., Seidman, J., Olortegui, M. P., Lang, D., Gratz, J., Miller, M. 
and Gottlieb, M. 2013. Fecal markers of intestinal inflammation and permeability 
associated with the subsequent acquisition of linear growth deficits in infants. Am. J. 
Trop. Med. H. 88: 390-396. 
Kunze, W., and J. Furness. 1999. The enteric nervous system and regulation of intestinal 
motility. Ann. Rev. Physiol. 61:117-142. 
38 
 
Larsson, L. I., J. Holst, R. Hakanson, and F. Sundler.  1975.  Distribution and properties of 
glucagon immunoreactivity in the digestive tract of various mammals: An 
immunohistochemical and innunochemical study.  Histochem.  44:281-290.   
Lavoie, B., Balemba,O., Godfrey, C.,Watson, C., Vassileva, G., Corvera, C. U., Nelson, M. T. 
and Mawe, G. M.  2010. Hydrophobic bile salts inhibit gallbladder smooth muscle 
function via stimulation of GPBAR1 receptors and activation of KATP channels. J. 
Physiol. 588:3295-3305. 
Leen, J. L., A. Izzo, C. Upadhyay, K. J. Rowland, P. E. Dube, S. Gu, S. P. Heximer, C. J. 
Rhodes, D. R. Storm, P. K. Lund, and P. L. Brubaker.  2011.  Mechanism of action of 
glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts.  
Endocrinol.  152:436-446.   
Le Huerou-Luron, I., Y. M. Petersen, B. Hartmann, J. J. Holst, and P. T. Sangild.  2002.  
Exogenous GLP-2 has limited effects on weaning-induced intestinal adaptation in piglets.  
J. Gastroenterol. 122:A557 (Abs.).   
Li, J., P. C. Pircher, I. G. Schulman, and S. K. Westin. 2005. Regulation of complement C3 
expression by the bile acid receptor FXR. J. Biol. Chem. 280:7427-7434. 
Liehr, M., A. Mereu, J. J. Pastor, J. C. Quintela, S. Staats, G. Rimbach, and I. R. Ipharraguerre. 
2017. Olive oil bioactives protect pigs against experimentally-induced chronic 
inflammation independently of alterations in gut microbiota. PloS One 12:e0174239. 
Liévin-Le Moal, V. and A. L. Servin. 2006. The front line of enteric host defense against 
unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and 
microbiota. Clin. Microb. Rev. 19:315-337. 
Lovshin, J., and D. J. Drucker. 2000. New frontiers in the biology of GLP-2. Regul. Peptides 
90:27-32. 
Lund, P. K. 1999.  IGFs and the digestive tract.  In: The IGF System: Molecular Biology, 
Physiology, and Clinical Applications, edited by C. T. Roberts and R. G. Rosenfeld.  
Totowa, NJ. Pages 517-544.   
Ma, T., and J. M. Anderson. 2006.  Tight Junctions and the intestinal barrier. In: Johnson, R., 
editor. Textbook of Gastrointestinal Physiology. Burlington, MA: Elsevier Academic 
Press. Pages 1559-1594. 
Madara, J., and J. Stafford. 1989.  Interferon-gamma directly affects barrier function of cultured 
intestinal epithelial monolayers. J. Clin. Invest.  83:724-727.   
Madsen K., S. A. Lewis, M. M. Tavernini, J. Hibbard, and R. N. Fedorak. 1997.  Interleukin 10 
prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits 
chloride secretion. J. Gastroenterol.  113:151-159. 
39 
 
Makishima, M., A. Y. Okamoto, J. J. Repa, H. Tu, R. M. Learned, A. Luk, M. V. Hull, K. D. 
Lustig, D. J. Mangelsdorf, and B. Shan. 1999. Identification of a nuclear receptor for bile 
acids. Science 284:1362-1365. 
Malmuthuge, N., M. Li, L. A. Goonewardene, M. Oba, and L. L. Guan. 2013. Effect of calf 
starter feeding on gut microbial diversity and expression of genes involved in host 
immune responses and tight junctions in dairy calves during weaning transition. J. Dairy 
Sci. 96:3189-3200. 
Margolskee, R. F., J. Dyer, Z. Kokrashvili, K. S. Salmon, E. Ilegems, K. Daly, E. L. Maillet, Y. 
Ninomiya, B. Mosinger, and S. P. Shirazi-Beechey. 2007. T1R3 and gustducin in gut 
sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc. Nat. Acad. Sci. 
USA 104:15075-15080. 
Martindale, R. G., T. M. Enomoto, and M. McCarthy. 2013. Chapter 28 - Nutritional and 
Metabolic Therapy A2 - Hemmings, Hugh C. Pages 487-502 in Pharmacology and 
Physiology for Anesthesia. T. D. Egan, ed. W.B. Saunders, Philadelphia. 
Maruyama, T., Y. Miyamoto, T. Nakamura, Y. Tamai, H. Okada, E. Sugiyama, T. Nakamura, H. 
Itadani, and K. Tanaka. 2002. Identification of membrane-type receptor for bile acids (M-
BAR). Biochem. Biophys. Res. Comm. 298:714-719. 
McCauley, R. D., K. A. Heel, K. J. Christiansen, and J. C. Hall.  1996.  The effect of minimum 
luminal nutrition on bacterial translocation and atrophy of the jejunum during parenteral 
nutrition.  J. Gastroenterol. Hepatol.  11:65-70. 
McOrist, S., and E. Corona-Barrera. 2015. Intestinal diseases in pigs. Pages 51-69 in Intestinal 
Health–Key to Maximise Growth Performance in Livestock. T. Niewold, ed. 
Wageningen Acadmeic Publishers, Wageningen, the Netherlands. 
Meale, S. J., L. N. Leal, J. Martín-Tereso, and M. A. Steele. 2015. Delayed weaning of Holstein 
bull calves fed an elevated plane of nutrition impacts feed intake, growth and potential 
markers of gastrointestinal development. Anim. Feed Sci. Tech. 209:268-273. 
Menzies, I., R. Pounder, S. Heyer, M. Laker, J. Bull, P. Wheeler, and B. Creamer. 1979. 
Abnormal intestinal permeability to sugars in villous atrophy. Lancet 314:1107-1109. 
Moeser, A. J., C. V. Klok, K. A. Ryan, J. G. Wooten, D. Little, V. L. Cook, and A. T. Blikslager. 
2007. Stress signaling pathways activated by weaning mediate intestinal dysfunction in 
the pig. Am. J. Physiol.-Gastrointest. Liver Physiol. 292:G173-G181. 
Mojsov S Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF.  1986. Preproglucagon gene 
expression in pancreas and intestine diversifies at the level of post-translational 
processing. J Biol. Chem. 261:11880-9. 
Morgan, L., R. Elliott, J. Tredger, J. Nightingale, and V. Marks. 1993. GLP-1 secretion in 
response to nutrients in man. Digestion 54: 374-376. 
40 
 
Morisset, J. 1993. Regulation and growth and development of the gastrointestinal tract. J. Dairy. 
Sci. 76:2080-2093. 
Munroe, D. G., A. K. Gupta, F. Kooshesh, T. B. Vyas, G. Rizkalla, H. Wang, L. Demchyshyn, Z. 
J. Yang, R. K. Kamboj, H. Chen, K. McCallum, M. Sumner-Smith, D. J. Drucker, and A. 
Crivici.  1999.  Prototypic G protein-coupled receptor for the intestinotrophic factor 
glucagon-like peptide 2.  Proc. Natl. Acad. Sci. USA. 96:1569-1573.   
NAHMS (National Animal Health Monitoring System).  2011.  Dairy, 2011, Part I: Reference of 
Dairy Cattle Health and Management Practices in the United States, 2011.  Pub. 
N480.1007. US Department of Agriculture: Animal and Plant Health Inspection Service: 
Veterinary Services (USDA:APHIS:VS), Centers for Epidemiology and Animal Health 
(CEAH), Fort Collins, CO.  
Nejdfors, P., M. Ekelund, B. Jeppsson, and B. R. Westrom. 2000. Mucosal in vitro permeability 
in the intestinal tract of the pig, the rat, and man: species- and region-related differences. 
Scand. J. Gastroenterol. 35:501-507. 
Niewold, T. 2015. General introduction- the gastrointestinal tract, the immune system and the 
maintenance of health. Pages 15-20 in Intestinal Health–Key to Maximise Growth 
Performance in Livestock. T. Niewold, ed. Wageningen Acadmeic Publishers, 
Wageningen, The Netherlands. 
Niewold, T. 2015. Intestinal health biomarkers in vivo. Pages 219-228 in Intestinal Health–Key 
to Maximise Growth Performance in Livestock. T. Niewold, ed. Wageningen Acadmeic 
Publishers, Wageningen, The Netherlands. 
Novak U., A.Wilks, G. Buell, and S. McEwen. 1987. Identical mRNA for pre-proglucagon in 
pancreas and gut. Eur. J. Biochem. 164:553-8. 
Nusrat A., J. R. Turner, and J. L. Madara. 2000.  Molecular physiology and pathophysiology of 
tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, 
cytokines, and immune cells. Am. J. Physiol. Gastrointest. Liver Physiol.  279:G851-
G857. 
Ørskov, C., B. Hartmann, S. S. Poulsen, J. Thulesen, K. J. Hare, and J. J. Holst.  2005.  GLP-2 
stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 
receptors.  Regul. Peptides.  124:105-112.   
Ørskov, C., J. J. Holst, S. Knuhtsen, F. G. Baldissera, S. S. Poulsen, and O. V. Nielsen. 1986. 
Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are 
secreted separately from pig small intestine but not pancreas. Endocrinol. 119:1467-1475. 
Papasouliotis, K., T. Gruffydd-Jones, A. Sparkes, P. Cripps, and W. Millard. 1993. Lactulose 
and mannitol as probe markers for in vivo assessment of passive intestinal permeability 
in healthy cats. Am. J. Vet. Res. 54:840-844. 
41 
 
Parker, H. E., K.Wallis, C. W. LeRoux, K. Y. Wong, F. Reimann, and F. M.  Gribble. 2012.  
Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion.  
Br. J. Pharmacol. 165:414-423. 
Penner, G. B., J. R. Aschenbach, K. Wood, M. E. Walpole, R. Kanafany-Guzman, S. Hendrick, 
and J. Campbell. 2014. Characterising barrier function among regions of the 
gastrointestinal tract in Holstein steers. Anim. Prod. Sci.  54:1282-1287. 
Pereira, A. P., I. C. Ferreira, F. Marcelino, P. Valentão, P. B. Andrade, R. Seabra, L. Estevinho, 
A. Bento, and J. A. Pereira. 2007. Phenolic compounds and antimicrobial activity of olive 
(Olea europaea L. Cv. Cobrançosa) leaves. Molecules 12:1153-1162.   
Petersen, Y. M., D. G. Burrin, and P. T. Sangild. 2001. GLP-2 has differential effects on small 
intestine growth and function in fetal and neonatal pigs. American J. Physiol. – Reg. 
Integrat. Comp. Physiol. 281:R1986-R1993. 
Petersen, Y. M., B. Hartmann, J. J. Holst, I. Le Huerou-Luron, C. R. Bjørnvad, and P. T. Sangild.  
2003.  Introduction of enteral food increases plasma GLP-2 and decreases GLP-2 
receptor mRNA abundance during pig development.  J. Nutr.  133:1781-1786.   
Peterson, L. W., and D. Artis. 2014. Intestinal epithelial cells: regulators of barrier function and 
immune homeostasis. Nat. Rev. Immunol. 14:141-153. 
Pié, S., J. Lallès, F. Blazy, J. Laffitte, B. Sève, and I. Oswald. 2004. Weaning is associated with 
an upregulation of expression of inflammatory cytokines in the intestine of piglets. J. 
Nutr. 134:641-647. 
Piegholdt, S., K. Pallauf, T. Esatbeyoglu, N. Speck, K. Reiss, L. Ruddigkeit, A. Stocker, P. 
Huebbe, and G. Rimbach. 2014. Biochanin A and prunetin improve epithelial barrier 
function in intestinal CaCo-2 cells via downregulation of ERK, NF-κB, and tyrosine 
phosphorylation. Free Radical Biol. Med. 70:255-264. 
Rafferty, E. P., A. R. Wylie, C. T. Elliott, O. P. Chevallier, D. J. Grieve, and B. D. Green. 2011. 
In vitro and in vivo effects of natural putative secretagogues of glucagon-like peptide-1 
(GLP-1). Scientia pharmaceutica 79:615-621. 
Rask, E., T. Olsson, S. Soderberg, O. Johnson, J. Secki, J. J. Holst, and B. Ahren. 2001. Impaired 
incretin response after a mixed meal is asociated with insulin resistance in nondiabetic 
men. Diabetes Care 24: 1640-1645. 
Refsdal, A. O. 2000. To treat or not to treat: a proper use of hormones and antibiotics. Anim. 
Reprod. Sci. 60-61:109-119.   
Reinecker, H., M. Steffen, C. Doehn, J. Petersen, I. Pfluger, A. Voss, and A. Raedler. 1991.  
Proinflammatory cytokines in intestinal mucosa. Immunol. Res.  10:247-248. 
Rincon, M. 2012.  Interleukin-6: From an inflammatory marker to a target for inflammatory 
diseases.  Trends Immunol.  33:571-577.   
42 
 
Rosa, F., S. Busato, F. C. Avaroma, K. Linville, E. Trevisi, J. S. Osorio, M. Bionaz.  2018.  
Transcriptional changes detected in fecal RNA of neonatal dairy calves undergoing a 
milk diarrhea are associated with inflammatory biomarkers.  PLoS One 13:e0191599 
Rothenberg, M. E., C. D. Eilertson, K. Klein, Y. Zhou, I. Lindberg, J. K. McDonald, R. B. 
Mackin, and B. D. Noe. 1995. Processing of mouse proglucagon by recombinant 
prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro. J. Biol. 
Chem. 270: 10 136 - 10 146. 
Rouille, Y., S. Martin, and D.F. Steiner. 1995. Differential processing of proglucagon by the 
subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or 
glucagon-like peptide. J. Biol. Chem. 270:488-496. 
Rowland, K. J., and P. L. Brubaker. 2011. The “cryptic” mechanism of action of glucagon-like 
peptide-2. Am. J. Physiol. Gastrointest. Liver Physiol. 301:G1-G8. 
Roy, P. M., A. Bradley, J. C. Kennedy, and T. Y. Ma.  2006.  Mechanism of interferon-gamma 
(IFN-gamma) induced increase in intestinal epithelial tight junction permeability: Cross-
talk between PI-3 kinase and NF-kappa by pathways. J. Gastroenterol. 130:A695.  
Sanchez-Quesada C., A. Lopez-Biedma, F. Warleta, M. Campos, G. Beltran, and J. J. Gaforio. 
2013. Bioactive properties of the main triterpenes found in olives, virgin olive oil, and 
leaves of Olea europaea. J. Agric. Food Chem. 61:12173-12182 
Sato, H., C. Genet, A. Strehle, C. Thomas, A. Lobstein, A. Wagner, C. Mioskowski, J. Auwerx, 
and R. Saladin.  2007.  Anti-hyperglycemic activity of TGR5 agonist isolated from Olea 
europaea.  Biochem. Biophys. Res. Commun.  362:793-798. 
Schroder K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004.  Interferon-gamma: an overview of 
signals, mechanisms and functions. J. Leukoc. Biol.  75:163-189.  
Sears, C. L. 2000. Molecular physiology and pathophysiology of tight junctions V. assault of the 
tight junction by enteric pathogens. Am. J.Physiol.-Gastrointest. Liver Physiol. 
279:G1129-G1134. 
Shaikh, M., K. Rajan, C. B. Forsyth, R. M. Voigt and A. Keshavarzian 2015. Simultaneous gas-
chromatographic urinary measurement of sugar probes to assess intestinal permeability: 
use of time course analysis to optimize its use to assess regional gut permeability. Clin. 
Chim. Acta 442:24-32. 
Shen, L., and J. R. Turner. 2006.  Role of epithelial cells in initiation and propagation of 
intestinal inflammation. Eliminating the static: tight junction dynamics exposed. Am. J. 
Physiol. Gastrointest. Liver Physiol. 290:G577-G582. 
Shin, E. D., J. L. Estall, A. Izzo, D. J. Drucker, and P. L. Brubaker.  2005.  Mucosal adaptation to 
enteral nutreints is dependent on the physiologic actions of glucagon-like peptide-2 in 
mice.  J. Gastroenterol. 128:1340-1353.   
43 
 
Shirazi-Beechey, S. P., K. Daly, M. Al-Rammahi, A. W. Moran, and D. Bravo. 2014. Role of 
nutrient-sensing taste 1 receptor (T1R) family members in gastrointestinal chemosensing. 
Br. J. Nutr. 111:S8-S15. 
Shirazi-Beechey, S., A. Moran, D. Batchelor, K. Daly, and M. Al-Rammahi. 2011. Glucose 
sensing and signaling; regulation of intestinal glucose transport. Proc. Nutr. Soc. 70:185-
193. 
Sigalet, D. L. 2012. The role of glucagon like peptide-2 in controlling intestinal function in 
human infants: Regulator or bystander? J. Anim. Sci. 90:1224-1232. 
Sigalet, D. L., E. de Heuvel, L. Wallace, E. Bulloch, J. Turner, P. Nation, P. R. Wizzard, B. 
Hartmann, M. Assad, and J. J. Holst. 2014. Effects of chronic glucagon-like peptide-2 
therapy during weaning in neonatal pigs. Regul. Peptides 188:70-80. 
Sigalet, D. L., L. E. Wallace, J. J. Holst, G. R. Martin, T. Kaji, H. Tanaka, and K. A. Sharkey.  
2007.  Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like 
peptide 2.  Am. J. Physiol. Gastrointest.  Liver Physiol. 293:G211-G221.   
Sjolund, K., G. Sanden, R. Hakanson, and F. Sundler. 1983. Endocrine cells in human intestine: 
An immunocytochemical study. J. Gastroenterol.  85:1120-1130. 
Soberon, F., E. Raffrenato, R. W. Everett, and M. E. Van Amburgh. 2012. Preweaning milk 
replacer intake and effects on long-term productivity of dairy calves. J. Dairy Sci. 
95:783-793. 
Soberon, F., and M. E. V. Amburgh. 2013. The effect of nutrient intake from milk of milk 
replacer of preweaned dairy calves on lactation milk yield as adults: a meta-analysis of 
current data. J. Anim. Sci. 91:706-712. 
Song, M., and J. A. Kellum. 2005.  Interleukin-6. Crit. Care Med.  33:S463-S465.  
Steele, M. A., G. B. Penner, F. Chaucheyras-Durand, and L. L. Guan. 2016. Development and 
physiology of the rumen and the lower gut: Targets for improving gut health. J. Dairy 
Sci. 99:4955-4966. 
Sun, X., H. Yang, K. Nose, S. Nose, E. Q. Haxhija, H. Koga, Y. Feng, D. H. Teitelbaum. 2008.  
Decline in intestinal mucosal IL-10 expression and decreased intestinal barrier function 
in a mouse model of total parenteral nutrition. Am. J. Physiol. Gastrointest. Liver 
Physiol. 294:G139-G147.  
Svensson, C., A. Linder, and S.-O. Olsson.  2006.  Mortality in Swedish dairy calves and 
replacement heifers.  J. Dairy Sci.  89:4769-4777.   
Tavares, W., D. J. Drucker, and P. L. Brubaker.  2000.  Enzymatic- and renal-dependent 
catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats.  Am. J. 
Physiol. Endocrinol. Metab.  278:E134-139. 
44 
 
Taylor-Edwards, C., D. Burrin, J. Matthews, K. McLeod, J. J. Holst, and D. Harmon. 2010. 
Expression of mRNA for proglucagon and glucagon-like peptide-2 (GLP-2) receptor in 
the ruminant gastrointestinal tract and the influence of energy intake. Dom. Anim. 
Endocrinol. 39:181-193. 
Taylor-Edwards, C. C., D. G. Burrin, J. J. Holst, K. R. McLeod, and D. L. Harmon. 2011. 
Glucagon-like peptide-2 (GLP-2) increases small intestinal blood flow and mucosal 
growth in ruminating calves. J. Dairy Sci. 94:888-898. 
Taylor-Edwards, C. C., D. G. Burrin, N. B. Kristensen, J. J. Holst, K. R. McLeod, and D. L. 
Harmon. 2012. Glucagon-like peptide-2 (GLP-2) increases net amino acid utilization by 
the portal drained viscera of ruminating calves. Animal 6:1985-1997. 
Taylor-Edwards, C. C., D. B. Edwards, M. J. Doig, E. S. Vanzant, K. R. McLeod, J. A. Boling, J. 
C. Matthews, and D. L. Harmon. 2008. Proglucagon and GLP-2 receptor mRNA 
distribution in the ruminant gastrointestinal tract. J. Anim. Sci. 86 (E-Suppl. 2):428. 
(Abstr.) 
Tazuke, Y., R. A. Drongowski, D. H. Teitelbaum, and A. G. Coran. 2003.  Interleukin-6 changes 
tight junction permeability and intracellular phospholipid content in a human enterocyte 
cell culture model. Pediatr. Surg. Int.  19:321-325. 
Thomas, C., A. Gioiello, L. Noriega, A. Strehle, J. Oury, G. Rizzo, A. Macchiarulo, H. 
Yamamoto, C. Mataki, M. Pruzanski, R. Pellicciari, J. Auwerx, and K. Schoonjans. 2009. 
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis. Cell Metab. 10:167-
177. 
Thymann T, I. Le Huërou-Luron, Y. M. Petersen, M. S. Hedemann, J. Elinf, B. B. Jensen, J. J. 
Holst, B. Hartmann, and P. T. Sangild. 2014.  Glucagon-like peptide 2 treatment may 
improve intestinal adaptation during weaning. J. Anim. Sci.  92:2070-2079. 
Travis, S., and I. Menzies. 1992. Intestinal permeability: functional assessment and significance. 
Clin. Sci. 82:471-488. 
Tsai, C. H., M. Hill, S. L. Asa, P. L. Brubaker, D. J. Drucker.  1997.  Intestinal growth-
promoting properties of glucagon-like peptide-2 in mice.  Am. J. Physiol. 273:E77-84.   
Turner, J. R. 2009. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 
9:799-809. 
Uhde, F. L., T. Kaufmann, H. Sager, S. Albini, R. Zanoni, E. Schelling, and M. Meylan. 2008. 
Prevalence of four enteropathogens in the faeces of young diarrhoeic dairy calves in 
Switzerland. Vet. Rec. 163:362-366. 
Uil, J. J., R. M. Van Elburg, F. M. Van Overbeek, C. J. J. Mulder, G. P. Vanberge-Henegouwen, 
and H. S. Heymans.  1996.  Clinical implications of the sugar absorption test: Intestinal 
permeability test to assess mucosal barrier function.  Scand. J. Gastroenterol.  Supp. 
233:70-78.   
45 
 
Van Italie, C. M., and J. M. Anderson.  2006.  Claudines and epithelial paracellular transport.  
Annu. Rev. Physiol.  68:403-429.   
Veterinary Feed Directive (VFD).  2015.  United States Food and Drug Administration.  
Accessed Jan 16, 2018.  https://www.fda.gov/AnimalVeterinary/DevelopmentApproval 
Process/ucm071807.htm 
Visioli, F., and C. Galli. 2002. Biological properties of olive oil phytochemicals. Crit. Rev. Food 
Sci. Nutr. 42:209-221. 
Walker, M. P., C. M. Evock-Clover, T. H. Elsasser, and E. E. Connor. 2015. Short 
communication: Glucagon-like peptide-2 and coccidiosis alter tight junction gene 
expression in the gastrointestinal tract of dairy calves. J. Dairy Sci. 98:3432-3437. 
Walsh, N. A., B. Yusta, M. P. DaCambra, Y. Anini, D. J. Drucker, and P. L. Brubaker.  2003.  
Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa.  Endocrinol.  
144:4385-4392.   
Waltner-Toews, D., S. Martin, and A. Meek. 1986. Dairy calf management, morbidity and 
mortality in Ontario Holstein herds. II. Age and seasonal patterns. Prev. Vet. Med. 4:125-
135. 
Watson C., C. J. Hoare, D. R. Garrod, G. L. Carlson, and G. Warhurst. 2005.  Interferon-gamma 
selectively increases epithelial permeability to large molecules by activating different 
populations of paracellular pores. J. Cell Sci.  118:5221-5230. 
Wijtten, P. J. A., J. van der Meulen, and M. W. A. Verstegen. 2011. Intestinal barrier function 
and absorption in pigs after weaning: A review. Br. J. Nutr. 105:967-981. 
Windeyer, M. C., K. E. Leslie, S. M. Godden, D. C. Hodgins, K. D. Lissemore, and S. J. 
LeBlanc. 2014. Factors associated with morbidity, mortality, and growth of dairy heifer 
calves up to 3 months of age. Prev. Vet. Med. 113:231-240. 
Windisch, W., K. Schedle, C. Plitzner, and A. Kroismayr. 2008. Use of phytogenic products as 
feed additives for swine and poultry. J. Anim. Sci. 86 (Suppl):E140-E148. 
Wood, K. M., S. I. Palmer, M. A. Steele, J. A. Metcalf, and G. B. Penner. 2015. The influence of 
age and weaning on permeability of the gastrointestinal tract in Holstein bull calves. J. 
Dairy Sci. 98:7226-7237. 
Xiao, Q., R. P. Boushey, D. J. Drucker, and P. L. Brubaker. 1999. Secretion of the intestinotropic 
hormone glucagon-like peptide-2 is differentially regulated by nutrients in humans. J. 
Gastroenterol.  117:99-105. 
Yang H., I. Kiristioglu, Y. Fan, B. Forbush, D. K. Bishop, P. A. Antony, H. Zhou, and D. H. 
Teitelbaum. 2002.  Interferon-gamma expression by intraepithelial lymphocytes results in 
a loss of epithelial barrier function in a mouse model of total parenteral nutrition. Ann. 
Surg. 236:226-234.    
46 
 
Yu, C., G. Jia, Y. Jiang, Q. Deng, Z. Chen, Z. Xu, X. Chen, and K. Wang. 2014. Effect of 
glucagon-like peptide 2 on tight junction in jejunal epithelium of weaned pigs though 
MAPK signaling pathway. As.-Austral. J. Anim. Sci. 27:733-742. 
Yusta, B., J. Estall, and D. J. Drucker.  2002.  Glucagon-like peptide-2 receptor activation 
engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and 
prevents apoptosis following inhibition of phosphatidylinositol 3-kinase.  J. Biol. Chem. 
277:24896-24906.   
Yusta, B., D. Holland, J. A. Koehler, M. Maziarz, J. L. Estall, R. Higgins, and D. J. Drucker. 
2009. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. 
J. Gastroenterol. 137:986-996. 
Yusta, B., L. Huang, D. Munroe, G. Wolff, R. Fantaske, S. Sharma, L. Demchyshyn, S. L. Asa, 
and D. J. Drucker. 2000. Enteroendocrine localization of GLP-2 receptor expression in 
humans and rodents. J. Gastroenterol. 119:744-755. 
Yusta, B., R. Somwar, F. Wang, D. Munroe, S. Grinstein, A. Klip, and D. J. Drucker. 1999. 
Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby 
hamster kidney fibroblasts expressing the rat GLP-2 receptor. J. Biol. Chem. 274:30459-
30467. 
Zhang, S., J. Aschenbach, D. Barreda, and G. Penner. 2013. Recovery of absorptive function of 
the reticulo-rumen and total tract barrier function in beef cattle after short-term feed 
restriction. J. Anim. Sci. 91:1696-1706. 
 
 
 
 
 
 
47 
 
CHAPTER 3.  INTAKE AND GROWTH IN TRANSPORTED DAIRY CALVES 
CLASSIFIED AS DIARRHEIC OR HEALTHY WITHIN THE FIRST 21 D AFTER 
ARRIVAL 
INTRODUCTION 
Intestinal disorders are common in newborn calves.  Several reports have estimated 
morbidity and treatment on dairy farms over the last several decades.  Curtis et al. (1988) 
estimated the incidence rate of diarrhea on New York Holstein herds to be 9.9 per 100 calves 
during the first 14 d and 5.2 per 100 calves from 15 to 90 d.  The median age of diarrhea was 6 d 
for the first 14 d of life and 30 d for 15 to 90 d of age period.  One report from Norway indicated 
a relatively low diarrheic incidence with only 4.7% of the samples being classified as diarrheic 
over the two year study (Gulliksen et al., 2009).  Meanwhile, a Dutch study observed a 
prevalence of diarrhea of 19.1% in calves under 22 d (Bartels et al., 2010).  In this study the 
percentage of calves (51.6%) with non-normal feces, which was classified as ‘custard-like’ feces 
or diarrhea, was highest in the second week compared to the first and third weeks of life (Bartels 
et al., 2010).  In Ontario herds the greatest risk for treatment for diarrhea was observed at 10 d of 
age (Waltner-Towes et al., 1986; Windeyer et al., 2014) with 23% of calves treated for diarrhea 
(Windeyer et al., 2014).  In the United States the most recent estimate was reported in a survey 
conducted in 2011, which showed approximately 25.3% of preweaned heifers had diarrhea and 
that diarrhea or other digestive problems accounted for 31% of the preweaning heifer mortality 
(NAHMS, 2011).  Furthermore, of the preweaning heifers that had digestive disorders 71.8% 
were treated with an antibiotic during this period (NAHMS, 2011).   
These estimates show that neonatal diarrhea is a very prevalent and reoccurring issue 
within calf management systems in the United States and the world.  Neonatal diarrhea is 
frequently observed from 3 to 21 d of age, but its onset and duration is determined by the number 
of pathogens involved and the immune condition of the animal (Butler and Clark, 1994). The 
major pathogens that have been identified as contributing to enteric challenge in calves during 
the preweaning period include Escherichia coli K99 (E. coli), Rotavirus, Coronavirus, 
Salmonella spp., and Cryptosporidium parvum (Izzo et al., 2011; Cho and Yoon, 2014). In a 
Spanish study the detection rate of E. coli, Rotavirus, Coronavirus and C. parvum was 11.9, 41.9, 
7.3, and 52.3% of samples (García et al., 2000) while a Swiss study estimated prevalence in 
diarrheic calves of 6, 59, 8, and 55% (Uhde et al., 2008), respectively.  The presence of enteric 
48 
 
pathogens in feces does not directly indicate the cause of diarrhea; however, there has been 
evidence to show a strong association between the two (De Rycke et al., 1986; García et al., 
2000).  Additionally, it is often observed that two or more enteropathogens can be detected at the 
same time, with C. parvum and Rotavirus being the most prevalent combination (de la Fuente et 
al., 1999; García et al., 2000).   
Many of the estimates for diarrhea in dairy calves are generated by visual observation of 
the feces and of the calf by either personnel working with the calves on a daily basis or by a herd 
veterinarian (Curtis et al., 1988; Gulliksen et al., 2009; Bartels et al., 2010; Windeyer et al., 
2014).  Other studies identify farms or individual calves with reported incidences of diarrhea to 
take fecal samples as a way to characterize incidence of different enteric pathogens (de la Fuente 
et al., 1999; García et al., 2000; Izzo et al., 2011).  Many of these reports have tried to 
characterize the incidence and major pathogens present across many farms in a larger region or 
country.  While visual observation of the feces is the most easily identifiable symptom of 
diarrhea it does not always directly indicate an infection of an enteric pathogen, which can be a 
limitation.  However, a scoring system can be used to rank the severity of diarrhea by identifying 
feces that are normal or abnormal with a set definition for each score.   A study conducted by 
Araujo et al. (2015) classified calves as diarrheic when calves presented an elevated fecal score 
for greater than or equal to three consecutive days.   
Health of calves has been connected to longevity, with calves that have been treated with 
antibiotics having decreased lifetime milk production (Soberon et al., 2012).  Moreover, the 
number of days that calves are sick in the first 4 mo of life has been shown to have negative 
effects on first-lactation 305-d ME and actual milk, protein, and fat production (Heinrichs and 
Heinrichs, 2011).  Increased plane of nutrition during the preweaning period is linked to 
improved potential lifetime production (Soberon et al., 2012; Soberon and Van Amburgh, 2013).  
As a result, strategies that can improve health and maximize growth in the preweaning period 
should improve production potential and longevity of replacement animals.  Therefore, the 
objectives of this experiment were to determine how the intake and growth of calves that are 
afflicted with diarrhea in the first 21 d after arrival compares to calves that remained healthy.   
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MATERIALS AND METHODS 
 The database was developed from 4 experiments completed at the University of Illinois 
(Urbana) between the Fall of 2013 and Fall of 2017 (Table 3.1).  Individual calf experimental 
data were obtained from Microsoft Excel (Microsoft Corp., Redmond, WA) files from each 
experiment.  Information for inclusion included experiments that recorded daily intakes of milk 
replacer (MR), free water (FW), electrolyte solution (EC), and starter intakes, as well as weekly 
body weight and growth measures.  A total of 313 (253 male and 60 female) Holstein dairy 
calves were included in the analyses.  Calves were enrolled within the first week of life.  At 
arrival to the research facility or selection at a local dairy farm, blood samples were taken from 
the jugular vein into 10-mL evacuated serum separation tubes (Becton Dickenson, Rutherford, 
NJ).  Blood was centrifuged at 1300 × g for 15 min and a refractometer was used to determine 
total protein (TP) concentration in the serum.  All calves were vaccinated based on normal 
facility protocols.    
Calf Housing 
 Calves were housed in south-facing individual hutches (Calf-tel, Hampel Corp., 
Germantown, WI) placed approximately 1.5 m apart.  Hutches were placed on a base of crushed 
rock, covered by landscape cloth and a layer of straw.  Straw was checked daily and more added 
as needed.  Temperature and humidity were determined using data from the local weather station 
(www.wunderground.com/history/). 
Feeding and Management 
 Calves were fed milk replacer (MR) twice daily at 0500 h and 1630 h at a rate and 
composition specific to each experimental protocol (Table 3.1).  The intake of MR was recorded 
daily.  Water was offered for ad libitum consumption for the duration of the trial and intake was 
recorded daily.  Starter was offered for ad libitum consumption for the duration of the trials and 
intake was recorded daily in three of the experiments.  One study (Study 2) did not offer starter 
during the first 21 d so data for starter intake was not included in the dataset.  Weekly means for 
individual calves were used in the database, calculated from daily intakes.  Total consumption 
for the 21 d after arrival for all variables was calculated for each calf.   
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Health 
 Health checks were performed daily.  Fecal scores were assigned on a 1 to 4 scale: 1 – 
normal and well formed; 2 = soft but still holds form; 3 = loose without form; and 4 = 
consistency of water.  Calves were considered to have diarrhea if they had a fecal score above 2.  
Overall appearance and behavior were also recorded.  After arrival rectal temperature was 
measured daily for 3 d and then at any time when a calf showed signs of illness throughout the 
duration of the study.  Navels were dipped in a navel solution as needed until dry. Animals were 
monitored multiple times daily for illness and dehydration status and treated as needed.  Flunixin 
meglumine (Phoenix Pharmaceutical, Inc., St. Joseph, MO) was administered to calves with a 
rectal temperature of 40˚C or above.  Medication was considered to be both an antibiotic and 
treatment with Flunixin meglumine.  An EC was administered as needed and amount consumed 
was recorded.  The amount of EC offered and the number of times per day offered were based on 
hydration status of the calf and amount of MR consumed.  The EC was offered first from a 
bottle; however, if the calf did not drink and required additional fluids to maintain hydration 
status the calf was force-fed the EC through an esophageal tube feeder.  The oversight and 
management decisions for the administration of medication and EC was determined by a single 
person within each study.   
Classification of Health Status 
Calves with a fecal score of > 2 for ≥ consecutive 3 d (Araujo et al., 2015) over the first 
21 d of each study were retrospectively classified as diarrheic (DIA; n = 96) while the remainder 
were retrospectively classified as healthy (HEA; n = 217).  Study 1 included 57 calves with 39 
classified as DIA and 18 classified as HEA.  Study 2 included 105 calves with 26 classified as 
DIA and 79 classified as HEA.  Study 3 included 63 calves with 7 classified as DIA and 56 
classified as HEA.  Study 4 included 88 calves with 24 classified as DIA and 64 classified as 
HEA. 
Statistical Analysis 
 Data were analyzed using PROC GLIMMIX of SAS version 9.4 (SAS Institute Inc., 
Cary, NC). Calf was the experimental unit.  For Gaussian data the model of variance analysis 
included classification, time as a repeated measure (when appropriate), and their interaction as 
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fixed effects.  Experiment was included as a random effect in all models (St-Pierre, 2001).  
Environmental temperature was included in the model as a covariate when statistically 
significant (P < 0.10).  For body weight and growth measures, initial measurements on day of 
arrival were used as a covariate to analyze data of each respective variable.  The model of 
variance analysis for total cumulative intakes included classification as a fixed effect, experiment 
as a random effect, and environmental temperature as a covariate when significant (P < 0.10).  
Binary data (refusal of milk replacer, occurrence of diarrhea, or administration of electrolyte) 
were analyzed with a binomial distribution with a logit link function and a model that included 
classification and time as repeated measures and their interaction as fixed effects.  Experiment 
was included as a random effect.  Count data (days refused milk replacer, days with diarrhea, and 
days given electrolytes) were analyzed with a negative binomial distribution using a log link 
function with the fixed effect of classification.  Experiment was included as a random effect.  
The corrected Akaike information criterion was used to select the best covariate structure in all 
models. Residuals were checked for homogeneity of variance and normality assumptions by 
residual plots and extended Levene test. Heterogeneous variances were handled by implementing 
error structures that allow for heterogeneous variances (Littell et al., 2006). Significance was 
declared at P ≤ 0.05 and trends discussed when 0.05 < P ≤ 0.10.  Results were separated using 
Tukey adjustment. 
RESULTS AND DISCUSSION 
 Enteric challenges in dairy calves continue to be one of the main health issues facing calf 
production today.  As expected with the objective of the analysis, the likelihood of elevated fecal 
score (fecal score > 2 for ≥ 3 d; Arajo et al., 2015) occurrence was greater for calves classified as 
DIA during the first 21 d of the experiments with calves being 5.86 (OR) times more likely to 
have elevated fecal score than HEA calves (P < 0.0001; Table 3.2).  Furthermore, the number of 
days that calves had an elevated fecal score in the first 21 d of the experiments was fewer for 
HEA calves compared to DIA calves (1.88 vs. 6.90 ± 1.19 d; P < 0.0001; Table 3.3). Specific 
identification of pathogens was not conducted in these experiments to determine the cause of 
elevated fecal score, but several common enteric pathogens are implicated in calf diarrhea and 
likely contributed to disease in these experiments (Cho and Yoon, 2014).  The timing of 
infection ranges from a few days after birth to 1 to 2 wk old or beyond, but several pathogens 
affect calves around 1 to 2 wk old (Cho and Yoon, 2014; Foster and Smith, 2009).  Figure 3.1 
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shows the number of calves by study on the day in which they were first classified as diarrheic.  
While the incidence of diarrhea, as classified in this dataset, between studies was quite variable 
the average overall for the calves included in this analysis was similar to a report from the United 
States indicating that 25.3% of preweaned heifers experience diarrhea (NAHMS, 2011).   
In these experiments the exact age relative to birth of the calves was unknown and the 
timing of calves first being classified as DIA was varied across the studies.  Calves from study 1 
had the highest number of calves classified as DIA (68%) and the majority of these calves were 
classified as DIA within the first 5 d after arrival.  These calves were estimated to be slightly 
older, however still under 1 wk old, than the other studies due to their origin.  Additionally, these 
calves had been transported the longest (5 h transport time and 470 km) and were purchased 
from a dealer who had collected calves from multiple farms and comingled the calves before 
transport to the research facility.  The calves from the other studies were sourced from a single 
local farm, within 2 to 3 days of birth, and selected by the research personnel based on initial 
total protein and visual health assessment for inclusion onto each study.  Those calves were 
transported only 30 min and 38 km to the research facility.  The number of calves classified as 
DIA in these studies was much less than study 1, ranging from 11.1% to 27.3%.  In general, 
there were lower incidences of being classified as diarrheic on the initial day after arrival of 
studies 2, 3, and 4, but over the course of the 21 d there were increased incidence from d 10 to 
15.  While the protocols for care were similar between studies, the incidence, timing, and 
duration of diarrheic episodes in calves was varied.  The stressors (comingling, transportation) 
that calves in study one faced were likely greater than the other studies which may have impaired 
their ability to cope as well with enteric challenge (Davis and Drackley, 1998).   
Total protein is often used on farms to evaluate passive immunity as an alternative to the 
gold standard that quantifies IgG1 by radial immunodiffusion (Tyler et al., 1996; McGuirk, 
2011).  It has been well established that failure of passive transfer is associated with increased 
mortality rates (Donovan et al., 1998; Tyler et al., 1998, 1999).  There were no differences in 
initial TP between classifications and values were above the recommended cutoff of 5.5 g/dL 
(McGuirk, 2011; P = 0.20; Table 3.4).  One experiment found that total protein was not a 
significant risk factor for diarrhea in the preweaning period (Donovan et al., 1998).  There are 
mixed results within the literature on the effect of successful passive transfer and reductions in 
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diarrhea in preruminant calves.  Several studies have observed no effect (McEwan et al., 1970; 
Caldow et al., 1988; Harp et al., 1989; Meganck et al., 2015), whereas other studies have shown 
a reduction in the incidence and severity of diarrhea (Boyd et al., 1974; Naylor et al., 1977; 
Fallon et al., 1987; Lora et al., 2018) related to measures of adequate passive transfer.  There are 
some indications that the type of enteropathogen, calf management, or environment may 
predispose calves to enteric challenge in the preweaning period.   
Seasonal effects have been implicated in predisposing calves to increased enteric 
morbidity.  Calves born in the winter had higher incidences of diarrhea than calves born in the 
summer (Waltner-Towes et al., 1986; Curtis et al., 1988).  Addtionally, calves born in the fall 
were more likely to have diarrhea compared to calves born in the spring or summer (Windeyer et 
al., 2014).  In our experiment, average ambient environmental temperature in the first 21 d after 
arrival was significantly greater for calves classified as DIA compared to HEA (13.4 vs 17.1 ± 
0.6; P = 0.0005; Table 3.4).   
Infections, both clinical and subclinical, in domestic food animals results in animals that 
eat less, grow more slowly, and are less efficient at converting feed to body tissue (Johnson, 
1998).  In this dataset, there were significant classification by time interactions for starter, milk 
replacer, and total dry matter intake over the course of the 21 d after arrival (Figure 3.2).  
Cumulative milk replacer intake was significantly decreased for calves classified as DIA 
compared to HEA (15.9 vs 16.6 ± 0.6 kg; P = 0.06; Table 3.4).  This was likely due to calves 
being more likely to refuse milk replacer when DIA compared to calves who were HEA (OR 
2.77; P < 0.0001; Table 3.2).  Reduction in feed intake in sick animals is mediated through 
inflammatory cytokines and is thought to be a protective mechanism in the short term (Johnson, 
1998; Dantzer, 2006).  It is recommended that calves should continue to be offered, and consume 
at least part of their normal milk or milk replacer throughout enteric challenges as it aids in 
recovery (Garthwaite et al., 1994; Quigley et al., 2006; McGuirk, 2011).  However, intake of 
milk replacer solids was still significantly reduced in DIA relative to HEA calves.  Additionally, 
cumulative starter dry matter intake was decreased for DIA versus HEA calves (0.9 vs 1.5 ± 0.5 
kg; P < 0.0001; Table 3.4).  As a result, cumulative total dry matter intake was significantly 
decreased for calves classified as DIA versus HEA (17.9 vs 16.8 ± 1.1 kg; P = 0.002).  
Promotion of early consumption of starter intake is critical for rumen development and function 
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in the preruminant calf (Drackley, 2008).  Depressed growth rates and risk of disease have been 
associated with reduced dry feed intake preweaning so maximizing milk intake early in calves’ 
lives is critical for continued growth (Khan et al., 2011; Steele et al., 2016).    
Diarrhea results in major water and electrolyte losses from the body through the feces 
(Davis and Drackley, 1998).  The reduced solids intake from milk replacer also resulted in a 
reduction in the cumulative water consumed from MR for DIA calves compared to HEA calves 
(104.0 vs 108.1 ± 3.4 L; P = 0.03; Table 3.4) in the first 21 d after arrival, as well as reductions 
within week compared to HEA calves (Table 3.5).  A significant classification by time 
interaction for water from milk replacer over the 21 d after arrival (Figure 3.3) indicated 
reductions in water intake from MR for calves classified as DIA.  There were no differences 
within week for FW intake or cumulative FW intake (Table 3.5).  A significant classification by 
time interaction over the course of the 21 d after arrival occurred because of numeric increases in 
FW intake for calves classified as DIA and tendencies for intake to be higher on d 3, 6, and 7 
(Figure 3.3).  Calves that were DIA were more likely to receive electrolytes (OR 394.39; P < 
0.0001; Table 3.2) and had greater days given electrolytes compared to HEA (0.22 vs. 2.05 ± 
1.34 d; P < 0.0001; Table 3.3).  There was a significant classification by time interaction with the 
general trend of greater consumption of electrolytes for calves classified as DIA over the course 
of the 21 d after arrival (Figure 3.3).  Overall, the total cumulative intake of electrolytes was 
increased in DIA calves compared to HEA calves (4.2 vs. 0.5 ± 0.4 L; P < 0.0001; Table 3.4) 
and within each week DIA calves consumed more electrolytes than HEA calves (P < 0.05; Table 
3.5).  Electrolytes are not recommended as a replacement for normal water consumed through 
milk, milk replacer, or ad libitum water, but are required as an additional source of fluids to 
correct dehydration (McGuirk, 2011).  Ultimately, there were no differences within week for 
total water intake (P > 0.05; Table 3.5). Similarly, no differences between classifications were 
found in cumulative total water intake.  Taken together, this indicates that with the reductions in 
water intake from milk or milk replacer and increased excretion of water in the feces (indicated 
by elevated fecal score), supplemental electrolyte solution is crucial to maintain overall water 
intake and electrolyte balance during enteric challenges in calves.   
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Water is the most important nutrient and must be consumed in the largest amount relative 
to all other nutrients (Murphy, 1992; Drackley, 2008).  It is recommended to provide free water 
access to calves soon after birth, in addition to the water consumed in milk or milk replacer 
(Drackley, 2008).  In our study, it is important to note that calves were not restricted in the 
amount of FW available to them in these experiments.  As a result the total water intake was not 
different.  If FW had been restricted the DIA calves might not have been able to maintain total 
water consumption, which could have resulted in a more severe imbalance in water and 
electrolytes.   Although hydration status was not measured in these experiments, other than 
visual assessment by the calf personnel, it may be interesting to evaluate in future experiments as 
an indicator of how changes in water intake may be influencing overall hydration status and how 
calves may be self regulating their water balance when challenged with enteric disease.   
In a survey of operations in the U. S. in the average age that water was first offered was 
6.6 ± 1.3 d with a range of 4.1 to 10.6 for operations classified as large or small, respectively 
(NAHMS, 2011).  However, it is important to provide water earlier to dairy calves as they 
increase the amount of free water they drink after both colostrum intake and transportation 
(Kertz et al., 1984; Thickett et al., 1981).  Soon after arrival all calves averaged approximately 
1.5 L/d of free water intake within the first week of age.  It is important to note that there are 
very few reported data on water intake in young calves.  In general the reported values averaged 
less than 2 L/d for the first 3 wk and then increased with starter intake and weaning (Kertz et al., 
1984; Thickett et al., 1981).  A more recent experiment compared water intake at two feeding 
levels, which were similar between milk replacer feeding levels and increased in response to 
starter intake (Quigley et al., 2006).  On the opposite spectrum, more recent work has reported 
water intake in calves given ad libitum access to milk (Hepola et al., 2008; de Passillé et al., 
2011).  The current version of the NRC (2001) suggests that water intake ranges from 1 L/d in 
the first week to 2.5 L/d by wk 4.  In the current dataset a range of 1.5 to 3 L/d was observed in 
calves under 3 weeks of age.   
Enteric disease is associated with reduced weight gain.  Actions of viruses, bacteria, and 
protozoa vary by species type and location within the intestine.  Damaged intestinal epithelium 
can cause prolonged malnutrition and reduced growth rates in affected calves due to 
malabsorption and fermentation of undigested milk in the intestinal lumen (Cho and Yoon, 
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2014).  Body weight and growth measures are shown in Table 3.6.  Initial BW did not differ 
between classifications (P = 0.49).  There was a classification by time interaction for BW over 
the course of the 21 d after arrival to the research facility with HEA calves being heavier 
compared to DIA (50.8 vs. 48.7 ± 0.5 kg; P = 0.0002).  Consequently, there was a tendency for 
HEA calves to have higher ADG compared to DIA (669 vs 491 ± 1.1 g/d; P = 0.07).  
Furthermore, there were significant classification by time interaction for hip height and heart 
girth (P < 0.008).  Body weight and growth measures are shown by week in Table 3.7.  There 
were differences between classifications for all variables except withers height ADG.  Health 
status, including diarrhea, has previously been shown to have a significant negative effect on 
growth during the first 6 mo of life (Donovan et al., 1998). There was a significant effect of 
classification on gain:feed for both milk replacer intake and total dry matter intake, with DIA 
calves being less efficient compared to HEA (Table 3.6).  The overall trend indicated that HEA 
calves were heavier and larger compared to DIA calves within 21 d of arrival.  Increased 
preweaning ADG has been positively linked to first-lactation milk yield (Soberon et al., 2012).  
Additionally, health of calves has been connected to longevity, with calves that have been treated 
with antibiotics having decreased lifetime milk production (Soberon et al., 2012).  Moreover, the 
number of days that calves are sick in the first 4 mo of life has been shown to have negative 
effects on first-lactation 305-d ME and actual milk, protein, and fat production (Heinrichs and 
Heinrichs, 2011).  
CONCLUSIONS 
 Our data emphasize the continued prevalence and impact of enteric disease on 
preweaning dairy calves.  Young calves with diarrhea have reductions in feed intake, reduced 
body weight gain, and reduced efficiency.  Serum total protein was not a good predictor for 
calves developing diarrhea after arrival.  Of note, our data highlights the differences in water 
intake from different sources provided to the preruminant calf.  It is critical to provide diarrheic 
calves with supplemental electrolytes in addition to normal milk or milk replacer intake, and ad 
libitum free water intake to help maintain fluid balance and overall total water intake.  
Understanding the deficit that diarrheic calves experience relative to their healthy counterparts is 
important in determining methods to minimize the severity and economic impact of this disease 
on calves within modern farm operations.   
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TABLES AND FIGURES 
Table 3.1. Experiments from which data were used in a pooled analysis to examine association of health of dairy calves with intake 
and growth in the first 21 d of arrival at research facility. 
Experiment Description Reference 
1 53 female Holstein calves receiving 1 of 3 treatments.  Calves were fed a commercial 28% 
protein and 15% fat milk replacer reconstituted to 15% solids.  Calves were fed at a 
feeding rate of 500 g/d from d 1-2, 750 g/d from d 3-7, and 1,000 g/d from d 8 to 21.  
Calves were fed starter for ad libitum intake.    
Morrison et al. (2017a) 
2 104 male Holstein calves receiving 1 of 5 milk replacer treatments.  Calves were fed a 
22% protein and 20% fat milk replacer reconstituted to 12.5% solids.  Calves were fed at a 
rate of 10% of BW per d from d 1-2, 12% of BW per d from d 3-7, and 14% of BW per d 
from d 8-21.  No starter was fed in the first 21 d.   
Morrison et al. (2017b) 
3 64 male Holstein calves receiving 1 of 4 treatments.  Calves were fed 28% protein and 
20% fat milk replacers at a rate of 500 g/d from d 1-2, 700 g/d from d 3-7, and 900 g/d 
from d 8 to 21.  The milk replacers were reconstituted to 13% solids.  Calves were fed 
starter for ad libitum intake.    
LaPierre (2016) 
4 88 male Holstein calves receiving 1 of 2 treatments.  Calves were fed a commercial 28% 
protein and 15% fat milk replacer at a feeding rate of 500 g/d from d 1-2, 750 g/d from 3-
7, 1,000 g/d from d 8 to 21.  The milk replacer was reconstituted to 15% solids.  Calves 
were fed starter for ad libitum intake.    
Morrison (2018) 
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Table 3.2. The logistic model for elevated fecal score, milk replacer refused, and electrolyte occurrence by comparison of dairy calves 
classified as healthy or diarrheic (fecal score > 2 for ≥ 3 consecutive days) in the first 21 d after arrival at research facility. 
Variable Comparison Coefficient SEM Odds ratio 95% CI P-Value 
Fecal score1 > 2 occurence 
Diarrheic- 
Healthy2 1.7962 0.08 5.86 4.99-6.88 <0.0001 
Milk replacer refused occurrence  
Diarrheic- 
Healthy2 1.0174 0.12 2.77 2.21-3.46 <0.0001 
Electrolyte occurrence 
Diarrheic- 
Healthy2 5.9773 0.33 394.39 205.53-756.77 <0.0001 
1 Fecal scores were assigned on a 1 to 4 scale: 1 – normal and well formed; 2 = soft but still holds form; 3 = loose without form; and 4 
= consistency of water. 
2The OR indicates the probability of an event occurring for the first classification in the comparison to the second classification. If the 
OR is greater than one the first classification in the comparison is more likely to have either diarrhea or be medicated then the second 
classification by a factor of the difference above one.  If the OR is less than one the first classification has a lower probability of 
occurring then the second classification.  
 
 
 
 
 
Table 3.3. The logistic model for days of elevated fecal score, milk replacer refused, and electrolyte administration by comparison of 
dairy calves classified as healthy or diarrheic (fecal score > 2 for ≥ 3 consecutive days) in the first 21 d after arrival at research facility. 
 Classification   
Variable Healthy Diarrheic SE P-Value 
Fecal score1 > 2, d 1.88 6.84 1.19 <0.0001 
Milk replacer refused, d 1.20 2.59 1.64 0.0001 
Electrolytes, d 0.22 2.05 1.34 <0.0001 
1 Fecal scores were assigned on a 1 to 4 scale: 1 – normal and well formed; 2 = soft but still holds form; 3 = loose without form; and 4 
= consistency of water. 
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Table 3.4.  Initial concentration of total protein in serum (g/dL), average ambient environmental temperature, and total cumulative 
intakes of free water, electrolyte, milk replacer water intake, and total water intake (L/d) by dairy calves classified as healthy or 
diarrheic (fecal score > 2 for ≥ 3 consecutive days) in the first 21 d after arrival at research facility.  
 Classification  P-values 
Variable Healthy Diarrheic SE Trt 
Initial serum total protein, g/dL 5.9 6.0 0.3 0.20 
Average environmental temperature, °C 13.4 17.1 0.6 0.0005 
Free water intake, L 43.9 47.9 6.5 0.26 
Electrolyte intake, L 0.5 4.2 0.4 <0.0001 
Milk replacer water intake, L 108.1 104.0 3.4 0.03 
Total water intake, L 151.1 154.0 10.9 0.50 
Starter dry matter intake, kg 1.5 0.9 0.5 <0.001 
Milk replacer dry matter intake, kg 16.6 15.9 0.6 0.02 
Total dry matter intake, kg 17.9 16.8 1.1 0.002 
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Table 3.5.  Cumulative intakes of free water, electrolyte, milk replacer water, and total water (L/d) by week for dairy calves classified 
as healthy or diarrheic (fecal score > 2 for ≥ 3 consecutive days) in the first 21 d after arrival at research facility.  
  Classification P-values 
Variable Week Healthy Diarrheic Trt 
Free water intake, L 1 13.8 15.8 0.12 
 2 14.0 13.8 0.84 
 3 15.7 16.2 0.75 
Electrolyte intake, L 1 0.22 1.30 <0.0001 
 2 0.03 1.55 <0.0001 
 3 0.22 1.34 <0.0001 
Milk replacer water intake, L 1 29.5 28.8 0.06 
 2 39.2 37.1 0.005 
 3 40.4 37.9 0.004 
Total water intake, L 1 43.4 45.0 0.28 
 2 53.0 51.4 0.34 
 3 55.7 54.3 0.42 
Starter dry matter intake, kg 1 0.25 0.14 0.004 
 2 0.42 0.19 <0.0001 
 3 0.83 0.32 <0.0001 
Milk replacer dry matter intake, kg 1 4.5 4.4 0.12 
 2 6.0 5.8 0.03 
 3 6.2 5.9 0.02 
Total dry matter intake, kg 1 4.8 4.6 0.02 
 2 6.3 5.9 0.003 
 3 6.9 6.2 <0.0001 
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Table 3.6.  Body weight and growth measures of dairy calves classified as healthy or diarrheic (fecal score > 2 for ≥ 3 consecutive 
days) in the first 21 d after arrival at research facility.  
 Classification  P-values 
Variable Healthy Diarrheic SE Trt Time Trt × Time 
Initial BW, kg 42.0 41.6 0.5 0.49 - - 
Body weight, kg 50.8 48.7 0.5 <0.0001 <0.0001 0.0002 
  ADG, g/d 669 491 119 <0.0001 <0.0001 0.07 
Final BW, kg 56.0 52.6 2.0 <0.0001 - - 
Gain: feed (milk replacer intake), g/g  0.83 0.59 0.08 <0.0001 0.005 0.13 
Gain:feed (total dry matter intake), g/g  0.77 0.56 0.08 <0.0001 0.0003 0.14 
Withers height, cm 80.7 80.4 0.3 0.13 <0.0001 0.18 
  ADG, cm/d 0.18 0.17 0.03 0.29 0.0001 0.17 
Hip height, cm 84.8 84.1 0.1 0.002 <0.0001 0.002 
  ADG, cm/d 0.20 0.16 0.03 0.008 <0.0001 0.04 
Heart girth, cm 83.8 82.8 0.2 <0.0001 <0.0001 0.008 
  ADG, cm/d 0.34 0.26 0.04 <0.0001 0.02 0.14 
Body length, cm 77.9 77.0 0.4 0.009 <0.0001 0.37 
  ADG, cm/d 0.30 0.27 0.03 0.31 <0.0001 0.003 
Hip width, cm 22.4 22.1 0.2 0.0002 <0.0001 0.12 
  ADG, cm/d 0.07 0.05 0.01 0.002 0.0004 0.39 
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Table 3.7.  Body weight and growth measures by week for dairy calves classified as healthy or diarrheic (fecal score > 2 for ≥ 3 
consecutive days) in the first 21 d after arrival at research facility.  
  Classification P-values 
Variable Week Healthy Diarrheic Trt 
BW, kg 1 46.2 44.8 <0.0001 
 2 50.7 48.8 <0.0001 
 3 55.5 52.4 <0.0001 
ADG, g/d 1 599 378 <0.0001 
 2 714 619 0.03 
 3 695 477 <0.0001 
Gain: feed, g/g milk replacer intake 1 0.89 0.57 <0.0001 
 2 0.81 0.68 0.01 
 3 0.77 0.52 <0.0001 
Gain:feed, g/g total dry matter intake 1 0.83 0.54 <0.0001 
 2 0.77 0.66 0.02 
 3 0.70 0.48 <0.0001 
Withers height, cm 1 79.3 79.4 0.89 
 2 80.6 80.3 0.19 
 3 82.2 81.6 0.02 
Withers height ADG, cm/d 1 0.11 0.14 0.34 
 2 0.20 0.16 0.30 
 3 0.23 0.19 0.26 
Hip height, cm 1 83.0 82.9 0.63 
 2 84.7 84.0 0.02 
 3 86.6 85.3 <0.0001 
Hip height ADG, cm/d 1 0.07 0.10 0.46 
 2 0.26 0.18 0.07 
 3 0.27 0.19 0.03 
Heart girth, cm 1 81.4 80.7 0.006 
 2 83.8 82.9 0.001 
 3 86.3 84.7 <0.0001 
Heart girth ADG, cm/d 1 0.31 0.23 0.02 
 2 0.36 0.33 0.10 
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Table 3.7 (Cont.)     
 3 0.36 0.22 0.0001 
Body length, cm 1 75.6 74.4 0.002 
 2 77.7 77.1 0.13 
 3 80.2 79.6 0.14 
Body length ADG, cm/d 1 0.25 0.05 0.001 
 2 0.30 0.38 0.20 
 3 0.35 0.38 0.71 
Hip width, cm 1 21.8 21.7 0.15 
 2 22.5 22.2 0.0008 
 3 22.9 22.5 <0.0001 
Hip width ADG, cm/d 1 0.05 0.02 0.03 
 2 0.10 0.08 0.25 
 3 0.06 0.05 0.52 
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Figure 3.1. Day of study when dairy calves were first classified as diarrheic (fecal score > 2 for 
≥ 3 consecutive days) in the first 21 d after arrival of four experiments included in the dataset.   
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a)                                   b) 
  
c)        
 
Figure 3.2. Starter (a), milk replacer (b), and total dry matter intake (c; g/d) by dairy calves 
classified as healthy (solid line) or diarrheic (dashed line; fecal score > 2 for ≥ 3 consecutive 
days) in the first 21 d after arrival at research facility. Error bars represent SE of the least squares 
means.  Time points with asterisks (*) differ (P ≤ 0.05, Tukey adjusted).  Time points with cross 
(†) differ (0.05 < P ≤ 0.10, Tukey adjusted). 
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a)                 b) 
  
     c)               d) 
  
Figure 3.3. Free water (a), electrolyte water (b), milk replacer water (c), and total water intake 
(d; L/d) by dairy calves classified as healthy (solid line) or diarrheic (dashed line; fecal score > 2 
for ≥ 3 consecutive days) in the first 21 d after arrival at research facility. Error bars represent SE 
of the least squares means.  Time points with asterisks (*) differ (P ≤ 0.05, Tukey adjusted).  
Time points with cross (†) differ (0.05 < P ≤ 0.10, Tukey adjusted).  
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ABSTRACT 
Glucagon-like peptide 2 (GLP-2) is a peptide released by the lower gut that has potent 
trophic and restorative effects on the intestinal epithelium. Two experiments were conducted to 
assess the effects of feeding rate and either metabolizable or nonmetabolizable glucose 
supplementation on GLP-2 concentrations in plasma and intestinal development in Holstein 
calves. In the first experiment, 48 newborn calves were assigned to 12 treatments (n = 4) 
corresponding to the factorial combination of 4 milk feeding amounts [1.75, 1.32, 0.88, and 
0.44% of body weight (BW) as dry matter (DM)] and 3 oral supplementation treatments (non-
supplemented, glucose-supplemented, and 3-O-methyl glucose-supplemented). In the second 
experiment 30 newborn calves (n = 10) were fed milk at a fixed rate of 1.75% of BW as DM and 
assigned to the same glucose supplementation treatments used in experiment 1 to investigate 
effects on intestinal development. In the first experiment, we found a saturating response of 
plasma GLP-2 to increasing feeding levels. The feeding rate at which 50% of the maximal GLP-
2 release occurred was estimated to be 0.53% of BW as DM or 30.3% of the maximum feeding 
rate (1.75% of BW as DM), whereas maximal secretion was estimated to be about 98.6 pmol/L. 
In turn, feeding 75, 50, or 25% of the maximal feeding rate (i.e., 1.75% BW as DM) resulted in 
plasma GLP-2 concentrations 87, 72, and 49% of that in fully fed calves, respectively. Neither 
metabolizable nor non-metabolizable glucose supplementation affected GLP-2 secretion and no 
interaction with feed intake level was detected. In the second experiment, no effect of glucose 
supplementation was observed on intestinal growth, mucosal cell proliferation, or expression of 
genes related to the actions of GLP-2. Nonetheless, we observed that a pool of genes of the GLP-
2 signaling pathway was more abundantly and coordinately regulated in the colon than in the 
ileum of these animals, indicating an opportunity for dietary induction of the peptide in this 
organ. In conclusion, during this experiment, plasma GLP-2 concentrations responded in a 
diminishing return fashion to milk intake but not to glucose supplementation, even at milk 
consumption levels of only 0.4% of BW as DM. 
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INTRODUCTION 
Glucagon-like peptide 2 (GLP-2) is an intestinally secreted peptide with trophic and 
regenerative properties for the intestinal epithelium (Burrin et al., 2000). Genes involved in the 
GLP-2 pathway are expressed along the gastrointestinal tract of ruminants (Connor et al., 2010), 
and the GLP-2 receptor appears to be fully operative as greater epithelial development and blood 
flow have been recorded in response to therapeutic application of exogenous GLP-2 in ruminants 
(TaylorEdwards et al., 2011; Connor et al., 2013). This peptide is known to induce proliferation 
of crypt cells, reduce mucosal apoptosis, decrease intestinal barrier permeability, and dampen 
inflammation in the gut (Drucker et al., 1996; Burrin et al., 2003; Drucker, 2005). These 
properties make it a potential target to maintain or enhance intestinal integrity in newborn milk-
fed calves.  
Secretion of GLP-2 is largely driven by luminal delivery of nutrients (Burrin et al., 2000), 
and its secretion has been augmented in response to greater energy intake in steers (Taylor-
Edwards et al., 2010). In addition to whole-feed intake, specific nutrients such as glucose might 
stimulate GLP-2 (Brubaker and Anini, 2003; Shirazi-Beechey et al., 2011). Infusing the 
duodenum of weaned sheep with glucose for 4 d increased its rate of transport 40- to 80-fold 
above that in control animals (Shirazi-Beechey et al., 1991), which may have been caused by an 
increase in GLP-2 secretion elicited through activation of the sweet taste receptor located in the 
gut (Shirazi-Beechey et al., 2011).  
Whereas a positive effect of increased energy intake and glucose infusion on GLP-2 
secretion and intestinal function has been observed in ruminants (ShiraziBeechey et al., 1991; 
Taylor-Edwards et al., 2010), no information is available on such responses in newborn milk-fed 
calves. However, knowledge regarding the effect of milk intake on endogenous GLP-2 secretion 
could be useful to identify when calves under usual farming circumstances (e.g., diarrhea 
episodes, restricted milk feeding) can benefit from exogenous GLP-2 administration or 
application of certain feed additive strategies with therapeutic potential that could be easier to 
implement under commercial schemes of animal production (Connor et al., 2015; de Diego-
Cabero et al., 2015). Understanding the GLP-2 response to the enteral supply of nutrients in 
milk-fed calves, however, precludes the determination of the milk intake range in which GLP-2 
secretion could be stimulated by nonpharmacological means (i.e., dietary interventions). 
Furthermore, addressing whether glucose supplementation can affect circulating GLP-2 
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concentrations when calves are fed variable amounts of milk will be useful to assess its potential 
to support intestinal integrity. Finally, given the absence of data in calves, this information will 
also be relevant to consider effect sizes, inter-calf variability, and adequate sample sizes in future 
research on GLP-2 with newborn calves where variation in food intake is to be considered.  
The specific set of hypotheses tested in this work were that (1) feeding rate affects GLP-2 
secretion in young calves; (2) the effect of metabolizable and nonmetabolizable glucose (i.e., 3-
O-methyl glucose, 3-O-M-G) on GLP-2 secretion depends on the feed intake level; and (3) 
supplementation with glucose or a nonmetabolizable glucose analog can effect organ size, 
epithelial morphometric dimensions, and proliferation compared with nonsupplemented calves 
and that this effect may differ between the small and large intestine. The aim of this work was to 
characterize the response of GLP-2 secretion to a range of feed intake amounts resembling the 
anorexic variation between intestinally healthy and diarrhea-ill calves, and to test the effect of 
metabolizable and nonmetabolizable glucose supplementation on GLP-2 secretion and intestinal 
development measures. 
MATERIALS AND METHODS 
Two experiments were conducted. In the first, we assessed the effect of feeding rate, 
glucose or 3-O-MG supplementation, and their interaction on plasma GLP-2 concentrations. In 
the second experiment, we investigated the effect of glucose or 3-O-M-G supplementation on 
epithelial cell proliferation, histological measures, and mRNA expression of genes related to the 
GLP-2 signaling pathway and intestinal development and function. 
Experiment 1 
All procedures were conducted with approval of the University of Illinois Institutional 
Animal Care and Use Committee (Urbana, IL). Forty-eight newborn male Holstein calves, 4 to 5 
d old, were purchased and transported to the University of Illinois Nutrition Field Laboratory 
research site. Calves were selected at a local farm in east-central Illinois. At time of selection, 
blood samples were taken from the jugular vein into a 10-mL evacuated serum separation tube 
(Becton Dickinson, Rutherford, NJ). Blood was centrifuged at 1,300 × g for 15 min, and a 
refractometer was used to determine total protein in the serum for all potential calves. Calves 
were selected based on total protein and visual health assessment and were identified with ear 
tags. All calves selected were given 2 mg of Se plus 100 mg of vitamin E (BO-SE, Merck 
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Animal Health, Kenilworth, NJ), 1 mL of vitamins A and D (Sparhawk Laboratories Inc., 
Lenexa, KS), and 2 mL of a nasal vaccine against bovine respiratory syncytial virus (Inforce 3, 
Pfizer, New York, NY). If a calf was chosen for the trial and had a total protein of <5.5 g/dL, the 
calf was given 50 mL of antiserum (Bovisera, Colorado Serum Co., Denver, CO) and 20 mL of 
clostridial C and D antitoxin (Boehringer Ingelheim, Ridgefield, CT). Calves were housed in 
individual calf hutches with straw bedding to contain pathogen shedding and provide comfort, 
respectively. Upon arrival, calves were weighed. Complete blocks of calves were made based 
upon BW at arrival and, within each block, the 12 treatments were randomly assigned (n = 4). In 
both experiments, calves were fed a commercial milk replacer (Excelerate, Milk Specialties 
Global, Eden Prairie, MN), which contained, on average, 28.4% CP, 44% lactose, and 15.8% fat 
on a DM basis. 
Treatment Allotment.  Experiment 1 included 12 treatments from a factorial combination of 2 
factors: feeding rate and supplement treatment. Feeding rate comprised 4 levels: 25, 50, 75, and 
100% of a standard feeding level of 1.75% of BW as DM on experimental d 6 and 7. In turn, 
supplement treatments were (1) control (commercial milk replacer without supplementation), (2) 
commercial milk replacer plus glucose (220 mg/kg of BW daily), and (3) commercial milk 
replacer plus 3-O-M-G (6 mg/kg of BW daily).  
Dose of glucose was based on a published study (Shirazi-Beechey et al., 1991) where 
activity of the sodium-glucose co-transporter 1 (SGLT1) in adult sheep (not fed milk) infused 
with 1.5 L/d of 30 mM d-glucose solutions achieved a 40- to 80-fold increase in the rate of 
glucose transport. One and a half liters of a 30 mM glucose solution provides about 8.1 g of 
glucose per day. Based on this research, we dosed ~10 g/calf daily. However, we must also 
account for the intake of hexose (i.e., 1 mol of glucose + 1 mol of galactose) from lactose in 
milk. For a 40-kg calf, with milk replacer DMI ranging from 0.44 or 1.75% of BW, glucose-
equivalent hexose intake is estimated to range from 77 to 310 g/d. Therefore, glucose-equivalent 
intake in the present study was approximately 9 to 38 times higher than that achieved in mature 
sheep by Shirazi-Beechey et al. (1991). Although inferring glucose doses from mature ruminants 
to elicit signaling in preruminant newborns might be inadequate given the different 
developmental stages, the lack of information on this subject with newborn calves forced us to 
use available information from sheep.  
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 The 3-O-M-G has been used previously at doses of approximately 0.16 g per kg of BW/d 
in sheep to upregulate SGLT1 activity (Shirazi-Beechey et al., 1991), and at ~1.1 g per kg of 
BW/d in mice to increase glucose-dependent insulinotropic peptide (GIP) and GLP-1 secretion 
(Moriya et al., 2009). We set a dose of 6 mg/kg of BW daily to supply ~300 mg/d for a 50-kg 
calf.   
 The adaptation and treatment periods were as follows. From d 1 to 5, calves were adapted 
to the milk replacer diet and housing conditions. Milk replacers were reconstituted to 12.5% 
solids and fed in 2 meals per day. Calves were fed milk replacer at a daily rate of 1.25% of BW 
(DM basis) for the first 2 d. During d 3 to 5, the amount of milk replacer was increased to 1.5% 
of BW. On d 6 and 7, calves were fed according to the experimental feeding rates described 
above (25, 50, 75, or 100% of the standard rate of 1.75% of BW as DM). On d 8, experimental 
measurements took place. Supplemental glucose treatments were introduced on d 6. Briefly, 
blood samples (10 mL) were taken from the jugular vein at −15, 15, 30, 60, 90, and 240 min 
relative to feeding time for measurement of GLP-2 concentrations in plasma. Supplemental 
glucose was mixed with the milk replacer. After 240 min, the experimental procedure ended and 
standard feeding resumed at a rate of 1.75% of BW as DM for all calves. 
 Before sample collection on d 8, calves were brought inside and tied in stalls. Calves 
were clipped on the neck around the jugular area to ease location of the vein for needle insertion. 
Blood samples were collected by jugular venipuncture using 18-gauge hypodermic disposable 
needles (3.8 cm long). Blood samples were collected into 10-mL tubes containing EDTA 
(Becton Dickinson) plus a pyrrolic acid-based dipeptidyl peptidase 4 inhibitor (catalog # DPP4, 
Millipore, St. Charles, MO). Samples were kept on ice for 15 min after collection and then 
centrifuged at room temperature for 15 min at 2,500 × g. The plasma was extracted and frozen at 
−20°C until further analyses. All plasma samples (700 μL) were extracted in a final 
concentration of 75% ethanol before GLP-2 measurements, as previously described (Taylor-
Edwards et al., 2011). Intact GLP-2 was measured using a radioimmunoassay previously 
described (Hartmann et al., 2000). Briefly, the antiserum (code no. 92160, developed as 
described in Wøjdemann et al., 1998) is directed against the N terminus of GLP- 2 and therefore 
measures only fully processed GLP-2 of intestinal origin. For standards, we used recombinant 
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human GLP-2 and the tracer was 125I-labeled rat GLP- 2 with an Asp33→Tyr33 substitution. 
The sensitivity was 2 pmol/L and intraassay coefficient of variation was <6%. 
Statistical Analysis. To test the hypothesis that plasma GLP-2 plasma concentration is affected 
by milk replacer feeding rate, glucose supplementation, or their interaction, secretion response 
data were analyzed as follows. Plasma GLP-2 concentrations visually appeared to follow a 
saturating pattern in response to feeding rate (Figure 4.1, left panel), albeit with seemingly large 
variation among calves within each feeding rate group. Therefore, we evaluated 4 possible 
contrasting models: a constant model: [GLP-2] = constant, where average plasma GLP-2 does 
not vary with feeding rate; a linear model: [GLP-2] = a + b × x, where average plasma GLP-2 
increases linearly with feeding rate; an exponential asymptotic model: [GLP-2] =  × (1 −
 𝑒−𝑏×𝐹𝑒𝑒𝑑𝑖𝑛𝑔 𝑅𝑎𝑡𝑒 , and a Michaelis-Menten model: [𝐺𝐿𝑃 − 2] =  [𝑎
1 +
𝑏
𝑥
⁄ ] , where average 
plasma GLP-2 increases in a saturating manner. In all cases, errors were assumed to follow a 
normal distribution with constant variance [𝑁𝐼𝐼𝐷(0, 𝜎2)]. The 4 models were compared based 
on Akaike information criteria (AIC) and Bayesian information criteria (BIC), which indicate 
the likelihood of observing the data given a particular model and include a penalty for an 
increasing number of parameters. Lower values of AIC and BIC indicate a better model. The 
residual standard error (RSE) was used to compare models with lower deviation between 
predicted and observed values being more desirable. The AIC, BIC, and RSE were 492, 497, and 
54; 400, 406, and 0.01; 381, 394, and 0.02; and 380, 394, and 0.02 for the constant, linear, 
exponential, and Michaelis-Menten models, respectively. Clearly, the constant representation 
(i.e., no effect of feeding rate on plasma [GLP-2]) showed the poorest fit to the data, with the 
largest AIC, BIC, and RSE, and although the linear model had about the same RSE (0.01 vs. 
0.02) as the exponential and Michaelis-Menten models, the latter 2 presented much smaller AIC 
and BIC values, indicating a better representation of the data despite the large inter-calf 
variation. Additionally, residual plots for the constant and linear models showed a curvilinear 
pattern, indicating that a nonlinear component remained unexplained. Because the 2 saturating 
functions provided similar goodness of fit, the Michaelis-Menten model was retained to explain 
the effect of feed intake level on [GLP-2] given the biological interpretability of its parameters. 
Naturally, newborn calves can consume milk at rates greater than 1.75% of their BW as DM and, 
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as a result, could reach higher plasma GLP-2 concentrations than we found or estimated using 
the asymptotic value of the Michaelis-Menten model. Hence, data modeling was only intended to 
explain observations reported herein. To assess whether such saturating response differed 
between supplemented treatments (i.e., the dependence of feeding rate on type of supplement), 
we tested whether the affinity constant and maximal velocity parameters were different among 
supplemented groups following methodology presented elsewhere (Ritz and Streibig, 2008). In 
addition, the area under the curve (AUC) for GLP-2 secretion after feeding was calculated for 
each calf and statistically tested for the effects of feeding rate, supplement, and their interaction, 
adjusting for pre-feeding basal GLP-2 plasma concentration.  
Milk intake measurements for each calf were averaged and analyzed according to a 
completely randomized experimental design including the effect of feeding rate and 
supplementation. Initial BW was included as a covariate:  
Yij = mean + BW + feeding ratei + supplementj + (feeding rate × supplement)ij + eij, 
where mean is the overall sample mean, BW is the initial BW, and eij is the deviation of each calf 
from the mean.  
Residuals from both nonlinear and linear models were checked by visual inspection of 
residual plots and extended Levene tests (Littell et al., 2006), and the homogeneity of variance 
and normality assumptions were met. The GLP-2 concentrations presented heterogeneous 
variance and thus the assumption of constant variance was replaced by a power function of the 
predicted values. The AUC treatment means were compared by Tukey’s pairwise comparison 
test. Nonlinear regression analysis was performed with the open source software R (R 
Development Core Team, 2011) using the package nlme (Pinheiro et al., 2015). 
Experiment 2 
Treatment Allotment.  Thirty newborn Holstein male calves were acquired in 2 batches from the 
same source as in experiment 1. The same prophylactic and biosecurity protocols from 
experiment 1 were applied. Complete blocks of calves were made based upon BW and, within 
each block, 1 of the following 3 supplement treatments was randomly assigned (n = 10) to each 
calf: (1) control (commercial milk replacer), (2) control plus glucose (220 mg/kg of BW daily), 
and (3) control plus 3-O-M-G (6 mg/kg of BW daily).  
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In this experiment, the adaptation and treatment periods were as follows. Calves were fed 
twice daily at a rate of 1.25% of BW (DM basis) daily divided into 2 feedings for the first 2 d. 
On d 3, the amount of milk replacer was increased to 1.75% of BW and then held constant 
through the end of the experiment. On d 7, glucose supplementation treatments were introduced 
and continued until the end of experiment at d 22 of age, when calves were harvested. Milk 
replacer intake was measured daily and averaged by week for each calf. Milk replacer fed was 
the same as in experiment 1.  
Plasma GLP-2. On d 12, calves were fitted with catheters in the jugular vein for blood sampling. 
On d 13, jugular venous samples were taken at −30, 0, 5, 15, 30, 60, 120, and 240 min relative to 
feeding for measurement of GLP-2 concentrations. Blood samples were collected into tubes 
containing EDTA plus pyrrolic acid-based dipeptidyl peptidase 4 inhibitor (catalog # DPP4, 
Millipore). Samples were processed as in experiment 1. Preserved plasma samples were analyzed 
for GLP-2 in the same manner as in experiment 1.  
Animal Harvest and Sample Collection. On d 22 of the experiment, calves were euthanized with 
an intravenous injection of pento-barbituric acid (1 mL/8 kg of BW). Samples from fore 
stomach, small intestine, and hindgut were collected immediately for various analyses as 
explained below. Digesta was manually removed and the weight and length of intestinal organs 
was recorded.  
Histomorphology. Sections of rumen (dorsal, ventral, proximal, and distal); duodenum; jejunum; 
ileum; and proximal, middle, and distal colon were collected and fixed in 10% formalin for 24 h, 
embedded in paraffin blocks, and stained with hematoxylin and eosin. Paraffin sections (5 μm 
thick) were cut and mounted onto glass slides, which were then scanned through a Nanozoomer 
microscopic scanner (Hamamatsu Photonics, Hamamatsu, Japan) at 40× to obtain digital scans 
on which papillae and villi height and width, and crypt width and depth were measured 
afterward.  
Cellular Proliferation. Abundance of labeled cell nuclei with the protein marker Ki67 in 
paraffin-embedded tissue sections from jejunum, ileum, and colon was measured as a proxy for 
cell proliferation following the manufacturer’s instructions (Vector Labs, Burlingame, CA). 
After immunostaining, the abundance of Ki-67 was assessed by scanning the slides on a 
Nanozoomer microscope (Hamamatsu Photonics) at 40× to obtain digital microscopic scans. The 
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digital image processing software AxioVision (Zeiss, Oberkochen, Germany) was used to 
compute the Ki-67–stained area based on a predefined pixel intensity on the microscopic scans.  
mRNA Expression. Epithelium scrapings from ileum and colon were collected into RNALater 
reagent (Qiagen, Hilden, Germany) to assess treatment effects on mRNA expression of genes 
related to the GLP-2 paracrine signaling pathway and functional or developmental traits.  
For mRNA extraction, tissue was homogenized in ice-cold Trizol using a bead beater 
(Invitrogen Corp., Carlsbad, CA). Afterward, extraction with acid-phenol chloroform was 
performed (Ambion, Austin, TX). Purification of mRNA and genomic DNA removal was carried 
out through a mRNAeasy mini kit (Qiagen) and incubation with DNase. The mRNA integrity 
was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). The 
RNA integrity was considered satisfactory when sample score was 6 or greater. Procedures to 
perform cDNA synthesis and quantitative reverse transcription PCR were as described 
previously (Ji et al., 2014).  
Gene expression was normalized using the geometric mean of 3 internal control genes 
validated as stable internal control genes following methodology presented elsewhere 
(Vandesompele et al., 2002): glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-2- 
microglobulin (B2M), and hypoxanthine phosphoribosyltransferase 1 (HPRT1); B2M and HPRT1 
have been used previously in calves (Connor et al., 2010).  
Genes selected to represent the GLP-2 pathway were proglucagon (GCG) and GLP-2 
receptor (GLP2R; Connor et al., 2010). Genes selected to represent the GLP-2 paracrine 
mediator network (Rowland and Brubaker, 2011) included keratinocyte growth factor (FGF7), 
endothelial nitric oxide synthase (NOS3), IGF-1 and IGF-2 (IGF1, IGF2), IGF1 receptor 
(IGF1R), vasoactive intestinal peptide (VIP), epidermal growth factor receptor (EGFR), heparin 
binding EGF-like growth factor (HBEGF), early growth response 1 (EGR1), c FOS proto-
oncogene (FOS), and neuregulin 1 (NRG1). Genes thought to be involved in the GLP-2 cellular 
signaling cascade (Rowland and Brubaker, 2011) were murine thymoma viral oncogene (AKT1) 
and phosphatidylinositol 3 biphosphate kinase (PIK3CA). In addition, a few previously reported 
functional marker genes were evaluated (Connor et al., 2010). For peptide transport, cell 
apoptosis, and cell proliferation, the expression of genes encoding for the solute carrier family 
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(SLC15A1), caspase 6 (CASP6), and proliferating cell nuclear antigen (PCNA) as well as cyclin 
D1 (CCND1), respectively, was assessed.  
Primers were designed using Primer Express 3.0 (Applied Biosystems, Carlsbad, CA) 
with amplicon size between 80 and 120 bp where possible. Pooled intestinal cDNA was used to 
test primers by running them in a 2% agarose gel. If a band of expected size was present in the 
gel, the amplicon was submitted for sequencing to the core DNA sequencing facility at Roy J. 
Carver Biotechnology Center at the University of Illinois (Urbana) and the sequencing results 
were searched using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to verify the primer 
specificity. Forward and reverse primers are presented in Table 4.1.  
Gene PCR amplification efficiency (Table 4.2) was calculated from the standard curve as 
follows:  
Efficiency = −10
(
−1
𝑆𝑙𝑜𝑝𝑒
)
. 
Then, mRNA abundance was computed as follows:  
mRNA abundance = 
1
(𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦)∆𝐶𝑡
 
where ΔCt = [Ctsample − (geometric mean of internal control genes)], and Ct = cycle threshold. 
The sequence of amplicons obtained from the primers was verified against the National Center 
for Biotechnology Information (NCBI) primer BLAST tool (https://blast.ncbi. 
nlm.nih.gov/Blast.cgi) and are presented in Table 4.3.  
Statistical Analysis. For milk intake, the model of variance analysis included treatment, week as 
a repeated measure, and their interaction as fixed effects. Initial BW was included as a covariate. 
Calf batch was included as a block but dropped from the model due to nonsignificance. Different 
error structures among repeated measures were evaluated and the one that minimized the 
adjusted and unadjusted AIC (AAIC and AIC), BIC, and −2 Ratio Log-likelihood, with the least 
number of parameters, was chosen. The model was  
Yijk = mean + BW + supplementi + Eij + weekk + (supplement × week)ik + eijk, 
where mean is the overall mean, BW is the initial BW, supplementi is the effect of glucose or 3-
O-M-G supplementation, weekk is the effect of time, (supplement × week)ik is the effect of the 
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interaction, and Eij and eijk are the error between calves within the same treatment and the error 
between repeated measures for the same calf, respectively.  
Similarly, for GLP-2 concentrations over time, the model included treatment, hour as a 
repeated measure, and their interaction as fixed effects. Error correlation structure among 
repeated measures was evaluated as mentioned above. The model was  
Yijk = mean + supplementi + Eij + hourk + (supplement × hour)ik + eijk,  
where mean, supplement, hour, and their interaction represent the overall mean and the 
respective linear effects, and Eij and eijk are the error between calves within the same treatment 
and the error between repeated measures for the same calf, respectively.  
A similar statistical linear model for nonindependent observations was used for 
gastrointestinal organ size, histomorphology, and cellular proliferation measures because 
repeated measures were performed on various anatomical regions of the same calf. The AUC for 
GLP-2 secretion was computed and compared among treatments in a one-way ANOVA.  
Residuals were checked for homogeneity of variance and normality assumptions by 
residual plots and extended Levene test. Heterogeneous variances were handled by implementing 
error structures that allow for heterogeneous variances (Littell et al., 2006).  
To account for potential correlations in the mRNA abundance from 21 genes that were 
measured simultaneously, a permutational multivariate ANOVA (PERMANOVA; Anderson, 
2001) was conducted on a Euclidean distance matrix built from the standardized variables (mean 
= 0, SD = 1) to test the hypothesis of an overall effect of supplement or intestinal section (i.e., 
ileum vs. colon) on overall gene expression. The model included effects of additive 
supplementation, intestinal section within calf, their interaction, and calf batch. In addition, a 
principal component analysis (PCA) ordination was used to visually identify treatment or organ 
site differences, taking all genes into account simultaneously, and to determine what genes drive 
the most variation in signaling pathway in ileum and colon (Johnson, 1998).  
Repeated-measures analyses were performed using PROC MIXED (SAS Institute Inc., 
2011). Multivariate analysis of gene expression data was carried out with the VEGAN (Oksanen 
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et al., 2012) and STATS packages in R open source software (R Development Core Team, 
2011). 
RESULTS 
Experiment 1 
In total, 46 calves completed the trial. Two calves were not sampled on d 8 because of 
health issues. One of the calves not sampled was on the 50% feeding rate plus 3-O-M-G 
treatment and the other was on the 100% feeding rate plus glucose. Milk Intake. As designed, 
there was a significant effect of feeding rate on milk replacer intake (P < 0.001). We detected no 
effect of glucose or 3-O-M-G supplementation on milk replacer intake (P < 0.98; Table 4.4). 
Given the observed DMI and the 44% lactose concentration of the milk replacer used, total 
glucose plus galactose intake from milk would have been about 85, 173, 268, and 363 g/d for 
feeding rates of 0.44, 0.88, 1.3, and 1.75% of BW as DM, respectively.  
GLP-2 Concentrations in Plasma. A MichaelisMenten equation (Figure 4.1, left panel) provided 
the best description of plasma [GLP-2] in response to the increasing feeding rate compared with 
a constant (i.e., no relationship) or a linear representation (i.e., linear increase in plasma [GLP-2] 
with feeding rate), as indicated by AIC, BIC, and residual plots, its parameter estimates Vmax 
and Km being different from zero (P < 0.01), and the model residuals following the NIID ~ (0, 
σ2 ) assumptions. In the Michaelis-Menten equation, Vmax is the maximum potential GLP-2 
secretion that would be attained at an extremely large feed intake and was estimated to be 98.61 
pmol/L; the affinity constant Km (i.e., the feeding rate required to reach 50% of Vmax) was 
estimated at 30.3 ± 9.5% equivalent to approximately 0.45% of BW on a DM basis (Figure 4.1, 
left panel). Visual appraisal of Figure 4.1 (left panel) suggests that at a feeding rate of 100%, a 
plateau in peptide secretion was approximated; thus, feed intakes above 1.75% of BW as DM 
could result in marginally smaller increases in GLP-2 secretion. If we considered the AUC for 
GLP-2 secretion among the various feeding rate treatments (Figure 4.1, right panel), we observed 
a wide variation for the 75% feeding rate in particular and 3 extreme observations, one in each of 
the 25, 50, and 100% feeding rate groups. Because these were not considered faulty data, they 
remained in the statistical analysis and were not leveraged up- or downward. The estimated AUC 
means for the 25, 50, 75, and 100% rates were 9,629, 14,188, 17,181, and 19,790 pmol/ L·min, 
respectively, indicating a numerical increment as feed intake increased. Taking the AUC for the 
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100% feeding rate as reference, calves in the 75, 50, and 25% feeding rate treatments reached 87, 
72, and 49% of the maximal GLP-2 level. The difference between the AUC for the 75 and 100% 
groups was not statistical and nor was the difference between groups 75 and 50%. The AUC for 
the 25% group was significantly lower than that achieved by the 75 and 100% feeding rates but 
was not different from 50% (Figure 4.1, right panel). It appears, therefore, that a feeding rate of 
50% of standard or 0.875% of BW on a DM basis was the threshold rate from which further 
reductions in the amount of milk fed down to 25% resulted in both numerical and statistical 
decreases in the circulating concentration of GLP-2 (Figure 4.1, right panel).  
It is important to highlight, however, that inter-calf variation was large (Figure 4.1, left 
panel) and although a saturating response of plasma [GLP-2] to milk intake explains the data 
best, a large portion of the residual variation is likely to be explained by unknown calf specific 
traits.  
Indeed, further examination of the data indicated that the maximal response in plasma 
GLP-2 concentration (i.e., Vmax) to milk intake had a strong linear dependency on the calf-
specific basal prefeeding concentration of the peptide in plasma (slope = 1.9 ± 0.3, P < 0.0001; 
Figure 4.2, right panel). In the observed range of basal concentrations from about 10 to 210 
pmol/L (Figure 4.2, left panel), plasma GLP-2 was estimated to increase linearly from below 50 
to almost 200 pmol/L at low feeding rates, whereas at a feeding rate of 100%, GLP-2 was 
estimated to reach about 300 pmol/L (Figure 4.2, right panel). The effect of basal prefeeding 
levels on postprandial GLP-2 secretion was reflected in the AUC. In Figure 4.3, both an 
exploratory nonparametric fit (solid line) and the actual linear regression (dashed line) indicate 
the strong positive relationship (P < 0.0001, R2 = 0.8) between basal concentrations and the 
GLP-2 AUC. Thus, for each unit increase in basal plasma GLP-2, we detected an approximate 
estimated increase of 241 ± 20 units in AUC (pmol/L·min).  
To discern whether such a strong effect of basal GLP- 2 plasma concentration was an 
indirect consequence of the feeding rate or supplement treatments, we conducted a 2-way 
ANOVA, whose results are presented in Figure 4.4. It is visually apparent that neither of the 2 
factors affected basal plasma GLP-2 concentration given the large overlap in the data distribution 
of both feeding level (P > 0.8) and supplemental glucose (P > 0.5) groups, which was 
statistically confirmed at a type 1 error rate of 5% (Figure 4.4, left and right panels). Given that 
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all other experimental conditions were similar among calves, this implies that calf intrinsic 
characteristics determine the basal GLP-2 secretion and hence a large portion of the postfeeding 
response.  
With respect to the hypothesis that glucose supplementation could directly or through an 
interaction with feeding rate affect GLP-2 secretion (Figure 4.5), we detected a tendency (P < 
0.09) for glucose-supplemented calves to have a lower Vmax (94 pmol/L) compared with control 
calves (101 pmol/L; Figure 4.5, left panel). This would suggest that glucose-supplemented calves 
presented a lower release of GLP-2. Control calves and 3-O-M-G calves did not differ in Km or 
Vmax. To determine whether this difference in maximal GLP-2 concentration in response to 
supplements translated into a difference in total peptide secretion over time, the AUC was 
compared among treatments. As shown in Figure 4.5 (right panel), the difference among the 
control, glucose, and 3-O-M-G treatment groups was not significant (P < 0.36). Furthermore, the 
interaction between feeding rate and supplementation for the AUC also was not significant (P < 
0.6). 
Experiment 2 
Feed Intake. Average milk DM intake was not different among control, glucose, and 3-O-M-G 
supplemented calves (P < 0.33), and no interaction between supplementation and time (P < 0.37) 
was evident (Table 4.5).  
GLP-2 Secretion. We observed no effect of treatment (P < 0.51) or its interaction with time 
postfeeding (P < 0.95) on average plasma GLP-2 concentration with respect to the control diet. 
Also, we did not (P < 0.52) observe an effect of supplement type on the AUC for GLP-2 
secretion (Table 4.6).  
Rumen and Intestine Size. Addition of glucose or 3-O-M-G to the milk replacer did not affect 
organ weight, expressed either in kilograms (P < 0.35) or as a percentage of BW (P < 0.39) or 
organ length (P < 0.41). The interaction between treatment and intestinal organ was also not 
statistically significant (P > 0.5; data not shown). 
Epithelium Morphometric Dimensions. The length and width of the rumen papillae (P < 0.45); 
the length (P < 0.84) and width (P < 0.83) of the villi in the duodenum, jejunum, and ileum; and 
crypt depth (P < 0.49) and width (P < 0.20) in duodenum, jejunum, ileum, and colon were 
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similar across the control, glucose, and 3-O-M-G groups. No interaction of treatments with 
intestinal section was detected (P > 0.50; data not shown).  
Cellular Proliferation. The average abundance of Ki-67–stained nuclei did not differ among 
control, glucose, and 3-O-M-G treatments (P < 0.16), and this lack of effect (P < 0.20) was 
consistent across intestinal sections (data not shown).  
Gene Expression of the GLP-2 Signaling Pathway. The PERMANOVA indicated that 
simultaneous expression of all genes involved in the GLP-2 signaling pathways (Table 4.7) was 
not affected (P < 0.68) by glucose or 3-O-M-G supplementation or the interaction with the 
intestinal sections (i.e., ileum and colon). Therefore, comparisons between treatments for specific 
genes are not reported. In contrast, simultaneous expression for all genes differed significantly (P 
< 0.014) between ileum and colon (Table 4.7). To identify which genes caused the most variation 
in this system, we followed the PERMANOVA with a PCA. Figure 4.6 displays the first 2 
principal components, which together accounted for ~75.3% of the variation in gene expression. 
All treatment groups clustered together with full overlap (Figure 4.6, left panel), whereas ileum 
and colon samples clustered distinctly apart (Figure 4.6, right panel). Principal component 1 
(PC1) explained most of the variation (66%) in gene expression related to the GLP-2 pathway. 
The genes driving such variation were EGFR, AKT1, NOS3, NRG1, GLP2R, and IGF1R, as 
indicated by a high positive correlation with PC1, and were associated with colon samples, 
whereas SLC15A1 and PCNA were negatively correlated with PC1and were associated with 
ileum samples (Table 4.8). These associations set forward for consideration that the GLP-2 
signaling cascade is better established in the colon than in the ileum of calves. In summary, 
neither glucose nor 3-O-M-G appeared to elicit any effects on GLP-2 secretion, intestinal 
development, or gene expression. 
DISCUSSION 
The present data indicate that GLP-2 secretion responds in a saturating manner to nutrient 
intake in young calves. We found that the marginal response in GLP-2 secretion diminished 
when the feeding rate exceeded 75% of the maximum (i.e., 1.32% of BW as DM), eventually 
reaching a plateau as indicated by similar AUC values for the 75 and 100% feeding rates. 
Feeding 75, 50, and 25% of the maximal feed intake (i.e., 1.75% BW as DM) resulted in plasma 
GLP-2 concentrations that were 87, 72, and 49% of that in fully fed calves, which is 
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quantitatively similar to previous observations in piglets (Burrin et al., 2000). The amount of 
food delivered to the intestine is a key regulator of GLP- 2 secretion and intestinal development 
(Rowland and Brubaker, 2011). Even when piglets were supplied with the same daily amount of 
nutrients, enteric administration of at least ~50% of the daily food allowance led to enhanced 
GLP-2 release and intestinal development compared with animals fed enterally. Although the 
evidence from the study remained circumstantial and other trophic peptides such as IGF-1 might 
have been involved, it is possible that GLP-2 elicited a large portion of the intestinal growth 
response (Burrin et al., 2000). In calves, the minimum intake of milk required to achieve 
sufficient secretion of GLP-2 to maintain intestinal development and function is unknown. This 
information could be useful to devise successful dietary or therapeutic interventions in certain 
situations. For instance, diarrhea-ill calves whose nutrient intake commonly drops well below 
1% of BW as DM for several days or limit-fed calves whose milk intake frequently ranges 
between 0.96 and 1.2% of BW as DM over the first 6 to 8 wk of life (Davis and Drackley, 1998) 
might benefit from exogenous GLP-2 therapy or any dietary intervention that stimulates the 
release of endogenous GLP-2. Yet, before such alternatives become possible, we have to 
quantify the causal relationship between the circulating concentration of GLP-2 and specific 
measures of intestinal growth and function such as organ and epithelial mass, mucosal 
permeability, nutrient absorption, and local blood flow. Given that food intake is the major driver 
of GLP secretion, the present study contributes novel information on the range of milk intake 
within which functional responses to GLP-2 could be assessed.  
Furthermore, there appears to be a major driver of GLP-2 secretion that is intrinsic to the 
individual calf. We detected a very large effect of basal secretion on maximal postfeeding 
plasma GLP-2 concentration, which was not related to either feeding rate or supplementation. 
This observation implies that either GLP-2 synthesis and release rates, clearance rates, or both 
vary from calf to calf. Calf variability in synthesis could be in turn due to total number of L cells, 
which can be thought of as the product of intestinal mass and L-cell density. On the other hand, 
clearance is proportional to the amount of dipeptidyl peptidase 4 (DPP4) secreted into circulation 
and renal clearance (Rowland and Brubaker, 2011). The bottom line is that possibly because of 
differences in such physiological traits, not all calves would benefit the same from a dietary 
intervention. To exploit this phenomenon, the variability in those underlying calf-specific 
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features or some proxy of them needs to be estimated. The pre- and postprandial data presented 
here may aid power calculations to study between-calf variability in the above traits.   
On the other hand, we could not detect an effect of glucose or 3-O-M-G supplementation 
on plasma GLP-2 concentration in either experiment 1 or 2. We failed to approximate an 
effective dose range and, at a milk intake of 1.75% of BW as DM (i.e., experiment 1), the supply 
of glucose plus galactose from milk had probably already saturated the sweet receptor-GLP-2 
signaling path. However, the data presented here indicate that the lack of effect was present even 
at low milk intakes (0.43% of BW as DM), when the GLP-2 secretion response was far from 
being saturated. This would suggest that at such low intake levels, even if glucose could indeed 
trigger release of GLP-2 (Shirazi-Beechey et al., 2011) in calves, the total intake of glucose plus 
galactose (~85 g/d) from milk would be more than enough to saturate sweet receptor–mediated 
GLP-2 release; therefore, this mechanism would be active at total glucose plus galactose intake 
levels somewhere between 0 and 85 g/d. Response evaluation in this range deserves attention.  
Taking into account that we used sheep data to set glucose doses, it is important to 
consider that sweet taste sensitivity and the concomitant signaling varies widely among species 
and even among strains within species (Pepino and Bourne, 2011). Thus, differences in sweet-
taste sensitivity and specificity between sheep and calves might have accounted for the lack of 
GLP-2 response.  
The distinctive profile of genes more abundantly expressed included GLP2R, EGFR, 
NOS3, NRG1, IGF1R, and AKT1 in the colon, which suggests that GLP-2 signaling and the 
resulting trophic or restorative actions may be much better established in this organ compared 
with the ileum of calves. Similar transcription profiles were observed previously in bovines 
during various physiological stages (Connor et al., 2010). Specifically, this mRNA expression 
profile points to a greater sensitivity of the colon to circulating GLP-2 due to greater abundance 
of its receptor and downstream effectors. Indeed, in murine models, enhanced blood 
concentration of GLP-2 has been associated with increased concentration of circulating short-
chain fatty acids (Tappenden et al., 1998) and colonic fiber fermentation (Cani et al., 2009), and 
both observations have resulted in improved epithelial function and intestinotrophic responses. 
These trophic responses are potentially mediated by IGF1 and EGF and their respective 
receptors, IGF1R and EGFR. As in the case of GLP2R, we noted that these 2 receptors were 
90 
 
more abundantly present in colon than in ileum of calves. The effects of these receptors could be 
mediated downstream by the phosphoinositide 3 kinase/protein kinase B and ErbB pathways 
(Tappenden and McBurney, 1998; Rowland and Brubaker, 2011), and genes involved in these 2 
signaling cascades were also distinctly expressed in the colon, but not the ileum, of calves used 
in this study. If the GLP-2 receptor and downstream effectors are actually more abundant in the 
calf colon, an opportunity exists to optimize the intestinal health and recovery responses to GLP-
2 through, for instance, strategies that promote hindgut fermentation. In this sense, although 
conventional research has mostly focused on rumen development to accelerate weaning, research 
on the manipulation of GLP-2 secretion by dietary means, its effect on the development and 
function of the hindgut, and its restoration upon an illness episode could help decrease morbidity 
and mortality during the first few weeks of life. 
CONCLUSIONS 
Calves fed at 1.32, 0.88, and 0.44% of BW as DM presented plasma GLP-2 
concentrations that were 87, 72, and 49% of the concentration observed in calves fed at 1.75% of 
BW as DM. Given the important role of GLP-2 in intestinal homeostasis, these observations may 
be of practical importance with respect to newborn calves experiencing low milk intake due to 
illness or restricted-feeding programs. Provision of metabolizable or nonmetabolizable glucose 
did not affect GLP-2 secretion, intestinal growth, or gene expression in ileum or colon. 
Furthermore, this lack of response did not depend on the feeding rate of milk replacer. Dose-
response curves for glucose intake below 85 g/d and specific to the young calf need to be 
developed to identify the potential to trigger GLP-2 secretion and capitalize on its trophic or 
functional properties. Finally, genes related to the actions of GLP-2 were more highly expressed 
in the colon than in the ileum. Therefore, more work is needed to better understand the 
relationship between GLP-2, colon integrity, and health of newborn calves. 
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TABLES AND FIGURES 
Table 4.1. Gene identification, accession number, and corresponding forward and reverse verified primers in experiment 2 
Gene NCBI Accession no. Forward Reverse 
GCG NM_173916.3 CCCTTCAGAACACAGAGGAGAAA GAGTGGCGCTTATCTTCATTGA 
DPP4 NM_174039.2 GGACGCTAGTTCTCCGGGC ACATTAGTGAGCGCCGGGTT 
FGF7 XM_005211861.1 AAGTTGCACAGGGCAGACAA GTTGCTGAGATGCTGTTTGCT 
NOS3 NM_181037.3 CGGAACAGCACAAGAGTTACAAGA TGTGTTGCTGGACTCCTTTCTC 
IGF2 NM_174087.3 CCTCCAGTTTGTCTGTGGGG GGGTGGCACAGTAAGTCTCC 
VIP AF503910.1 CTTCTTGTGTTCCTGACGCTGTT AGAGCCGAAGGTGCTCCAA 
EGFR AY486452.1 AACTGTGAGGTGGTCCTTGG CATATCCGGCAACCTCCTGG 
HBEGF NM_001144090.1 GCCATCTAGATTGGGCCTCC ACCCAGATCCCACTGGACAT 
FOS BT029837 GCAAAACGCATGGAGTGTGT AAAAGAGACGCAGACCCAGG 
EGR1 BC118328 TGTGATGATGCTGTGACGATTC ACTCTGACACATGCTCCGAT 
PIK3CA NM_174574 ATTGGCCTCCAATCAAGCCT CACCGAACAGCAAAACCTCG 
SLC15A1 BC140526 ACTCCGTCTCCCAGACACAA CCACCCAACAGAGTGTCCTG 
CASP3 AY575000 TGGCCTGTCAGAAAATACCAGT TCCGGTACTTTGAGTTTCGCC 
CASP6 NM_001035419.2  CACAGGACAGACACGCCAGAT AAGTCGGCTCCAGCAGGAA 
PCNA BC103068 GAACCTCACCAGCATGTCCA ACGTGTCCGCGTTATCTTCA 
HPRT1 NM_001034035.2 GCTGGCTCGAGATGTGATGA TCCAACAGGTCGGCAAAGAA 
IGF1 NM_001077828.1 CCAATTCATTTCCAGACTTTGCA CACCTGCTTCAAGAAATCACAAAA 
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Table 4.1 (Cont.) 
AKT1 NM_173986.2 GGATTACCTGCACTCGGAAAAG TCCGAAGTCGGTGATCTTGAT 
GAPDH NM_001034034 TTGTCTCCTGCGACTTCAACA TCGTACCAGGAAATGAGCTTGAC 
B2M NM173893.3 TCCAGCGTCCTCCAAAGATT CCCATACACATAGCAGTTCAGGTAA 
IGF1R NM_001244612.1 CGACATCCACAGCTGTAACCAT AGGAATGTCATCTGCTCCTTCTG 
RG1 XM_005226076.1 CGGTCAGTCCCTTCGTGGAA GGTTGCAGTGGAACGAGTTGA 
CCND1 BC112798.1 GATGCCAACCTCCTCAACGA GGCAGGATCTCCTTCTGCAC 
ATP5B BC116099.1 AGCATTTGGGTGAGAGCACA GTCTCAGGGCCAACAGGAAT 
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Table 4.2. Reverse transcription quantitative PCR performance for all genes measured in ileum and colon in experiment 21 
Gene Ct median Median ΔCt Slope R2 Efficiency 
GCG 23.76 3.52 -3.28 0.99 2.01 
EGFR 24.81 4.70 -3.27 0.99 2.02 
EGR1 24.14 4.13 -3.29 0.99 2.01 
FGF7 27.63 7.37 -2.87 0.99 2.23 
FOS 24.42 4.39 -3.31 0.98 2.00 
AKT1 21.32 1.34 -2.91 0.97 2.20 
CASP6 21.43 1.34 -3.29 0.99 2.01 
HBEGF 27.75 7.79 -2.96 0.98 2.17 
IGF1 26.16 6.12 -3.01 0.99 2.14 
IGF-2 23.90 3.73 -3.10 0.99 2.10 
NOS3 25.71 5.45 -3.07 0.99 2.11 
PCNA 22.74 2.53 -3.35 0.99 1.98 
PIK3CA 24.49 4.41 -3.42 0.98 1.95 
SLC15A1 22.81 2.98 -3.07 0.98 2.11 
VIP 29.58 9.45 -2.95 0.99 2.17 
ATP5B 19.96 0.12 -3.26 0.99 2.02 
CCND1 24.93 4.82 -3.52 0.99 1.92 
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Table 4.2 (Cont.) 
IGF1R 24.88 4.69 -3.29 0.99 2.01 
NRG1 26.24 6.14 -3.20 0.99 2.05 
GLP2R 25.31 5.18 -2.92 0.99 2.20 
1 Ct median= median cycle threshold (Ct) from all ileum and colon samples from 45 calves; slope and R2 = slope and coefficient of 
determination of the standard curve. 
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Table 4.3. Sequence of amplicons obtained from primers and verified against the National Center for Biotechnology Information 
primer BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) in experiment 2 
Amplicon Sequence  
GCG CTCGGCGATCCAGATCAGATCAATGAAGATAAGCGCCACTC 
FGF7 GTATCAGCGTGTTATCACAGACAAAGTCAAGTAGCAAACAGCATCTCAGCAAC 
NOS3 CAGCGTCTCTGCTCAGACCCGCTGTGTCCTCCTGGCGGCGGAGAGAAGGAGTCCAGCAACACA 
IGF2 
CGACATCAGCCGCATACCGACGCAGCCTGTGCATCGATGGAGAGTGTTGCTTCCGAAGCTGCGACCTGGCCCTGCTGGAGACT
TACTGTGCCACCC 
VIP GCTCTTTTTGGAGCACTTC 
EGFR ACCTTTCTTTTCTCAGACCATCCAGGAGGTTGCCGGATATG 
HBEGF AACAGAATATGTCCAGTGGGATCTGGGT 
FOS CATCGTAGAGCGTTAGTTAGTAGCATGTGGAGCAGGCCTGGGTCTGCGTCTCTT 
EGR1 TCTTGGTATTATCGGAGCATGTGTCAGAGT 
PIK3CA CATTACCCAGATCCTATGGTTCGAGGTTTTTGCTGTTCGGTG 
SLC15A1 CAGGTCTGTCCTGGGGGCAGGACACTCTGTTGGGTGGA 
CASP6 TTATACACTTCCGTGCTGGAGCCGACTT 
PCNA AGACAATCATTACCTTAAGAGCTGAGATAACGCGGACACGT 
HPRT1 CCTCGTGTTGCTCAGGGGGGCTATAAGTTCTTTGCCGACCTGTTGGA 
IGF1 AATCAGCAGTCTTCACCCAATTATTTAAGTGCTGCTTTTGTGATTTCTTGAAGCAGGTG 
AKT1 CTCAGCTGAGACTCATGCTGGACAGGACGGGCACATCAAGATCACCGACTTCGGA 
GAPDH CACTCTTCTCTCGAGTCTGGGGGCGTGCATTGCCTCACGACCACTTTGTCAAGCTCATTTCCTGGTACGAAAT 
B2M GCAATGAACACCACAGAAGATGGAAGCAATTACTGAACTGCTATGTGTATGGGA 
IGF1R ACTTTGTCTTTGCAAGAACCATGCCTGCAGAAGGAGCAGATGACATTCCT 
GLP2R TGTGTGCTGCCTCATCACTCTGGATGTCTCTGTCCCTGCCTTCCTACTTACCTTGGTGGCGCGAAGAGAACTCAGGAAGGGC 
NRG1 TCCTTGTGTACGGCACACGGCGTCGGGAGAGTATGACCACCACGCCCAGCAATTTCAACTCGTTCCACTGCAACC 
CCND1 GGAGGAACGTACGCGCCCTCGGGTATCCTACTTCAAGTGTGTGCAGAAGGAGATCCTGC 
ATP5B TGGTTAGAGGTCAGAAAGTCCTGGATTCTGGTGCACCAATCAGAATTCCTGTTGGCCCTG 
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Table 4.4. Least square treatment means for milk intake on d 6, 7 and 8 in experiment 1 
Variable Milk DMI, kg/d P-value 
Feeding rate   <0.0001 
  25% 0.193 ± 0.009d  
  50% 0.392 ± 0.01c  
  75% 0.608 ± 0.009b  
  100% 0.824 ± 0.01a  
Supplement1  0.98 
  Control 0.50 ± 0.06  
  Glucose 0.49 ± 0.06  
  3-O-M-G 0.51 ± 0.06  
a-dMeans within a column with different superscripts indicate statistical difference. 
1Control treatment = commercial milk replacer without supplementation; glucose = 
commercial milk replacer plus glucose (220 mg/kg of BW daily); and 3-O-M-G = commercial 
milk replacer plus 3-O-methyl glucose (6 mg/kg of BW daily). 
 
 
 
Table 4.5. Least squares treatment means for milk intake in experiment 2 
 Treatment1  P-value2 
 Control Glucose 3-O-M-G SE Trt Trt x week 
Milk DMI, kg/d 0.7 0.69 0.71 0.008 0.33 0.37 
1Control treatment = commercial milk replacer without supplementation; glucose = 
commercial milk replacer plus glucose (220 mg/kg of BW daily); and 3-O-M-G = commercial 
milk replacer plus 3-O-methyl glucose (6 mg/kg of BW daily). 
2Trt= treatment effect; Trt × week: treatment by week interaction effect. 
 
 
 
Table 4.6. Treatment means for plasma glucagon-like peptide-2 concentration [GLP-2] and area 
under the curve (AUC) in experiment 2 
Item 
Treatment1 
SE 
P-value2 
Control Glucose 3-O-M-G Trt2 Min. Trt x Min.3 
[ GLP-2], pmol/L  38.0 47.0 32.8 10.5 0.51 < 0.0001 0.95 
AUC, pmol/L·min 9204 12667 8766 2905 0.52 NA3 NA3 
1Control treatment = commercial milk replacer without supplementation; glucose = 
commercial milk replacer plus glucose (220 mg/kg of BW daily); and 3-O-M-G = commercial 
milk replacer plus 3-O-methyl glucose (6 mg/kg of BW daily). 
2Trt= treatment effect; Trt × min: treatment by minute interaction effect. 
3NA = not applicable.  
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Table 4.7. Permutational multivariate ANOVA (PERMANOVA) test for treatment and 
intestinal section effects on the glucagon-like peptide-2 pathway gene expression in 
experiment 2 
Source df 
Sum of 
squared 
distances 
Mean 
square F-value R2 P-value 
Calf batch  1 66.63 66.63 5.46 0.06 0.002 
Treatment  2 27.62 13.81 1.13 0.03 0.68 
Intestinal section1 1 390.24 390.24 31.89 0.37 0.014 
Treatment × intestinal 
section 2 18.43 9.22 0.75 0.02 0.746 
Residuals 43 526.08 12.23    
Total 49 1029.0     
1 Ileum and colon 
 
 
 
Table 4.8. Correlation between genes explaining 66% of variation in the glucagon-like 
peptide-2 signaling pathway and principal component 1 (PC1) in experiment 2 
PC EGFR AKT1 NOS3 NRG1 GLP2R IGF1R SLC15A1 PCNA 
PC1 0.94 0.91 0.91 0.9 0.8 0.78 -0.51 -0.44 
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Figure 4.1. Left panel: Scatter plot of circulating glucagon-like peptide-2 (GLP-2) 
concentration in response to feeding rate (FR) in milk fed calves in experiment 1 as 
represented by a Michaelis-Menten equation [maximal plasma GLP-2 concentration 
(Vmax) = 98.61, feeding rate at which GLP-2 plasma concentration reaches half Vmax (Km) 
= 30.3]. Dots within each feeding rate are means of observations at 15, 30, 60, 90, and 240 
min relative to feeding time.  Right panel: Effect of feeding rate on the area under the 
circulating GLP-2 concentration curve (AUC). Lower- and upper-most bars are maximum 
and minimum values, respectively, excluding outliers; upper and lower box sides are 25th 
and 75th percentiles, and solid horizontal line is the median or 50th percentile.  Groups 
sharing the same letters do not differ at P = 0.05. 
a a 
ab b 
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Figure 4.2. Distribution of basal (i.e. prefeeding) plasma glucagon-like peptide-2 
(GLP-2) concentrations (left panel) in experiment 1. Predicted relationship between 
basal plasma GLP-2 levels and feeding rate with postfeeding GLP-2 concentrations 
(right panel; Vmax = maximal plasma GLP-2 concentration).   
Vmax = 8.7 + 1.9*[GLP-2]Basal 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Relationship between basal (i.e. prefeeding) plasma glucagon-like peptide-
2 concentration [GLP-2] and area under concentration curve (AUC) in experiment 1. P 
< 0.0001, R2 = 0.80. Dashed line corresponds to linear fit (AUC=241*[GLP-2basal]), 
whereas solid line represents nonparametric Loess fit. 
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Figure 4.4. Effect of feeding rate (left panel) and supplement type (right panel) on 
basal (i.e. prefeeding) plasma glucagon-like peptide-2 (GLP-2) concentrations 
(pmol/L) in experiment 1. 3-O-M-G = 3-O-methyl glucose.  Lower- and upper-most 
bars are maximum and minimum values, respectively, excluding outliers; upper and 
lower box sides are 25th and 75th percentiles, and solid horizontal line is the median or 
50th percentile.  
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Figure 4.5. Left panel: Difference in glucagon-like peptide-2 (GLP-2) concentration between 
control and glucose-supplemented milk-fed calves in response to feeding rate (FR) (Vmax-
Control = 101 pmol/L, Vmax-Glucose = 94 pmol/L, Km = 30.3%; Vmax = maximal plasma GLP-2 
concentration, Km = feeding rate at which GLP-2 plasma concentration reaches half Vmax) in 
experiment 1. Right panel: Effect of supplement on area under  GLP-2 concentration curve 
(AUC).  3-O-M-G = 3-O-methyl glucose.  Lower- and upper-most bars are maximum and 
minimum values, respectively, excluding outliers; upper and lower box sides are 25th and 75th 
percentiles, and solid horizontal line is the median or 50th percentile. 
Vmax
Control
 = 101 pM/mL 
Vmax
Glucose
 = 94 pM/mL 
P = 0.09 
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Figure 4.6. Intestinal mRNA samples ordered according to principal components 
(PC) analysis into control (gray circles), glucose (white circles) and 3-O-M glucose 
(black circles) (left panel); and ileum (white circles) and colon (gray circles) (right 
panel) of calves in experiment 2. 
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ABSTRACT 
Diarrhea episodes in dairy calves involve profound alterations in the mechanism controlling gut 
barrier function that ultimately compromise intestinal permeability to macromolecules, including 
pathogenic bacteria. Intestinal dysfunction models suggest that a key element of intestinal 
adaptation during the neonatal phase is the nutrient-induced secretion of glucagon-like peptide 
(GLP)-2 and associated effects on mucosal cell proliferation, barrier function, and inflammatory 
response. Bioactive molecules found in Olea europaea have been shown to induce the release of 
regulatory peptides from model enteroendocrine cells. The ability to enhance GLP-2 secretion 
via the feeding of putative GLP-2 secretagogues is untested in newborn calves. The objectives of 
this study were to determine whether feeding a bioactive extract from Olea europaea (OBE) 
mixed in the milk replacer (1) can stimulate GLP-2 secretion beyond the response elicited by 
enteral nutrients and, thereby, (2) improve intestinal permeability and animal growth as well as 
(3) reduce the incidence of diarrhea in preweaning dairy calves. Holstein heifer calves (n = 60) 
were purchased, transported to the research facility, and blocked by body weight and total serum 
protein and assigned to 1 of 3 treatments. Treatments were control (CON), standard milk replacer 
(MR) and ad libitum starter; CON plus OBE added into MR at 30 mg/kg of body weight 
(OBE30); and CON plus OBE added into MR at 60 mg/kg of body weight (OBE60). The 
concentration of GLP-2 was measured at the end of wk 2. Intestinal permeability was measured 
at the onset of the study and the end of wk 2 and 6, with lactulose and d-mannitol as markers. 
Treatments did not affect calf growth and starter intake. Compared with CON, administration of 
OBE60 increased the nutrient-induced response in GLP-2 by about 1 fold and reduced MR 
intake during the second week of study. Throughout the study, however, all calves had 
compromised intestinal permeability and a high incidence of diarrhea. The GLP-2 response 
elicited by OBE60 did not improve intestinal permeability (lactulose-to-d-mannitol ratio) and 
incidence of diarrhea over the course of the preweaning period. The response in GLP-2 secretion 
to the administration of OBE reported herein warrants further research efforts to investigate the 
possibility of improving intestinal integrity through GLP-2 secretion in newborn calves.   
KEY WORDS: Glucagon-like peptide-2 (GLP-2), intestine, permeability, dairy calf 
 
 
109 
 
SHORT COMMUNICATION 
Intestinal disorders are common in newborn calves. A survey conducted in the United 
States in 2011 showed that about 25% of preweaned heifers had diarrhea and that diarrhea or 
other digestive problems accounted for 31% of the preweaning heifer mortality (NAHMS, 2011). 
Neonatal diarrhea is frequently observed from 3 to 21 d of age, but its onset and duration is 
determined by the number of pathogens involved and the immune condition of the animal (Butler 
and Clark, 1994). Regardless of the etiology, diarrhea episodes involve profound alterations in 
the mechanism controlling gut barrier function that ultimately compromise intestinal 
permeability to macromolecules, including pathogenic bacteria.  
Past and recent studies in pig models of intestinal dysfunction suggest that a key element 
of intestinal adaptation during the neonatal and early postweaning phases is the nutrient-induced 
secretion of GLP-2 and associated effects on mucosal cell proliferation, barrier function, and 
inflammatory response (Burrin et al., 2003; Cameron and Perdue, 2005; Sigalet et al., 2007; 
Ipharraguerre et al., 2013). In calves, episodes of diarrhea are associated with decreases in 
intake, and we have recently shown that the concentration of circulating GLP-2 decreases 
remarkably when ingestion drops below 0.875% of the calf BW (Castro et al., 2016). In addition 
to nutrients, however, bioactive molecules extracted from Olea europaea have been shown to 
induce the secretion of GLP-1, which is co-secreted with GLP-2, in model enteroendocrine cells 
via activation of the bile acid receptor TGR5 (Bala et al., 2014). Furthermore, recent work in 
newborn or weanling piglets showed that the enteral administration of the primary bile acid 
chenodeoxycholic acid, a TGR5 agonist, to newborn or weanling piglets increases endogenous 
GLP-2 secretion and intestinal growth (Jain et al., 2012; Ipharraguerre et al., 2013).  
The ability to enhance endogenous GLP-2 secretion via the feeding of plant-derived 
GLP-2 agonists is an attractive and yet unexplored approach for promoting intestinal adaptation 
and function in newborn calves. If this expectation is met, then the incidence of intestinal 
disorders and associated preweaning growth limitation should be reduced. The objectives of our 
study were to determine whether an extract from Olea europaea (OBE; Lucta S.A., Montornes 
del Valles, Spain), with a high content of polyphenols, triterpenic acids, long-chain fatty 
alcohols, unsaturated hydrocarbons, tocopherols and sterols with antioxidative and anti-
inflammatory properties, (1) can stimulate GLP-2 secretion beyond the response elicited by 
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enteral nutrients and thereby (2) improve intestinal permeability and animal growth as well as (3) 
reduce the incidence of diarrhea in preweaning dairy calves. 
All procedures used in this experiment were approved by the University of Illinois 
Institutional Animal Care and Use Committee. Sixty heifer calves, less than 1 wk old, were 
purchased from a cattle dealer in southern Wisconsin and transported (approximately 470 km 
and 5 h transport time) to the University of Illinois Nutrition Field Laboratory research site 
(Urbana, IL). Animals were brought in 2 groups (batch) of 30 calves 2 wk apart to facilitate 
processing and early sample collection. At arrival, calves were rehydrated with an oral 
electrolyte solution (C.H.E.E.R.S., Nouriche Nutrition Ltd., St. Louis, MO). An hour after 
electrolyte administration, blood samples were taken from the jugular vein into a 10-mL 
evacuated serum separation tube (Becton Dickinson, Rutherford, NJ). Blood was kept at room 
temperature for 20 min and centrifuged at 1,300 × g for 15 min at 20°C. A refractometer was 
used to determine total protein from the serum for all calves. Initial measurements of BW, body 
length, heart girth, withers height, hip height, and hip width were obtained at the same time as 
blood sampling. All calves were given 2 mL of BO-SE (Merck Animal Health, Kenilworth, NJ), 
1 mL of vitamin A and D (Sparhawk Laboratories Inc., Lenexa, KS), and 2 mL of Inforce 
(Pfizer, New York, NY).  
This study was conducted as a randomized block design. At arrival and within the 2 
batches, calves were blocked by initial BW and TP and then randomly assigned within block to 1 
of 3 treatments. Calves were allowed to acclimatize to their new environment for 1 d before 
treatments were first administered. The treatments were standard milk replacer (MR) and ad 
libitum starter (control; CON); CON with OBE dosed in the MR at 30 mg/kg of BW (OBE30); 
and CON with OBE dosed in the MR at 60 mg/kg of BW (OBE60). The doses of OBE were 
estimated using allometric scaling of the amount of OBE required to induce GLP-2 secretion in 
weanling pigs in a pilot study and were adjusted weekly based on the corresponding dose and 
calf BW. The total amount of OBE fed to each calf was divided in 2 so that half of the daily 
allotment was given at each MR feeding. 
Calves were housed in south-facing individual hutches (Calf-tel, Hampel Corp., 
Germantown, WI) placed ~1.5 m apart from one another. Calves were fed twice daily at 0500 
and 1630 h. The MR was a commercial 28.5% CP and 15% fat formula (Milk Specialties Global, 
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Eden Prairie, MN) reconstituted to 15% solids. The feeding rate of MR per calf was 500 g/d 
during d 1 and 2, 750 g/d from d 3 to 7, 1,000 g/d from d 8 to 42, and 500 g/d from d 43 to 49. 
The intake of MR was recorded daily. Calf starter and water were offered for ad libitum 
consumption for the duration of the trial and intake was recorded daily. After d 49, MR was 
removed completely and only starter and water were given. Body weight, body length, heart 
girth, withers height, hip height, and hip width were measured weekly for the duration of the 
trial. Body weight and growth measures were obtained after the morning feeding. The 
assessment of intestinal permeability was conducted during the day before treatment initiation (d 
0), 2 wk after treatment exposure (d 13), and during the week before weaning (d 41). To this end, 
lactulose (0.5 g/kg of BW) and d-mannitol (0.1 g/kg of BW) were used as permeability markers 
and administered in the MR during the morning feeding (Hall, 1999). One hour after feeding 
(dosing) blood was collected via jugular venipuncture into a 10-mL evacuated serum separation 
tube and a 10-mL K2EDTA-coated blood collection tube (Becton Dickinson). Blood for serum 
separation was allowed to clot at room temperature and then centrifuged at 1,300 × g for 15 min 
at 20°C. Serum and plasma were divided into aliquots in polypropylene tubes and stored at 
−20°C until analyzed. Determination of serum lactulose and d-mannitol concentrations was 
performed by ultra HPLC-MS (Xevo G2 Tof, Waters, Milford, MA) with an electrospray 
ionization source operating in negative mode. Serum extract was injected (5 µL) onto a BEH 
amide column (2.1 mm × 100 mm, 1.7 µm, Waters). The mobile phases were water and 0.1% 
NH4OH, and methanol and 0.1% NH4OH. Elution conditions, at a flow rate of 0.3 mL/min, 
were 90% methanol + 0.1% NH4OH maintained for 2 min, linear gradient from 90 to 60% in 4 
min, and equilibration to initial conditions over 4 min. Column and auto-sampler chamber 
temperatures were maintained at 45 and 4°C, respectively. The operating conditions were source 
temperature = 120°C; desolvation temperature = 350°C; desolvation gas = 900 L/h; cone gas = 
10 L/h; capillary voltage = 0.5 kV; cone voltage = 30 V; and extraction cone = 4 V. Leucine 
enkephalin at a concentration of 2 µg/mL was used as a lock mass for mass accuracy and infused 
at a flow of 5 µL/min. Chromatograms were processed using Quanlynx software (v4.1, Waters).  
On d 12, blood samples were collected into 10-mL tubes containing EDTA (Becton 
Dickinson) plus a pyrrolic acid-based dipeptidyl peptidase 4 inhibitor (catalog#: DPP4, EMD 
Millipore, St. Charles, MO) before feeding and 1 h after feeding. Samples were kept on ice for 
15 min after collection and then centrifuged at room temperature for 15 min at 2,500 × g. The 
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plasma was extracted, put in liquid nitrogen, and stored at −20°C until further analyses. All 
plasma samples (700 μL) were extracted in a final concentration of 75% ethanol before GLP-2 
measurements as previously described (Taylor-Edwards et al., 2010). Intact GLP-2 was 
measured using a radioimmunoassay as previously described (Hartmann et al., 2000). Briefly, 
the antiserum (code no. 92160), developed as described in Wøjdemann et al. (1998), is directed 
against the N terminus of GLP-2 and, therefore, measures only fully processed GLP-2 of 
intestinal origin. For standards, we used recombinant human GLP-2 and the tracer was 125I-
labeled rat GLP2 with an Asp33→Tyr33 substitution. The sensitivity was 2 pmol/L and intra-
assay coefficient of variation below 6%. 
Data were analyzed using PROC GLIMMIX of SAS version 9.4 (SAS Institute Inc., 
Cary, NC). For Gaussian data (intake, MR intake as a percentage of BW, ADG, gain-to-feed 
ratio, permeability, and GLP-2 concentration) the model of variance analysis included treatment, 
time as a repeated measure (when appropriate), and their interaction as fixed effects. Block and 
batch were included as random effects in all models; however, block was not significant and 
therefore not used for statistical analyses. Initial measures of calf BW were included as a 
covariate for intake, BW, ADG, and gain-to-feed ratio. Because enteral nutrient supply is the 
primary stimulus for GLP-2 secretion (Burrin and Stoll, 2003), results for GLP-2 concentrations 
were analyzed unadjusted and covariate-adjusted using mean MR intake during the first 2 wk of 
study as covariate. Binary data (occurrence of diarrhea) were analyzed with a binomial 
distribution with a logit link function and included treatment and time as repeated measures and 
their interaction as fixed effects. Count data (days with diarrhea) were analyzed with a negative 
binomial distribution using a log link function with the fixed effect of treatment. Akaike 
information criterion was used to select the best covariate structure. Residuals were checked for 
homogeneity of variance and normality assumptions by residual plots and extended Levene test. 
Heterogeneous variances were handled by implementing error structures that allow for 
heterogeneous variances (Littell et al., 2006). Significance was set at P ≤ 0.10 and results were 
separated using Tukey adjustment. Additionally, the magnitude of treatment effect on the plasma 
concentration of GLP-2 (effect size) was assessed by calculating the 90 and 95% confidence 
intervals for the quotient between treatment (OBE30 and OBE60) and control group. Data are 
reported as least squares means according to treatment effects if no interactions are significant, 
or according to the highest order interaction detected. 
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We found no differences in final BW at wk 7 (73.8, 71.3, and 74.1 ± 2.5 kg for CON, 
OBE30, and OBE60, respectively), ADG (651.2, 608.4, and 641.0 ± 58.6 g/d for CON, OBE30, 
and OBE60, respectively), gain-to-feed ratio (0.60, 0.58, and 0.59 ± 0.06 kg/kg for CON, 
OBE30, and OBE60, respectively), or body conformation measurements (P > 0.10) among 
treatments throughout the experiment (data not shown). The prefeeding concentration of GLP-2 
in plasma was similar among treatments (Table 5.1). Upon MR feeding, GLP-2 increased for all 
groups albeit to a greater extent for the OBE treatments (P < 0.06). Compared with CON, 
however, this response was significantly higher only for the OBE60 group (P = 0.05). Estimation 
of the OBE effect size (Figure 5.1) indicates that OBE60 increased GLP-2 relative to CON on 
average by about 1 fold (33 pmol/L), and that, depending on the confidence level, this response 
could have reached up to either 5 (65 pmol/L; 90% CI) or 7 fold (72 pmol/L; 95% CI). These 
results are in line with previous data from in vitro and in vivo studies demonstrating that 
targeting TGR5 with endogenous (Jain et al., 2012; Ipharraguerre et al., 2013) or exogenous 
agonists (Katsuma et al., 2005; Thomas et al., 2009) has the potential to stimulate GLP-2 
secretion. 
The secretion of GLP-2 is mainly driven by the amount of feed ingested by calves 
(Castro et al., 2016).  Although we found no differences (P > 0.10) in starter intake (251.2, 
188.5, and 258.4 ± 38.9 g/d for CON, OBE30, and OBE60, respectively) or total DM ingestion 
(1,096.5, 1,028.5, and 1,093.3 ± 44.0 g/d for CON, OBE30, and OBE60, respectively) among 
experimental groups, we did note a treatment by time interaction (P < 0.03) for the consumption 
of MR during the preweaning period. This interaction was caused by OBE60 calves, which 
consumed less MR than CON and OBE30 calves during the wk 2 of the study (869 vs. 937 and 
929 g/d, respectively). Importantly, after wk 2, all calves achieved similar MR intake, which 
averaged 953 g/d until weaning. This finding suggests that poor MR palatability resulting from 
the feeding of OBE at the highest dose could not have played a role in limiting MR intake of 
OBE60 calves. As indicated below, differences in disease load among treatments did not appear 
either to account for the described alterations in MR intake. Alternatively, such a response could 
be attributed to the anorectic properties of GLP-2 (Guan, 2014) and, in particular, of the co-
secreted GLP-1 (Turton et al., 1996), whose plasma concentration also should have increased in 
response to the administration of OBE60. However, intake of MR as a percentage of BW was not 
different (P > 0.10) and averaged 1.5% of BW for all treatments. This feeding level is well above 
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the critical point for GLP-2 secretion identified by Castro et al. (2016) of 0.875% of BW in 
preweaned dairy calves, at which point GLP-2 secretion is significantly reduced. Certainly, 
adjusting GLP-2 concentration using MR intake as a covariate did not alter the aforementioned 
effect of OBE60 on the pre- and postfeeding circulating concentrations of GLP-2 (Table 5.1). 
Therefore, the difference in MR intake during wk 2 likely had minimal effects on GLP-2 
secretion because the attained feeding rate should have promoted near maximal nutrient 
dependent secretion of GLP-2 for all treatments. 
The incidence of diarrhea was high in our study, suggesting that all calves were highly 
challenged with enteric pathogens. Across treatments, calves were 3.88 and 9.93 times more 
likely (P < 0.0001) to have diarrhea in wk 1 compared with wk 2 and 3, respectively. 
Additionally, calves were 2.56 times more likely (P < 0.0001) to develop such a disease in wk 2 
than 3. In relation to treatment groups, CON animals were 0.62 and 0.54 times less likely (P < 
0.001) to have scours than OBE30 and OBE60 calves, respectively. During the first 3 wk of 
study, however, we found no differences between OBE30 and OBE60 calves for the incidence of 
scours. Furthermore, during the same period the number of days with diarrhea did not differ (P = 
0.32) among treatments groups (7.05, 8.35, and 9.05 d with diarrhea for CON, OBE30, and 
OBE60 calves, respectively). 
Enteric challenges result in disruption of intestinal barrier by altering the tight junction 
proteins or causing damage to enterocytes (Sears, 2000; Groschwitz and Hogan, 2009; 
Ulluwishewa et al., 2011). The lactulose/d-mannitol test has been validated to assess small 
intestine permeability in many species, including calves (Hall, 1999; Klein et al., 2007). 
Lactulose is a marker of the paracellular permeability in the small intestine, or unrestricted entry 
of macromolecules, whereas mannitol is a marker of the transcellular absorption of small 
molecules (Bjarnason et al., 1995; Hall, 1999). The lactulose-to-d-mannitol ratio was not 
affected by treatment or its interaction with time (P > 0.10), but we found a significant time 
effect (P < 0.0001). The evolution of intestinal permeability illustrated by the lactulose-to-d-
mannitol ratio indicates that permeability increased remarkably at 2 wk of age for all treatment 
groups (Figure 5.2). This high serum lactulose-to d-mannitol ratio would suggest damaged villi 
in the small intestine, allowing greater flux of large molecules across the intestinal mucosa 
during wk 2 (Hall, 1999). These results agree with the aforementioned incidence of diarrhea and 
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findings from Araujo et al. (2015), who showed diarrheic calves had higher serum lactulose-to d-
mannitol ratios even soon after birth. It is important to note that the serum lactulose levels 
observed in our study were 2.2 times greater than those observed by Araujo et al. (2015) in 
diarrheic calves, highlighting the compromised intestinal integrity of calves across all treatments 
in this trial. Furthermore, the lactulose to-d-mannitol ratio observed in our study is also much 
higher than other studies have reported in dairy calves across all time points (Branco Pardal et 
al., 1995; Klein et al., 2007, 2008). Previous studies have shown greater blood flow and 
epithelial development in response to salutary application of GLP-2 (Taylor-Edwards et al., 
2011; Connor et al., 2013). In addition, GLP-2 has also been found to reduce intestinal barrier 
permeability and inhibit inflammation in the gut (Drucker et al., 1996; Burrin et al., 2003; 
Drucker, 2005). Therefore, it is likely that the preexisting health status of calves enrolled in our 
study might have been too poor for the OBE60-induced secretion of GLP-2 to improve their 
intestinal permeability and health. 
In summary, our study demonstrates that it is possible to induce the secretion of 
endogenous GLP-2 in dairy calves and that OBE can be used for such a purpose. However, the 
increase in GLP-2 secretion did not elicit improvements in permeability and gut function 
enabling calves to overcome the severity of the enteric challenge. This suggests that the 
magnitude or timing relative to disease onset of the increase in GLP-2 secretion might have not 
been adequate to improve intestinal health of calves. In view of these observations, it seems 
reasonable to propose that further research is warranted to investigate the possibility of 
improving intestinal integrity through OBE-induced GLP-2 secretion in newborn calves. 
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TABLE AND FIGURES 
Table 5.1.  Concentrations of glucagon-like peptide-2 (GLP-2) and permeability markers in plasma of dairy calves fed OBE in milk 
replacer during the preweaning period (wk 1-7).  
a, b Means within a row with different superscripts differ (P = 0.05). 
1CON = control, OBE30 = bioactive extract from Olea europaea fed in the milk replacer at 30 mg/kg of BW, OBE60 = bioactive 
extract from Olea europaea fed in the milk replacer at 60 mg/kg of BW.  
2GLP-2 sampled during wk 2 immediately before milk replacer feeding (pre-feeding) and 60 min after milk replacer feeding (post-
feeding).  
3Delta = post-feeding GLP-2 concentration – pre-feeding GLP-2 concentration.    
4GLP-2 concentrations adjusted using mean milk replacer intake during the first 2 weeks of study as covariate. 
4Mannitol, Lactulose and Lactulose/D-mannitol measured wk 0, 2, and 6.   
 Treatments1  P-values 
Variable CON OBE30 OBE60 SE Trt Time Trt*Time 
GLP-22        
  Pre-feeding, pmol/L 30.6 31.8 30.4 3.2 0.95 - - 
  Post-feeding, pmol/L 67.5 72.9 100.4 11.7 0.13 - - 
  Delta3, 36.9b 42.4 ab 69.9 a 13.2 0.06 - - 
Adjusted GLP-24        
  Pre-feeding , pmol/L 30.6 31.8 30.4 3.2 0.94 - - 
  Post-feeding , pmol/L 68.3 72.3 100.1 11.9 0.15 - - 
  Delta 3  38.4 b 41.6b 69.4a 14.1 0.07 - - 
Permeability indicators        
  Mannitol5, μg/mL 1.32 1.33 1.30 0.09 0.98 <0.0001 0.99 
  Lactulose5, μg/mL 33.64 33.98 34.33 0.92 0.87 <0.0001 0.65 
  Lactulose/D-mannitol5 27.56 27.21 28.30 1.56 0.88 <0.0001 0.77 
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Figure 5.1. Confidence intervals of the quotient between treatments and control (effect size) for 
the change in plasma glucagon-like peptide-2 (GLP-2) concentration in response to feeding of a 
bioactive extract from Olea europaea (OBE) in the milk replacer (delta) to heifer Holstein 
calves.  OBE30/CON (●) = bioactive extract from Olea europaea fed in the milk replacer at 30 
mg/kg of BW followed by control; OBE60/CON (■) = bioactive extract from Olea europaea fed 
in the milk replacer at 60 mg/kg of BW followed by control.    
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Figure 5.2. Evolution of lactulose/D-mannitol ratio in heifer Holstein calves fed a milk replacer 
(CON; solid line), or the same milk replacer supplemented with a bioactive extract from Olea 
europaea at 30 mg/kg of BW (OBE30; dashed line) or 60 mg/kg of BW (OBE60; dotted line) 
over a 6 wk time period (trt: P = 0.88; time: P < 0.001; trt × time: P = 0.77).  Values are LSM ± 
SEM.   
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CHAPTER 6.  EFFECT OF A BIOACTIVE EXTRACT FROM THE OLIVE (OLEA 
EUROPAEA) FED TO DAIRY CALVES IN THE PREWEANING PERIOD ON INTAKE, 
GROWTH, AND BLOOD METABOLITES 
INTRODUCTION 
Intestinal disorders are common in newborn calves. A survey conducted in the United 
States in 2011 showed that about 25% of preweaned heifers had diarrhea and that diarrhea or 
other digestive problems accounted for 31% of the preweaning heifer mortality (NAHMS, 2011). 
Neonatal diarrhea is frequently observed from 3 to 21 d of age, but its onset and duration is 
determined by the number of pathogens involved and the immune condition of the animal (Butler 
and Clark, 1994). Regardless of the etiology, diarrhea episodes involve profound alterations in 
the mechanism controlling gut barrier function that ultimately compromise intestinal 
permeability to macromolecules, including pathogenic bacteria.  
Past and recent studies in pig models of intestinal dysfunction suggest that a key element 
of intestinal adaptation during the neonatal and early postweaning phases is the nutrient-induced 
secretion of GLP-2 and associated effects on mucosal cell proliferation, barrier function, and 
inflammatory response (Burrin et al., 2003; Cameron and Perdue, 2005; Sigalet et al., 2007; 
Ipharraguerre et al., 2013). In calves, episodes of diarrhea are associated with decreases in 
intake, and we have recently shown that the concentration of circulating GLP-2 decreases 
remarkably when ingestion drops below 0.875% of the calf BW (Castro et al., 2016). 
Additionally, bioactive molecules extracted from Olea europaea have been shown to induce the 
secretion of GLP-1, which is co-secreted with GLP-2, in model enteroendocrine cells via 
activation of the bile acid receptor TGR5 (Bala et al., 2014). Furthermore, recent work in 
newborn or weanling piglets showed that the enteral administration of the primary bile acid 
chenodeoxycholic acid, a TGR5 agonist, to newborn or weanling piglets increases endogenous 
GLP-2 secretion and intestinal growth (Jain et al., 2012; Ipharraguerre et al., 2013).  
Although not yet explored, an ability to enhance endogenous GLP-2 secretion via the 
feeding of plant-derived GLP-2 agonists would be a potentially attractive approach for 
promoting intestinal adaptation and function in newborn calves. If demonstrated, then the 
incidence of intestinal disorders and associated preweaning growth limitation may be reduced. 
The objectives of our study were to determine whether an extract from Olea europaea (OBE; 
Lucta S.A., Montornes del Valles, Spain), with a high content of polyphenols, triterpenic acids, 
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long-chain fatty alcohols, unsaturated hydrocarbons, tocopherols and sterols with antioxidative 
and anti-inflammatory properties, (1) can stimulate GLP-2 secretion beyond the response elicited 
by enteral nutrients and, thereby, (2) improve intestinal permeability and animal growth, as well 
as (3) reduce the incidence of diarrhea in preweaning dairy calves.   
MATERIALS AND METHODS 
Calves, Arrival, and Processing 
All procedures used in this experiment were approved by the University of Illinois 
Institutional Animal Care and Use Committee. Sixty female calves, less than 1 wk old, were 
purchased from a cattle dealer in southern Wisconsin and transported (approximately 470 km 
and 5 h transport time) to the University of Illinois Nutrition Field Laboratory research site 
(Urbana, IL). Animals were brought in 2 groups (batches) of 30 calves 2 wk apart to facilitate 
processing and early sample collection. At arrival, calves were rehydrated with an oral 
electrolyte solution (C.H.E.E.R.S., Nouriche Nutrition Ltd., St. Louis, MO). An hour after 
electrolyte administration, blood samples were taken from the jugular vein into a 10-mL 
evacuated serum separation tube (Becton Dickinson, Rutherford, NJ). Blood was kept at room 
temperature (20°C) for 20 min and centrifuged at 1,300 × g for 15 min at 20°C. A refractometer 
was used to determine total protein (TP) from the serum for all calves. Initial measurements of 
BW, body length, heart girth, withers height, hip height, and hip width were obtained at the same 
time as blood sampling. All calves were given 2 mL of BO-SE (Merck Animal Health, 
Kenilworth, NJ), 1 mL of vitamin A and D  (Sparhawk Laboratories Inc., Lenexa, KS), and 2 mL 
of Inforce (Pfizer, New York, NY). 
This study was conducted as a randomized block design. At arrival and within the 2 
batches, calves were blocked by initial BW and TP and then randomly assigned within block to 1 
of 3 treatments. Calves were allowed to acclimatize to their new environment for 1 d before 
treatments were first administered. The treatments were standard milk replacer (MR) and ad 
libitum starter (control; CON); CON with OBE dosed in the MR at 30 mg/kg of BW per day 
(OBE30); and CON with OBE dosed in the MR at 60 mg/kg of BW per day (OBE60). The doses 
of OBE were estimated using allometric scaling of the amount of OBE required to induce GLP-2 
secretion in weanling pigs in a pilot study and were adjusted weekly based on the corresponding 
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dose and calf BW. The total amount of OBE fed to each calf was divided in two so that half of 
the daily allotment was given at each MR feeding. 
Calf Housing 
Calves were housed in south-facing individual hutches (Calf-tel, Hampel Corp., 
Germantown, WI) placed ~1.5 m apart from one another.  Hutches were placed on a base of 
crushed rock, covered by landscape cloth and a layer of straw.  Straw was checked daily and 
more added as needed.  Temperature and humidity were determined using data from the local 
weather station (www.wunderground.com/history/). 
Feeding and Management 
Calves were fed twice daily at 0500 and 1630 h. The milk replacer (MR) was a 
commercial 28.5% CP and 15% fat formula (Excelerate, Milk Specialties Global, Eden Prairie, 
MN) reconstituted to 15% solids.  The feeding rate of MR per calf was 500 g/d during d 1 and 2 
after arrival, 750 g/d from d 3 to 7, 1,000 g/d from d 8 to 42, and 500 g/d from d 43 to 49.  The 
MR was fed once per day from d 43 to 49.  The intake of MR was recorded daily.  Calf starter 
(AMPLI-Calf® Starter 22, Purina Animal Nutrition LLC, Gray Summit, MN) and water were 
offered for ad libitum consumption for the duration of the trial and intake was recorded daily.  
After d 49, MR was removed completely and only starter and water were given.  
Feed Analysis 
Milk replacers were sampled once weekly and stored at −20˚C until analysis.  Composite 
samples were created to represent each month and were analyzed by Dairy One (Ithaca, NY) for 
DM, CP, SP, fat, and ash by standard wet chemistry methods (www.dairyone.com).  Values for 
ME were estimated from chemical composition as described (www.dairyone.com). 
Starter was sampled weekly and stored at −20˚C until analysis.  Composite samples were 
created to represent each month and were analyzed by Dairy One using wet chemistry techniques 
for DM, CP, SP, ADF, aNDF, lignin, fat, ash, and starch. 
Body Growth and Measurements 
Body weight, body length, heart girth, withers height, hip height, and hip width were 
measured upon arrival and weekly thereafter for the duration of the trial.  Body weight and 
125 
 
growth measures were obtained at the same time relative to feeding and day specified for each 
group of calves based on their arrival date. 
 Health 
 Health checks were performed daily.  Fecal scores were assigned on a 1 to 4 scale: 1 – 
normal and well formed; 2 = soft but still holds form; 3 = loose without form; and 4 = 
consistency of water.  Respiratory scores were assigned on a 1 to 5 scale: 1 = normal; 2 = open 
mouth breathing; 3 = open mouth breathing with mucus; 4 = dry cough, and 5 = wet cough.  
Calves were considered to have diarrhea if they had a fecal score above 2 and a respiratory 
infection if the score was above 1.  Overall appearance and behavior were also recorded.  After 
arrival, rectal temperature was measured daily for 3 d and at any time when a calf showed signs 
of illness throughout the duration of the study.  Navels were dipped in povidone iodine as needed 
until dry. Animals were monitored multiple times daily for illness and dehydration status and 
treated as needed.  Flunixin meglumine (Phoenix Pharmaceutical, Inc., St. Joseph, MO) was 
administered to calves with a rectal temperature of 40˚C or above.  An electrolyte solution 
(C.H.E.E.R.S., Nouriche Nutrition Ltd., St. Louis, MO) was administered as needed.   
Blood Sampling 
Blood metabolites were evaluated during the day before treatment administration (d 0), 2 
wk after treatment exposure (d 13), during the week before weaning (d 41), and during the week 
after weaning (d 55).  One hour after feeding (dosing) blood was collected via jugular 
venipuncture into a 10 mL evacuated serum separation tube (Benton Dickinson).  Blood was 
allowed to clot at room temperature (20°C) and then centrifuged at 1,300 × g for 15 min at 20°C.  
Serum was divided into aliquots in polypropylene tubes and stored at -20°C until analyzed.  A 
chemistry panel was conducted to determine concentrations of creatinine (milligrams/deciliter), 
urea N (milligrams/deciliter), total protein (grams/deciliter), albumin (grams/deciliter), globulin 
(grams/deciliter), Ca (milligrams/deciliter), P (milligrams/deciliter), Na (micromols/liter), K 
(micromols/liter), Cl (micromols/liter), glucose (milligrams/deciliter), alkaline phosphatase 
(units/liter), creatine phosphokinase (CPK; units/liter), total bilirubin (milligrams/deciliter), 
cholesterol (milligrams/deciliter), glutamate dehydrogenase activity (GLDH; units/liter), 
bicarbonate (micromols/liter), Mg (milligrams/deciliter), triglycerides (milligrams/deciliter), and 
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anion gap were performed by automated enzymatic analysis procedures at the University of 
Illinois College of Veterinary Medicine diagnostic laboratory (Urbana, IL).   
Statistical Analysis 
Data were analyzed using PROC GLIMMIX of SAS version 9.4 (SAS Institute Inc., 
Cary, NC). For Gaussian data (intake, MR intake as a percentage of BW, ADG, gain-to-feed 
ratio, growth, and blood metabolites) the model of variance analysis included treatment, time as 
a repeated measure (when appropriate), and their interaction as fixed effects. Block and batch 
were included as random effects in all models; however, block was not significant and therefore 
not used for statistical analyses. Initial measures of calf BW were included as a covariate for 
intake, BW, ADG, and gain-to-feed ratio. Initial measures of stature were included as a covariate 
for the respective variable.  Binary data (occurrence of diarrhea and medication) were analyzed 
with a binomial distribution with a logit link function and included treatment and time as 
repeated measures and their interaction as fixed effects. Count data (days with diarrhea and 
medicated) were analyzed with a negative binomial distribution using a log link function with the 
fixed effect of treatment. The corrected Akaike information criterion was used to select the best 
covariate structure. Residuals were checked for homogeneity of variance and normality 
assumptions by residual plots and extended Levene test. Heterogeneous variances were handled 
by implementing error structures that allow for heterogeneous variances (Littell et al., 2006). 
Significance was declared at P ≤ 0.05 and trends discussed when 0.05 < P ≤ 0.10.  Results were 
separated using Tukey adjustment. Data are reported as least squares means according to 
treatment effects if no interactions were significant, or according to the highest order interaction 
detected. 
RESULTS 
Environment 
Two groups of calves were brought to the research facility within 2 wk of each other and 
environmental conditions were recorded for the duration of the experiment. The daily mean high 
temperature was 27°C and the low temperature was 17°C, which is above the lower critical 
temperature for young calves (NRC, 2001). Within these environmental temperatures, average 
MR intake for the preweaning period should have allowed for 570 g/d of energy allowable ADG 
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and 820 g/d of apparent digestible protein allowable gain from MR consumed under 
thermoneutral conditions according to NRC (2001).   
Intakes 
Overall intakes of DM, CP, and ME from MR, starter, and total intake for the pre- and 
post-weaning periods are shown in Table 6.1.  There was a treatment by time interaction (P = 
0.03) for the consumption of MR during the preweaning period (Figure 6.1).  Calves fed OBE60 
tended (P = 0.08) to consume less MR (869 g/d) during wk 2 compared to CON (937 g/d), but no 
difference compared to OBE30 (929 g/d).  After wk 2 there was no differences in MR intake 
among treatments.   
There were no differences (P > 0.10) in starter intake (251.2, 188.5, and 258.4 ± 38.9 g/d 
for CON, OBE30, and OBE60, respectively) or total DM ingestion (1,096.5, 1,028.5, and 
1,093.3 ± 44.0 g/d for CON, OBE30, and OBE60, respectively) among experimental groups pre-
weaning. There were no differences (P = 0.11) in starter intake postweaning (2062.7, 1958.1, and 
2015.5 ± 162.8 g/d for CON, OBE30, and OBE60, respectively).  Starter intake over the course 
of the experiment is shown in Figure 6.2.   
Growth 
Mean BW, ADG, feed efficiency (gain:feed), and growth measurements for the 
preweaning period (wk 1 to 7) are presented in Table 6.2. Initial BW was not different among 
treatments (P = 0.95).  Mean preweaning BW (59.3, 57.6, and 57.8 ± 1.6 kg for CON, OBE30, 
and OBE60, respectively) and BW at weaning (wk 7; 73.8, 71.3, and 74.1 ± 2.5 kg for CON, 
OBE30, and OBE60, respectively) were not different (P > 0.10) among treatments.  Furthermore, 
there were no differences in ADG (651.2, 608.4, and 641.0 ± 58.6 g/d for CON, OBE30, and 
OBE60, respectively), gain:feed ratio (0.60, 0.58, and 0.59 ± 0.06 kg/kg for CON, OBE30, and 
OBE60, respectively), or body measurements in the preweaning period.   
Mean BW, ADG, gain:feed, and growth measurements for the postweaning period (wk 8 
to 9) are presented in Table 6.3. After weaning there continued to be no difference (P > 0.10) in 
final BW at wk 9 (82.4, 81.0, and 83.7 ± 3.1 kg for CON, OBE30, and OBE60, respectively), 
ADG (609.6, 602.3, and 609.8 ± 98.3 g/d for CON, OBE30, and OBE60, respectively), or gain-
to-feed ratio (0.28, 0.27, and 0.26 ± 0.04 kg/kg for CON, OBE30, and OBE60, respectively).  
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There were no differences in hip height, heart girth, or body length in the 2 wk after weaning. A 
treatment by time interaction was observed for withers height (88.9, 89.1, and 89.2 ± 0.6 cm for 
CON, OBE30, and OBE60, respectively) and hip width (24.2, 24.0, and 24.0 ± 0.19 cm for 
CON, OBE30, and OBE60, respectively) however, compared within week with a Tukey-Kramer 
adjustment there were no differences among treatments.  The evolution of calf BW is shown in 
Figure 6.3.   
Average environmental temperature for the calves was within thermoneutral conditions 
for young calves under 3 wk of age (NRC, 2001).  The ADG for wk 1 to 7 of the study averaged 
633 g/d, and expected energy allowable ADG under thermoneutral conditions was 570 g/d from 
milk replacer and 720 g/d from average intake of both milk replacer and starter in the 
preweaning period.  In the postweaning period (wk 8 to 9) the ADG averaged 607 g/d among 
treatments and was estimated to support 650 g/d energy allowable ADG (NRC, 2001). 
Health 
There were no differences in initial serum total protein with averages of 5.13, 4.93, and 
5.07 g/dL (SE = 0.17; P = 0.68) for calves fed CON, OBE30, and OBE60, respectively.  One calf 
from treatment CON and one calf from OBE30 was not included in the final analysis because 
they were sick at arrival and did not recover.  Overall, two calves in CON died, one from E. coli 
and one from bacterial pneumonia.  Three calves in OBE30 died from E. coli and 4 calves from 
OBE60 died from E. coli.   Eight of the calves died within the first 2 wk of arrival.  This fact 
paired with the main identified bacterial cause would indicate a severe enteric challenge soon 
after birth that did not allow the calves to recover.  Two of the calves had chronic enteric 
challenges and were euthanized on d 51 of the experiment because they were not improving and 
were not consuming sufficient starter to facilitate successful weaning.   
Table 6.4 shows the logistic models for the occurrence of diarrhea (score > 2) and 
medication with antibiotics.  Calves fed CON were less likely to have diarrhea in the first 21 d 
when compared to OBE30 and OBE60 (OR 0.62; P = 0.006 and OR 0.54; P = 0.0004).  
However, there was no difference in the likelihood of diarrhea between the two treatments 
supplemented with OBE (P = 0.59). Similarly, calves fed CON were less likely to be medicated 
with antibiotics compared to OBE30 and OBE60 (OR 0.51; P = 0.005 and OR 0.58; P = 0.03).  
Table 6.5 shows the logistic models for the number of days with diarrhea, the duration of 
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treatment with antibiotics, and the number of days electrolytes were given.  There were no 
differences (P > 0.10) among treatments in the number of days calves experienced diarrhea, days 
given electrolytes, or days medicated.   
Blood Metabolites 
Concentrations of blood metabolites are presented in Table 6.6.  There was a significant 
interaction (P = 0.05) for total protein in the preweaning period.  However, with a Tukey-Kramer 
adjustment there were no differences among treatments for total protein.  Numerically, calves fed 
OBE30 had higher total protein compared to CON and OBE60 (5.44 vs. 5.38 and 5.37 ± 0.11 
g/dL, respectively).  Furthermore, there tended be treatment by time interactions for globulin, 
Na, and glucose.  The Tukey-Kramer adjustment revealed no significant interactions of 
treatments within weeks for globulin or glucose.  During wk 2 Na was significantly increased for 
calves fed CON compared to OBE60 (138.2 vs. 135.0 mmol/L; P = 0.05). 
DISCUSSION 
Phytogenic feed additives, or plant derived compounds, have previously been 
incorporated into livestock feed as a method to improve productivity, promote performance, and 
to improve food quality from those animals (Windisch et al., 2008).  The use of a bioactive 
extract from the olive (Olea europaea) as a plant derived agonist of GLP-2 secretion, in order to 
promote health and growth, has yet to be evaluated in newborn calves before this experiment.  
Bioactive molecules extracted from OBE have been shown to induce the secretion of GLP-1, 
which is co-secreted with GLP-2, in model enteroendocrine cells via activation of the bile acid 
receptor TGR5 (Bala et al., 2014). In chapter 4 (Morrison et al., 2017) of this dissertation we 
observed an increase in the secretion of GLP-2 when OBE was supplemented at 60 mg/kg of BW 
per d relative to CON indicating that OBE was able to stimulate increased GLP-2 secretion in 
dairy calves (Morrison et al., 2017).  Previous work in LPS challenged piglets has shown 
positive effects on growth when supplemented with OBE, thought to be mediated through anti-
inflammatory effects by the inhibition of IL1B and promotion of intestinal integrity (Leihr et al., 
2017).  Therefore, the objective was to determine if the bioactive extract OBE could improve 
animal growth and reduce incidence of diarrhea in preweaning dairy calves through its potential 
anti-oxidative and anti-inflammatory properties.   
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We had hypothesized that OBE would stimulate secretion of GLP-2 and improve gut 
permeability.  As decribed in Morrison et al. (2017) there was increased secretion of GLP-2 for 
OBE60 during wk 2.  GLP-2 is linked to nutrient intake (Castro et al., 2016) so the lower intake 
did not impair secretion during this time.  It is unlikely that the increased GLP-2 (and GLP-1) 
secretion caused the reduction in intake, due to its anorectic properties (Guan et al., 2014) 
because of there was no difference in GLP-2 secretion for OBE60 compared to control, which 
did not have a reduction in intake during wk 2.  While it appeared that GLP-2 secretion was 
stimulated it did not appear to result in any positive effects relative to enteric disease or growth 
measures.  Enteric challenges result in disruption of intestinal barrier by altering the tight 
junction proteins or causing damage to enterocytes (Sears, 2000; Groschwitz and Hogan, 2009; 
Ulluwishewa et al., 2011).  In the first 21 d, calves fed CON were less likely to have diarrhea 
compared to calves fed either level of OBE, while there was no difference in the number of days 
with diarrhea among all treatments.  Furthermore, calves fed CON were less likely to be 
medicated compared to the two OBE treatments.   
In pigs fed OBE increases in mRNA abundance of CDH1, OCLN, and ZO-1 were 
observed in the ileum and increases in TEER during in vivo experiments have been observed 
(Liehr et al., 2017).  This indicates improved integrity of the intestinal mucosa.  Measurements 
of intestinal permeability at arrival for the current experiment indicated that calves may have had 
compromised intestinal permeability before treatment administration began.  Araujo et al., 
(2015) observed that sick calves had higher concentrations of lactulose at birth when 
administered a dual marker permeability test.  The average lactulose concentration across 
treatments in the current experiment was 7.0 µg/mL for calves at arrival, while healthy calves 
from Araujo et al., (2015) consistently averaged below 5 µg/mL.  Similar increases in serum 
lactulose in the 2 wk after birth or arrival was observed in both healthy and sick calves, but to a 
greater extent in sick calves between the current experiment and the study conducted by Araujo 
et al., (2015). 
There are two types of inflammatory processes (Jiminez et al., 2015; Murakami and 
Hirano, 2012) which can classified as clinical or subclinical chronic inflammation (SCI; Liehr et 
al., 2017).  Clinical inflammation can result from bacterial infection, while SCI is much milder 
but more persistent immune response (Ashley et al., 2012).  Initial activation of the immune 
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system results in release of inflammatory cytokines, tumor necrosis factor alpha (TNF-α) and 
interleukin 1 beta (IL1B; Dinarello, 2007).  If concentrations continue to be increased then they 
can induce metabolic changes such as anorexia and shift in nutrient utilization for maintenance 
(Rakhshandeh et al., 2010; Liehr et al., 2017).  This may partly explain the reduction in MR 
intake during the second week for OBE60 with a 7% reduction relative to the control.  However, 
we did not measure concentrations of inflammatory cytokines so we are unable to say if this 
slight anorexia may be due to increased inflammatory cytokines or the effect of OBE on these 
parameters.  In piglets SCI can be induced with low level LPS injections, which results in 
elevated IL-1B concentrations.  When induced, a reduction in intake has been observed 
compared to the control of 23% (Liehr et al., 2017).  This has been partially mitigated to 13% of 
control with OBE supplementation thought to be through inhibition of IL-1B (Liehr et al., 2017).  
Although there were decreased intakes in OBE60 calves in wk 2 compared to control and overall 
high enteric challenge, we are uncertain of the severity and persistency relative to that observed 
in SCI induced models to make a direct comparison.  More research is needed to evaluate 
inflammatory cytokines and the role OBE may play in alleviating some of the challenges calves 
experience under these conditions.   
The estimated ADG in the preweaning period from the NRC (2001) was 720 g/d based 
on the average MR and starter intake but the observed ADG during this period was only 633 g/d.  
The estimates from NRC were calculated using thermoneutral conditions however, the daily 
mean high temperature averaged 27°C during the duration of the experiment which is at the 
upper limit of the thermoneutral range (NRC, 2001; Scibilia et al., 1987).  While there were not 
differences among treatments for ADG and other growth measures, there are several factors that 
can influence maintenance requirements including normal functions to support life, thermal 
regulation, response to infection (Griebel et al., 1987), and other stresses related to transportation 
and housing (Drackley, 2008).  Some of this reduction from the estimated ADG could be 
attributed to calves expending more energy to mitigate heat stress through panting or sweat 
(Drackley, 2008), which has been estimated to increase maintenance up to 20% to 30% in 
growing cattle (NRC, 2001).  Additionally, deviations from expected ADG could have also been 
attributed to the high number of days that calves experienced diarrhea across treatments and the 
subsequent response to infection (Griebel et al., 1987).   
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Two different inclusion levels of OBE were evaluated in this experiment.  Inclusion level 
was calculated based on work in pigs based on the amount of OBE required to induce GLP-2 
secretion but more work should be done to evaluate optimal inclusion level within a calf diet to 
illicit the greatest increase in GLP-2.  Bioavailability of polyphenolic compounds are very low in 
the small intestine with only 5% to 10% estimated to be absorbed in the small intestine (Faria et 
al., 2014).  Information on bioavailability of polyphenols in ruminants is scarce but there are 
some indications that at least part of the polyphenols are protected from the rumen (Gessner et 
al., 2017).  In monogastrics, bioavailability is influenced by the chemical structure of the 
polyphenol and its association with other plant cell constituents (Gessner et al., 2017).  Plant 
polyphenols also interact with host microbiota that changes the composition of polyphenol 
metabolites, which might explain health promoting effects (Gessner et al, 2017).  However, 
research with OBE did not observe any changes in colonic microbiota in response to OBE 
supplementation (Leihr et al., 2017).  Evaluating various concentrations of inclusion under 
different experimental settings will help elucidate the optimal inclusion level to promote growth 
and health of dairy calves.   
CONCLUSIONS  
Calves were exposed to high enteric challenge so OBE was unable to overcome the 
interruptions in gut barrier permeability to improve health and growth of calves relative to the 
control.  More research is needed to understand the effect of OBE on the inflammatory process 
in dairy calves.  It is possible that a timing relative to onset of challenge should be earlier or the 
dose level may need to be higher in dairy calves to observe benefits in health and growth.   
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TABLES AND FIGURES 
Table 6.1.  Intakes of dry matter (DM), crude protein (CP), and metabolizable energy (ME) from 
milk replacer, starter and total intake of dairy calves fed a bioactive extract from the olive (Olea 
europaea) in milk replacer during the preweaning period (wk 1 to 7). 
1CON = control, OBE30 = bioactive extract from Olea europaea fed in the milk replacer at 30 
mg/kg of BW, OBE60 = bioactive extract from Olea europaea fed in the milk replacer at 60 
mg/kg of BW.  
 Treatments1  P-values 
Variable CON OBE30 OBE60 SE Trt Time Trt×Time 
Pre-weaning (wk 1 to 7) 
  Milk Replacer        
    DM, g/d 846.4 840.6 834.7 9.3 0.68 <0.0001 0.03 
    CP, g/d 248.9 247.0 245.5 2.8 0.69 <0.0001 0.03 
    ME, kcal/d 3680 3654 3629 40 0.68 <0.0001 0.03 
  Starter        
    DM, g/d 251.2 188.5 258.4 38.9 0.39 <0.0001 0.97 
    CP, g/d 61.7 46.3 63.5 9.5 0.39 <0.0001 0.96 
   ME, kcal/d 768 576 789 119 0.39 <0.0001 0.96 
  Total        
    DM, g/d 1096.5 1028.5 1093.3 44.0 0.47 <0.0001 0.84 
    CP, g/d 310.2 293.1 309.0 11.0 0.48 <0.0001 0.77 
    ME, kcal/d 4440 4226 4418 141 0.51 <0.0001 0.72 
Post-weaning (wk 8 to 9) 
  Starter        
    DM, g/d 2062.7 1958.1 2015.5 162.8 0.90 <0.0001 0.11 
    CP, g/d 503.3 477.8 491.8 39.7 0.90 <0.0001 0.11 
   ME, kcal/d 6291.3 5972.1 6147.3 496.4 0.90 <0.0001 0.11 
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Table 6.2.  Body weight and growth measurements of dairy calves fed a bioactive extract from 
the olive (Olea europaea) in milk replacer during the preweaning period (wk 1 to 7). 
1CON = control, OBE30 = bioactive extract from Olea europaea fed in the milk replacer at 30 
mg/kg of BW, OBE60 = bioactive extract from Olea europaea fed in the milk replacer at 60 
mg/kg of BW.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Treatments1  P-values 
Variable CON OBE30 OBE60 SE Trt Time Trt×Time 
Initial BW, kg 40.2 40.2 40.5 0.81 0.95 - - 
Mean BW, kg  59.3 57.6 57.8 1.6 0.59 <0.0001 0.75 
Final BW, kg (wk 7) 73.8 71.3 74.1 2.5 0.67 - - 
ADG, g/d 651.2 608.4 641.0 58.6 0.82 <0.0001 0.48 
Gain:feed, kg/kg 0.60 0.58 0.59 0.06 0.85 <0.0001 0.51 
        
Withers height, cm 82.1 82.2 82.0 0.5 0.86 <0.0001 0.80 
  ADG, cm/d 0.21 0.20 0.21 0.01 0.83 0.01 0.64 
Hip height, cm 86.5 86.3 85.8 0.10 0.41 <0.0001 0.61 
  ADG, cm/d 0.22 0.20 0.20 0.02 0.66 0.08 0.46 
Heart girth, cm 87.4 86.8 87.0 1.00 0.63 <0.0001 0.43 
  ADG, cm/d 0.33 0.31 0.33 0.03 0.58 0.002 0.49 
Body length, cm 80.7 81.2 80.3 1.03 0.67 <0.0001 0.50 
  ADG, cm/d 0.26 0.26 0.27 0.02 0.90 0.20 0.72 
Hip width, cm 22.6 22.4 22.4 0.77 0.27 <0.0001 0.34 
  ADG, cm/d 0.06 0.05 0.05 0.01 0.48 0.0003 0.11 
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Table 6.3.  Body weight and growth measurements in the two weeks post weaning (wk 8 to 9) of 
dairy calves fed a bioactive extract from the olive (Olea europaea) in milk replacer during the 
preweaning period (wk 1 to 7). 
1CON = control, OBE30 = bioactive extract from Olea europaea fed in the milk replacer at 30 
mg/kg of BW, OBE60 = bioactive extract from Olea europaea fed in the milk replacer at 60 
mg/kg of BW.  
 Treatments1  P-values 
Variable CON OBE30 OBE60 SE Trt Time Trt×Time 
Mean BW, kg  80.0 78.3 80.8 4.0 0.93 <0.001 0.52 
Final BW, kg (wk 9) 82.4 81.0 83.7 3.1 0.83 - - 
ADG, g/d 609.6 602.3 609.8 98.3 0.99 <0.001 0.24 
Gain:feed, kg/kg 0.28 0.27 0.26 0.04 0.79 0.008 0.12 
        
Withers height, cm 88.9 89.1 89.2 0.6 0.96 <0.001 0.04 
  ADG, cm/d 0.16 0.24 0.17 0.03 0.18 0.88 0.09 
Hip height, cm 93.0 93.7 91.8 0.8 0.28 <0.001 0.19 
  ADG, cm/d 0.16 0.19 0.16 0.03 0.63 0.02 0.13 
Heart girth, cm 98.2 96.9 97.3 1.1 0.73 <0.001 0.64 
  ADG, cm/d 0.32 0.30 0.27 0.03 0.63 0.35 0.46 
Body length, cm 89.5 89.4 88.4 0.89 0.67 <0.001 0.90 
  ADG, cm/d 0.28 0.26 0.09 0.06 0.04 0.21 0.73 
Hip width, cm 24.2 24.0 24.0 0.19 0.59 <0.001 0.006 
  ADG, cm/d 0.06 0.02 0.06 0.03 0.06 0.40 0.11 
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Table 6.4. The logistic model for diarrhea (wk 1 to 3) and medication (wk 1 to 7) occurrence by comparison of treatments of dairy 
calves fed a bioactive extract from the olive (Olea europaea) in milk replacer during the preweaning period (wk 1 to 7). 
Variable Comparison Coefficient SEM Odds ratio 95% CI P-Value 
Diarrhea occurrence       
 CON-TRT301 -0.4772 0.1739 0.62 0.44-0.87 0.006 
 CON –TRT60 -0.6012 0.1707 0.55 0.39-0.77 0.0004 
 TRT30-TRT60 -0.1240 0.1661 0.88 0.64-1.22 0.46 
Medicated        
 CON-TRT301 -0.6768 0.24 0.51 0.31-0.82 0.005 
 CON –TRT60 -0.5387 0.25 0.58 0.36-0.96 0.03 
 TRT30-TRT60 0.1481 0.21 1.15 0.76-1.76 0.47 
1The OR indicates the probability of either diarrhea or medication for the first treatment in the comparison to the second treatment. If 
the OR is greater than one the first treatment in the comparison is more likely to have either diarrhea or be medicated then the second 
treatment by a factor of the difference above one.  If the OR is less than one the first treatment has a lower probability of occurring 
then the second treatment.  
 
 
Table 6.5. The logistic model for days of diarrhea, respiratory, medication, and electrolyte occurrence by comparison of treatments of 
dairy calves fed a bioactive extract from the olive (Olea europaea) in milk replacer during the preweaning period (wk 1 to 7). 
 Treatment1   
Variable CON TRT30 TRT60 SE P-Value 
Diarrhea, d 7.05 8.35 9.05 1.13 0.32 
Electrolytes, d 0.74 1.08 1.82 1.59 0.30 
Medicated1, d 2.23 3.57 3.73 1.46 0.42 
1CON = control, OBE30 = bioactive extract from Olea europaea fed in the milk replacer at 30 mg/kg of BW, OBE60 = bioactive 
extract from Olea europaea fed in the milk replacer at 60 mg/kg of BW.  
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Table 6.6.  Concentrations of metabolites in serum sampled (wk 2 and 6) from dairy calves fed a 
bioactive extract from the olive (Olea europaea) in milk replacer during the preweaning period 
(wk 1 to 7). 
1CON = control, OBE30 = bioactive extract from Olea europaea fed in the milk replacer at 30 
mg/kg of BW, OBE60 = bioactive extract from Olea europaea fed in the milk replacer at 60 
mg/kg of BW.  
2 CPK: creatine phosphokinase; GLDH: glutamate dehydrogenase activity. 
 
 
 
 Treatments1  P-values 
Variable CON TRT30 TRT60 SE Trt Time Trt*Time 
Creatinine, mg/dL 0.85 0.76 0.85 0.04 0.05 0.23 0.54 
BUN, mg/dL 10.16 9.13 10.30 0.37 0.05 0.32 0.60 
Total Protein, g/dL 5.38 5.44 5.37 0.11 0.88 <0.0001 0.05 
Albumin, g/dL 2.72 2.68 2.75 0.05 0.50 0.20 0.70 
Globulin, g/dL 2.66 2.77 2.63 0.10 0.62 <0.0001 0.06 
Albumin/Globulin 1.06 1.06 1.09 0.04 0.85 <0.0001 0.16 
Ca, mg/dL 9.95 10.04 10.07 0.07 0.48 0.12 0.24 
P, mg/dL 8.06 7.55 7.86 0.19 0.19 <0.0001 0.40 
Mg, mg/dL 2.12 1.78 1.88 0.19 0.44 0.38 0.41 
Na, mmol/L 138.38 137.26 136.50 0.49 0.06 0.006 0.06 
K, mmol/L 4.85 4.78 4.86 0.06 0.51 0.49 0.22 
Na/K 28.58 28.83 28.18 0.42 0.36 0.33 0.40 
Cl, mmol/L 99.44 98.28 98.68 0.52 0.28 0.07 0.80 
Glucose, mg/dL 107.68 107.53 107.37 4.23 0.99 0.0004 0.07 
Triglycerides, mg/dL 36.8 40.5 35.1 3.79 0.54 0.02 0.49 
Alkaline Phosphorus, 
U/L 236.15 217.93 231.53 22.47 0.84 0.02 0.78 
CPK2, U/L 187.38 322.39 166.43 106.88 0.55 0.43 0.30 
Cholesterol, mg/dL 66.54 64.87 67.91 3.91 0.86 0.06 0.96 
GLDH2, U/L 41.67 31.97 34.20 7.55 0.59 0.02 0.41 
Bicarbonate, mmol/L 26.30 27.60 26.62 0.71 0.27 0.53 0.57 
Anion Gap 16.59 16.17 16.20 0.29 0.58 0.45 0.58 
138 
 
 
Figure 6.1. Evolution of milk replacer intake in heifer Holstein calves fed a milk replacer (CON; 
solid line), or the same milk replacer supplemented with a bioactive extract from Olea europaea 
at 30 mg/kg of BW (OBE30; dashed line) or 60 mg/kg of BW (OBE60; dotted line) over the 
preweaning period (trt: P = 0.68; time: P < 0.001; trt × time: P = 0.02).  Values are LSM ± SEM.   
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Figure 6.2. Evolution of starter intake in heifer Holstein calves fed a milk replacer (CON; solid 
line), or the same milk replacer supplemented with a bioactive extract from Olea europaea at 30 
mg/kg of BW (OBE30; dashed line) or 60 mg/kg of BW (OBE60; dotted line) over the 
experimental period (trt: P = 0.68; time: P < 0.001; trt × time: P = 0.97).  Values are LSM ± 
SEM.   
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Figure 6.3. Evolution of BW in heifer Holstein calves fed a milk replacer (CON; solid line), or 
the same milk replacer supplemented with a bioactive extract from Olea europaea at 30 mg/kg 
of BW (OBE30; dashed line) or 60 mg/kg of BW (OBE60; dotted line) during wk 1-7 (trt: P = 
0.84; time: P < 0.001; trt × time: P = 0.98).  Values are LSM ± SEM.   
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CHAPTER 7.  DETERMINATION OF OPTIMAL DOSAGE OF A BIOACTIVE 
EXTRACT FROM THE OLIVE (OLEA EUROPAEA) IN PROMOTING THE 
SECRETION OF GLP-1 AND ITS EFFECTS ON THE HEALTH AND GROWTH OF 
PREWEANING DAIRY CALVES 
INTRODUCTION 
Digestive disorders, including diarrhea, remain prevalent in the preweaning period of 
dairy calves, with over 25% of heifers in the United States being affected (NAHMS, 2011).  
Diarrheal challenges are associated with extensive alterations to the mechanistic control of 
barrier function and results in increased permeability and susceptibility to further bacterial 
invasion across the intestinal mucosa (Cameron and Perdue, 2005).  Prevention of intestinal 
dysfunction through stimulation of glucagon-like peptide-2 (GLP-2) has been evaluated 
previously in pig models as a way to increase mucosal cell proliferation, improve barrier 
function, and dampen the inflammatory response (Burrin et al., 2003; Cameron and Perdue, 
2005; Sigalet et al., 2007; Ipharraguerre et al., 2013).  In dairy calves, decreased intake is 
negatively associated with GLP-2 circulation when intake is below 0.875% of calf BW (Castro et 
al., 2016). Finding alternatives to maintain intestinal function in times of reduced intake could 
help maintain health and minimize the deleterious effects of enteric pathogens in preweaning 
dairy calves.   
Olea europaea has a high content of polyphenols, triterpenic acids, long-chain fatty 
alcohols, unsaturated hydrocarbons, tocopherols, and sterols with antioxidative and anti-
inflammatory properties (Ghanbari et al., 2012; Sanchez-Quesada et al., 2013; Periera et al., 
2007).  This bioactive extract has been shown to stimulate the secretion of GLP-1, which is co-
secreted with GLP-2, by activating the bile acid receptor TGR5 in enteroendocrine cells (Bala et 
al., 2014) and in mice (Rafferty et al., 2011).  Previously, we have shown that feeding OBE to 
dairy calves increased the secretion of GLP-2 but intestinal permeability was not improved, 
likely because of the severity of enteric challenges of the calves under investigation (Morrison et 
al., 2017).   
Toll like receptors (TLRs) respond to lipopolysaccharide (LPS) and lipoteichoic acids 
(LTA) by initiating a response to different bacterial challenges.  Activation of TLRs results in a 
signaling cascade including MyD88 and NFκB to increase production and secretion of pro-
inflammatory cytokines like tumor necrosis factor-α (TNFα) and interleukin-1β (IL-1β; Takeuchi 
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et al., 1999; Lien and Ingalls, 2002; Al).  Inflammatory changes can be evaluated at a 
transcriptomic level in the gastrointestinal tract by looking at genes related to the inflammatory 
response (i.e., TLR2, TLR4, NFKB1, TNFA, and IL1B) from RNA extracted from fecal samples 
(Rosa et al., 2018).   
The previous experiment evaluated 30 or 60 mg of OBE/kg of BW, dosages estimated 
using allometric scaling from a pig study.  It was unclear from the results if a higher dose of 
OBE might be necessary to elicit a response in dairy calves comparable to other species 
(Morrison et al., 2017).  Therefore the objectives of the following experiments were first, to 
determine the optimal inclusion level of OBE to promote maximal GLP-1 and GLP-2 secretion 
in preweaned calves.  Second, we aimed to determine if that dose of OBE can improve intestinal 
permeability and reduce inflammation.  Finally, we determined if these changes could reduce the 
incidence of diarrhea and improve growth of dairy calves through the preweaning period.  
MATERIALS AND METHODS 
All procedures were conducted under approval of the University of Illinois Institutional 
Animal Care and Use Committee.   
Experiment 1 
 The first experiment was conducted at the University of Illinois Dairy Unit (Urbana, IL) 
from February 18 to March 4, 2017.  Three male and two females were selected.  Calves were 
selected after 14 d of age to avoid the time of highest susceptibility of enteric pathogens and all 
calves selected were in good health.  The average calf age (mean ± SD) was 21 ± 6.2 d at the 
beginning of the trial and all calves completed the experiment before starting weaning.  Milk 
replacer intake did not change for the duration of the experiment.   
The study was conducted as a 5 × 5 Latin square design with five calves and five periods.  
Five doses of OBE (0, 60, 90, 120, and 180 mg/kg of BW per day) were randomly assigned to 
each calf during the five periods so that all treatment doses were represented in each period.  
Treatments were only administered once per period.  Only half of the experimental dose was 
given at time of treatment administration to mimic what would be added under normal (twice 
daily) feeding circumstances in a milk replacer.  The periods were 3 d with 2 d of washout and 1 
d of sampling.  Calves were fed a commercial 28.5% CP and 15% fat formula milk replacer 
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(MR; Milk Specialties Global, Eden Prairie, MN) two times daily at 0700 h and 1800 h.  Calves 
were offered a commercial starter (Purina Animal Nutrition LLC, Gray Summit, MN) for ad 
libitum consumption.  Milk replacer and starter intake was recorded daily.  Water was offered for 
ad libitum consumption but intake was not measured.   
On the day of sampling starter was removed and calves were offered their normal 
allotment of MR at 0700 h.  At 1100 h, all calves were weighed on a platform scale to determine 
the amount of OBE to be administered for the period.  At 1300 h, water buckets were removed to 
avoid potential influences of gut fill and water kinetics between calves when treatment was 
administered.  At 1600 h calves were administered a bolus with the amount of OBE in 7.5-mL 
gelatin capsules (Torpac, Fairfield, NJ).  To administer the bolus, calves were given a bottle with 
0.94 L of warm water to initiate the suckle reflex.  The bolus was given and the calf was 
immediately allowed access to the bottle to ensure the capsule was swallowed and the remainder 
of the water was consumed by the calf.  Calves receiving the 0 mg/kg dose received an empty 
bolus.  Blood was collected at 0, 15, 30, 60, 90, and 120 min relative to dosing.  Blood was 
collected into a 10-mL tube containing EDTA (Becton Dickinson) and a cocktail of enzyme 
inhibitors [DPP-IV inhibitor (10 µL/mL blood; catalog#: DPP4, EMD Millipore, St. Charles, 
MO) and protease inhibitors (10 µL/mL blood; catalog#: P2714, Sigma-Aldrich, St. Louis, 
MO)].  Samples were kept on ice for 15 min after collection and then centrifuged at room 
temperature for 15 min at 2,500 × g.  Aliquots of the plasma were separated and frozen in liquid 
nitrogen, and stored at -80°C until further analyses.  After sampling was completed, starter and 
water were returned to the calves and normal MR feeding continued.   
The plasma concentration of GLP-1 was measured using a commercially available 
ELISA kit (S-1359, Bachem Americas Inc., Torrance, CA).  Each sample was run in duplicate 
using the manufacturers’ recommended protocols.  The GLP-1 assay cross-reacts with human, 
bovine, guinea pig, mouse, and rat GLP-1 (7-36) amide with a range of 0.30 to 3,000 pmol/L.   
Statistical Analysis 
Data were analyzed using PROC MIXED of SAS version 9.4 (SAS Institute Inc., Cary, 
NC).  The concentration change (delta) of GLP-1 was calculated for all time points relative to 
time point 0 (before dose administration).  To analyze response of GLP-1 the model of variance 
analysis included calf, treatment, period, and time and the interaction of treatment and time as 
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fixed effects.  There was a significant effect of time after sampling administration.  As a result 
the delta change at 60 min relative to treatment administration was used to determine the optimal 
dose for maximizing the secretion of GLP-1 from OBE.  Dose rates of OBE and the delta change 
were evaluated using 3 preplanned contrasts: (1) the linear effect of increasing OBE; (2) the 
quadratic effect of increasing OBE; and (3) the cubic effect of increasing OBE.  Significance was 
declared at P ≤ 0.05 and trends discussed when 0.05 < P ≤0.10 
Experiment 2  
Calves, Arrival, and Processing 
 The second experiment was conducted from May 18 to November 5, 2017.  Eighty-eight 
male Holstein calves, 2 to 3 d old, were selected at a single local farm in east-central Illinois.  
Two batches of calves were brought to the University of Illinois Nutrition Field Laboratory 
(Urbana, IL).  The first group of 54 calves was brought to the research facility between May 18th 
and May 25th and the second group of 34 calves was brought between August 31st and September 
3rd.  The number of calves in the groups depended on calf availability at the dairy farm and space 
limitations at the research facility.  At the time of selection, blood samples were taken from the 
jugular vein into 10-mL evacuated serum separation tube (Becton Dickenson, Rutherford, NJ).  
Blood was centrifuged at 1300 × g for 15 min and a refractometer was used to determine total 
protein concentration in the serum for all potential calves.  Calves were selected based on total 
protein and visual health assessment.  All calves selected were ear tagged, given 2 mL of BO-SE 
(Merck Animal Health, Kenilworth, NJ), 1 mL of vitamins A and D (Sparhawk Laboratories, 
Inc., Lenexa, KS), and 2 mL of Inforce (Pfizer, New York, NY).  After selection, calves were 
transported to the research site approximately 30 min away.  Initial measurements of BW, body 
length, heart girth, withers height, hip height, and hip width were obtained after arrival at the 
research facility.   
Experimental Design and Treatments 
 Experiment 2 was conducted as a randomized block design.  At arrival within the two 
batches, calves were blocked by initial BW and TP and randomly assigned to one of two 
treatment doses of Olea europaea extract fed at a rate of 0 mg/kg of BW per day (CON) or 60 
mg/kg of BW per day (OBE).  The total allotment of OBE per day for each calf was split in two 
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and mixed into the MR for d 1 to 49 of the study.  The treatment dose rate was determined and 
adjusted weekly after BW measures are made.  During d 43 to 49 when calves were only fed MR 
once daily, the treatment at 1630 h was mixed with 50 mL of warm water and dosed to the calves 
with a 60-mL syringe while the CON calves were only give 50 mL of warm water.   
Calf Housing 
 Calves were housed in south-facing individual hutches (Calf-tel, Hampel Corp., 
Germantown, WI) placed approximately 1.5 m apart.  Hutches were placed on a base of crushed 
rock, covered by landscape cloth and a layer of straw.  Straw was checked daily and more added 
as needed.  Temperature and humidity were determined using data from the local weather station 
(www.wunderground.com/history/). 
Feeding and Management 
 Calves were fed a commercial milk replacer (MR; Milk Specialties Global, Eden Prairie, 
MN) twice daily at 0500 h and 1630 h.  The MR was formulated to contain 28.5% CP and 15% 
fat, and was reconstituted to 15% solids.  The feeding rate of MR per calf was 500 g/d during d 1 
and 2 after arrival, 750 g/d from d 3 to 7, 1,000 g/d from d 8 to 42, and 500 g/d from d 43 to 49.  
The MR was fed only once daily from d 43 to 49.  After d 49, MR was removed completely and 
only starter and water were given.  The intake of MR was recorded daily.  A texturized calf 
starter (AMPLI-Calf® Starter 20, Purina Animal Nutrition LLC, Gray Summit, MN) and water 
were offered for ad libitum consumption for the duration of the trial and intake was recorded 
daily.   
Feed Analysis 
Milk replacers were sampled once weekly and stored at −20˚C until analysis.  Composite 
samples were created to represent each month and were analyzed by Dairy One (Ithaca, NY) for 
DM, CP, and ME by standard wet chemistry methods (www.dairyone.com).  Values for ME 
were estimated from chemical composition as described (www.dairyone.com).  Starter was 
sampled weekly and stored at −20˚C until analysis.  Composite samples were created to 
represent each month and were analyzed by Dairy One using wet chemistry techniques for DM, 
CP, and ME. 
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Body Growth and Measurements 
 Body weight, body length, heart girth, withers height, hip height, and hip width were 
measured upon arrival and weekly thereafter for the duration of the trial.  Body weight and 
growth measures were obtained at the same time relative to feeding and day specified for each 
group of calves based on their arrival date.   
Health 
 Health checks were performed daily.  Fecal scores were assigned on a 1 to 4 scale: 1 – 
normal and well formed; 2 = soft but still holds form; 3 = loose without form; and 4 = 
consistency of water.  Respiratory scores were assigned on a 1 to 5 scale: 1 = normal; 2 = open 
mouth breathing; 3 = open mouth breathing with mucus; 4 = dry cough, and 5 = wet cough.  
Calves were considered to have diarrhea if they had a fecal score above 2 and a respiratory 
infection if the score was above 1.  Overall appearance and behavior also were recorded.  After 
arrival rectal temperature was measured daily for 3 d and then at any time when a calf showed 
signs of illness throughout the duration of the study.  Navels were dipped in Super 7+ Navel dip 
(Vetericyn Animal Wellness, Rialto, CA) as needed until dry. Animals were monitored multiple 
times daily for illness and dehydration status and treated as needed.  Flunixin meglumine 
(Phoenix Pharmaceutical, Inc., St. Joseph, MO) was administered to calves with a rectal 
temperature of 40˚C or above.  An electrolyte solution (Land O’Lakes Electrolyte System, Land 
O’Lakes Inc., Arden Hills, MN) was administered as needed.  Calves were not castrated or 
dehorned until after completion of the study.   
Blood Collection and Analysis 
Blood metabolites were evaluated during the day before treatment administration (d 0), 2 
wk after treatment exposure (d 13), during the week before weaning (d 41), and during the week 
after weaning (d 55).  One hour after feeding (dosing) blood was collected via jugular 
venipuncture into a 10 mL evacuated serum separation tube (Benton Dickinson).  Blood was 
allowed to clot at room temperature (20°C) and then centrifuged at 1,300 × g for 15 min at 20°C.  
Serum was divided into aliquots in polypropylene tubes and stored at -20°C until analyzed.  A 
chemistry panel was conducted to determine concentrations of creatinine (milligrams/deciliter), 
urea N (milligrams/deciliter), total protein (grams/deciliter), albumin (grams/deciliter), globulin 
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(grams/deciliter), Ca (milligrams/deciliter), P (milligrams/deciliter), Na (micromols/liter), K 
(micromols/liter), Cl (micromols/liter), glucose (milligrams/deciliter), alkaline phosphatase 
(units/liter), aspartate aminotransferase (AST; units/liter), gamma-glutamyl transferase (GGT; 
units/liter), creatine phosphokinase (CPK; units/liter), total bilirubin (milligrams/deciliter), 
cholesterol (milligrams/deciliter), glutamate dehydrogenase activity (GLDH; units/liter), 
bicarbonate (micromols/liter), Mg (milligrams/deciliter), triglycerides (milligrams/deciliter), and 
anion gap were performed by automated enzymatic analysis procedures at the University of 
Illinois College of Veterinary Medicine diagnostic laboratory (Urbana, IL).   
The assessment of intestinal permeability was conducted on the day of arrival (d 0), 
before the first treatment administration, 2 wk after treatment exposure (d 13), during the week 
before weaning (d 41), and the week after weaning (d 55).  Lactulose (0.5 g/kg of BW) and D-
mannitol (0.1 g/kg of BW) were used as permeability markers and administered in the MR 
during feeding on those respective days (Hall, 1999).  On d 55 when MR was not being offered 
the lactulose and D-mannitol were dissolved in 1 L of warm water and dosed to the calves in a 
nipple bottle to ensure they consumed all of the permeability markers.  One hour after feeding 
(dosing) blood was collected via jugular venipuncture into a 10-mL evacuated serum separation 
tube and a 10-mL K2EDTA-coated blood collection tube (Becton Dickinson).  Blood was 
centrifuged at 1,300 × g for 15 min at 20°C.  Serum and plasma were divided into aliquots in 
polypropylene tubes and stored at -20°C until analyzed.    
Determination of serum lactulose and D-mannitol concentrations was performed by ultra-
HPLC-MS (Xevo G2 Tof, Waters, Milford, MA) with an electrospray ionization source 
operating in negative mode. Serum extract was injected (5 µL) onto a BEH amide column (2.1 
mm × 100 mm, 1.7 µm, Waters). The mobile phases were water and 0.1% NH4OH, and 
methanol and 0.1% NH4OH. Elution conditions, at a flow rate of 0.3 mL/min, were 90% 
methanol + 0.1% NH4OH maintained for 2 min, linear gradient from 90 to 60% in 4 min, and 
equilibration to initial conditions over 4 min. Column and auto-sampler chamber temperatures 
were maintained at 45 and 4°C, respectively. The operating conditions were source temperature 
= 120°C; desolvation temperature = 350°C; desolvation gas = 900 L/h; cone gas = 10 L/h; 
capillary voltage = 0.5 kV; cone voltage = 30 V; and extraction cone = 4 V. Leucine enkephalin 
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at a concentration of 2 µg/mL was used as a lock mass for mass accuracy and infused at a flow 
of 5 µL/min. Chromatograms were processed using Quanlynx software (v4.1, Waters). 
On d 13, blood samples were collected, before feeding and 1 h after feeding, into a 10-
mL tube containing EDTA (Becton Dickinson) and a cocktail of enzyme inhibitors [DPP-IV 
inhibitor (10 µL/mL blood; catalog#: DPP4, EMD Millipore, St. Charles, MO) and protease 
inhibitors (10 µL/mL blood; catalog#: P2714, Sigma-Aldrich, St. Louis, MO)].  Samples were 
kept on ice for 15 min after collection and then centrifuged at room temperature for 15 min at 
1,300 × g.  The plasma was aliquoted, put in liquid N2, and stored at -80°C until further analyses.  
The plasma concentration of GLP-1 was measured using a commercially available ELISA kit.  
Each sample was run in duplicate using the manufacturers’ recommended protocols.  The GLP-1 
assay cross reacts with human, bovine, guinea pig, mouse, and rat GLP-1 (7-36) amide with a 
range of 0.30 to 3,000 pmol/L (S-1359, Bachem Americas Inc., Torrance, CA).   
Fecal sample collection, RNA isolation, cDNA Synthesis, Primer Design and Evaluation, and 
Quantitative PCR 
 Fresh fecal samples were collected from the rectum on day 13, after the morning feeding.  
Fecal samples were immediately flash-frozen in liquid N2. Samples were kept at -80°C until 
further analysis.  
A subset of 10 calves per treatment was randomly selected for fecal RNA extraction.  The 
RNA isolation from fecal samples was carried out using the RNeasy Plus Mini Kit (Quiagen, 
Cat. No. 74134), following the manufacturer’s instructions with some modifications as described 
by Rosa et al. (2018).  The complementary DNA (cDNA) were formed according to Bionaz and 
Loor (2007) and modified as described by Rosa et al. (2018).  The qPCR reaction was performed 
in a 7900HT Fast Real-Time PCR system (Applied Biosystems, USA) in MicroAmp® Optical 
384-well Reaction Plate (Applied Biosystems, USA) as described by Bionaz and Loor (2007).  
The genes glyceraldehyde 3-phospate dehydrogenase (GAPDH), ribosomal protein S15a 
(RPS15A), Peptidylprolyl isomerase A (PPIA), β-actin (ACTB), β-2-microglobulin (B2M), and 
ribosomal protein 9 (RPS9) were used as internal control genes (ICG).  With the exception of 
PPIA, which was designed and sequenced by Rosa et al. (2018) all other ICGs were obtained 
from Kadegowda et al. (2009). The geometric mean of the internal control genes was used to 
normalize the expression.  The targeted genes selected (Table 7.1) to be evaluated in fecal RNA 
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samples were related to the inflammatory response (i.e., TLR2, TLR4, NFKB1, TNFA, IL1B, and 
MYD88). 
Statistical Analysis 
 Data were analyzed using PROC GLIMMIX of SAS version 9.4 (SAS Institute Inc., 
Cary, NC). For Gaussian data (intake, MR intake as a percentage of BW, ADG, gain:feed, 
growth, and blood metabolites) the model of variance analysis included treatment, time as a 
repeated measure (when appropriate), and their interaction as fixed effects. Block and batch were 
included as random effects in all models; however, block was not significant and therefore was 
removed from for statistical models. Initial measures of calf BW were included as a covariate for 
intake, BW, ADG, and gain-to-feed ratio. Because enteral nutrient supply is the primary stimulus 
for GLP-1 secretion (Burrin et al., 2003), results for GLP-1 concentrations were analyzed both 
unadjusted and covariate-adjusted using mean MR intake during the first 2 wk of study as a 
covariate.  Binary data (occurrence of diarrhea and medication) were analyzed with a binomial 
distribution with a logit link function in a model that included treatment and time as repeated 
measures and their interaction as fixed effects. Count data (days with diarrhea and medicated) 
were analyzed with a negative binomial distribution using a log link function with the fixed 
effect of treatment. The corrected Akaike information criterion was used to select the best 
covariate structure. Residuals were checked for homogeneity of variance and normality 
assumptions by residual plots and extended Levene test. Heterogeneous variances were handled 
by implementing error structures that allow for heterogeneous variances (Littell et al., 2006). 
Significance was declared at P ≤ 0.05 and trends discussed when 0.05 < P ≤ 0.10.  Results were 
separated using Tukey adjustment. Data are reported as least squares means according to 
treatment effects if no interactions are significant, or according to the highest order interaction 
detected. 
RESULTS 
Experiment 1 
The average concentration of GLP-1, the concentration of GLP-1 at each time point, and 
the delta concentration of GLP-1 from 0 to 60 min are shown in Table 7.2.  There were no linear, 
quadratic, or cubic effects of OBE dose rate on mean GLP-1 concentration among doses (P > 
0.10).  The cubic effect was significant (P = 0.007) for the delta change from time point 0 to time 
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point 60.  The greatest positive change was observed at a treatment levels of 60 and 180 mg/kg 
of BW (delta change = 8.7 and 6.2 pmol/L, respectively).   
Experiment 2 
Environment.  Two groups of calves were brought to the research facility at two different 
times and environmental conditions were recorded for each group. For the first group of calves 
(n = 54) the daily mean high temperature was 29°C and the low temperature was 17°C.  The 
second group of calves (n = 34) had a daily mean high temperature was 24°C and the low 
temperature was 11°C.  While the average low temperature for group 2 is below the lower 
critical temperature for young calves (NRC, 2001) during the first 3 wk of the experiment the 
temperature was within thermoneutral conditions for young calves. Within these environmental 
temperatures, average MR intake for the preweaning period should have allowed for 580 g/d of 
energy allowable ADG and 880 g/d of apparent digestible protein allowable gain under 
thermoneutral conditions according to NRC (2001). 
Intakes.  Overall intakes of DM, CP, and ME from MR, starter, and total intake are 
shown in Table 7.3 and Figure 7.1, as well as water intake.  There was no difference between 
treatments for MR, starter, or total dry matter intake in the preweaning period, during weaning, 
or in the postweaning period (P > 0.10).  There were no differences in water intake in the 
preweaning or weaning periods (P > 0.10).  There was a numerical (P = 0.11) treatment by time 
interaction for water intake in the 2 wk postweaning with an average intake of 13.4 and 11.2 ± 
4.2 kg/d for CON and OBE, respectively.   
Growth.  Mean BW, ADG, feed efficiency (gain:feed), and growth measurements for the 
preweaning period (wk 1 to 7) are presented in Table 7.4.  There were no differences in initial 
BW (P = 0.68).  There were no differences between treatments for mean BW during the 
preweaning period or BW at weaning (wk 7) between treatments (P > 0.10; Figure 7.2).  There 
was no difference in ADG or gain:feed.  Preweaning there were no differences in growth of 
withers height, heart girth, or hip width.  Preweaning, there was a treatment by time interaction 
for hip height (89.6 vs 88.9 ± 0.3 cm; P = 0.04; Figure 7.3) and body length (84.4 vs 84.6 ± 0.6; 
P = 0.04) and subsequent ADG of both measures, with CON compared to OBE, respectively.   
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 Mean BW, ADG, feed efficiency (gain:feed), and growth measurements for the 
postweaning period (wk 8 to 9) are presented in Table 7.5.  There were no differences in mean 
BW, final BW at wk 9, ADG, or gain:feed in the postweaning period (P > 0.10).  Additionally, 
there were no differences in body growth measures in the postweaning period (P > 0.10).   
Average environmental temperature for the calves was above the lower critical 
temperature for calves under 3 wk of age (NRC, 2001).  The ADG for wk 1 to 7 of the study 
averaged 827 g/d, and expected energy allowable ADG under thermoneutral conditions was 650 
g/d from milk replacer intake and 720 g/d from average intake of both milk replacer and starter 
in the preweaning period.  During the weaning week (wk 7) expected energy allowable ADG 
was estimated to be 570 g/d.  In the postweaning period (wk 8 to 9) the ADG averaged 866 g/d 
among treatments and was estimated to support 700 g/d energy allowable ADG (NRC, 2001). 
Health.  Initial serum total protein at arrival averaged 6.82 and 6.76 (SE = 0.31; P = 
0.48) for calves on CON vs OBE, respectively.  There were no calves that died over the course 
of the experiment.  One calf from CON was removed from the experiment at the end of wk 7 
because of suppressed starter intake that would not have supported successful weaning.  Table 
7.6 shows the logistic models for the occurrence of diarrhea (score > 2), medication with 
antibiotics, and electrolyte administered throughout different time periods.  There were no 
differences between CON and OBE for the occurrence of scours, electrolyte administration, 
medication for digestive issues in the first 3 wk, or medication over the course of the preweaning 
period (P > 0.10).   
Table 7.7 shows the logistic models for the number of days with diarrhea, given 
electrolytes, and medication.  There were no differences between CON and OBE for days with 
diarrhea in the first 3 wk of the experiment (2.52 vs. 2.29 ± 0.84; P = 0.57).  There were no 
differences between CON and OBE for days given electrolytes (0.72 vs. 0.55 ± 1.22; P = 0.24).  
The number of days given medication for any type of illness (P > 0.10) was not different 
between treatments.  Although not significant (P = 0.11) the difference for days medicated for 
digestive issues in the first 3 wk of the experiment followed the same pattern for days with 
diarrhea dn electrolyte administration, with calves fed CON having more days medicated 
compared to OBE fed calves (0.48 vs. 0.23 ± 0.32 d, respectively).  There was no difference 
between treatments for days medicated over the preweaning period (P > 0.10).   
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Blood Metabolites.  The concentrations of blood metabolites are shown in Table 7.8 for 
samples taken during wk 2, 6, and 8 of the experiment.  There tended to be an increase in 
phosphorus in the CON calves compared to OBE fed calves (8.2 vs 7.9 ± 0.14 mmol/L; P = 
0.10).  Additionally, there was a significant treatment by time interaction for anion gap between 
treatments (19.1 vs 19.0 ± 0.5; P = 0.01) but there were no differences between treatments during 
each wk when adjusted by Tukey-Kramer.  There were no differences the other blood 
metabolites measured during the experiment (P > 0.10).   
GLP-1 Concentrations in Plasma.  The concentrations of GLP-1 relative to feeding on d 
14 of the experiment are presented in Table 7.9.  There tended to be an increase in the 
concentration of GLP-1 before feeding for calves fed OBE compared to calves fed CON (307.9 
vs 211.7 ± 134.6 pmol/L, respectively; P = 0.06).  There was no difference in the postfeeding 
GLP-1 concentration between treatments (204.0 vs 185.1 ± 76.7 pmol/L; P = 0.71).  The delta 
change from pre to post feeding concentration of GLP-1 tended to be different between 
treatments with a greater change in the OBE fed calves compared to the CON calves (9.1 vs -
106.0 ± 74.4 pmol/L, for CON and OBE, respectively; P = 0.10).  There were no differences in 
GLP-1 concentration when adjusted for average MR intake during the 3 d before feeding (P > 
0.10).  
Intestinal Permeability.  Measures of permeability are shown in Table 7.9.  There were 
no differences in initial D-mannitol (1.83 vs 1.82 ± 0.15 μg/mL, for CON and OBE, respectively; 
P = 0.97) or in initial lactulose (4.49 vs 3.93 ± 0.56 μg/mL, for CON and OBE, respectively; P = 
0.48).  Additionally, there were no differences in initial lactulose/D-mannitol ratio (2.32 vs 2.22 
± 0.13 μg/mL, for CON and OBE, respectively; P = 0.59).  Permeability was also evaluated in 
wk2 and after weaning (wk 8).  In week 2 there was a tendency (P = 0.06) for calves fed OBE to 
have a higher concentration of D-mannitol compared to calves fed CON (1.35 vs. 1.14 ± 0.12 
μg/mL, respectively).  There were no differences between treatments for lactulose or 
lactulose/mannitol in wk 2.  In week 8 there were no differences in the concentration of D-
mannitol (1.87 vs. 1.79 ± 0.14 μg/mL; P = 0.61), lactulose (3.66 vs. 3.56 ± 0.26 μg/mL; P = 
0.76), or lactulose/mannitol (1.97 vs. 2.00 ± 0.08 μg/mL; P = 0.68) 
Genes involved in the inflammatory response in fecal RNA.  The relative mRNA 
expression of genes related to the inflammatory response are shown in Table 7.10.  There was no 
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difference between treatments in the expression of TNFA (P = 0.74).  The expression of NFKB1 
was significantly increased in calves fed OBE compared to CON (P < 0.01)  In contrast, the 
expression of  IL1B and MYD88 was significantly reduced in calves supplemented with OBE 
relative to CON (P ≤ 0.05). There were no differences (P > 0.10) in expression of TLR2 or TLR4 
between treatments.  
DISCUSSION 
Use of methods that promote maintenance of permeability and intestinal integrity during 
diarrheal or weaning challenges in young calves could mitigate some of the enteric disorders that 
over 25% of preweaning dairy calves experience in the United States (NAHMS, 2011).  Gut 
trophic hormones, like GLP-2, have been used in pig models to increase mucosal cell 
proliferation, improve barrier function, and dampen the inflammatory response (Burrin et al., 
2003; Cameron and Perdue, 2005; Sigalet et al., 2007; Ipharraguerre et al., 2013).  Furthermore, 
GLP-2 has been shown to effectively alleviate compromised intestinal integrity by promoting 
tight junction expression and increase mucin production and villus length in infected calves 
(Walker et al., 2015; Connor et al., 2016; Connor et al., 2017).   
Promoting secretion of GLP-1, co-secreted with GLP-2, through bile acids has been 
shown to be mediated through a G protein-coupled receptor (Thomas et al., 2009; Katsuma et al., 
2005; Kidd et al., 2008; Parker et al., 2012).  Additionally, bioactive molecules extracted from 
Olea europaea (OBE) have been shown to induce the secretion of GLP-1 via activation of the 
bile acid receptor TGR5 (Rafferty et al., 2011; Bala et al., 2014).  Previously, we have shown 
that feeding OBE to dairy calves increased the secretion of GLP-2 but intestinal permeability 
was not improved, likely because of the severity of enteric challenges of the calves under 
investigation (Morrison et al., 2017).  Therefore, we sought to determine the optimal inclusion 
level of OBE to promote maximal GLP-1 secretion in preweaned calves and how that inclusion 
level impacts intestinal permeability and inflammation.  Finally, we determined if these changes 
could reduce the incidence of diarrhea and improve growth of dairy calves through the 
preweaning period. 
 In the first experiment we sought to determine the optimal level of OBE to induce the 
maximal response of GLP-1 release.  Secretion of GLP-1 is nutrient dependent (Estall and 
Drucker, 2006) so calves were bolused varying levels of OBE with water, after being fasted for 9 
157 
 
h before treatment administration to determine the secretion of GLP-1 in response to only OBE.  
A cubic response was found for the delta change from pre dosing to post dosing for calves 
bolused increasing rates of OBE.  The greatest delta change in concentration was observed at 
OBE doses of 60 and 180 mg/kg of BW.   While both levels resulted in a relatively small delta 
change in the first experiment, it did not seem to indicate a dose of OBE greater than 60 mg/kg 
of BW would be warranted. Therefore, a dose of 60 mg/kg of BW was used for experiment 2.   
  In the second experiment, the prefeeding GLP-1 concentrations ranged from 211.7 to 
307.9 pmol/L, while the postfeeding values ranged from 185.1 to 204.0 pmol/L.  In piglets, GLP-
1 concentrations have been shown to range from 10 to 20 pmol/L (Ipharraguerre et al., 2013), 
while work in adult cattle has shown a range of 16 to 30 pmol/L (Zapata et al., 2015). The values 
in this experiment were quite elevated relative to these other two comparisons.  However, to the 
author’s knowledge, there is little information about circulating GLP-1 concentrations in calves.  
In previous work within our lab we have evaluated the response of GLP-2 to two levels of OBE 
(30 and 60 mg/kg of BW) inclusion in milk replacer and observed a 1 fold increase in GLP-2 
secretion relative to control (Morrison et al., 2017).  Previous measurements on GLP-2 
concentrations in calves have ranged from 30 pmol/L prefeeding to up to 100 pmol/L 
postfeeding (Castro et al, 2016; Morrison et al., 2017).  
 In the current experiments, the prefeeding concentrations were unexpectedly high for 
both treatments relative to the postfeeding concentrations (60 min relative to feeding).  While 
basal levels of GLP-2 are quite variable from calf to calf (Castro et al., 2016), most studies show 
increases in the concentrations of GLP-2 and GLP-1 relative to nutrient intake in calves (Castro 
et al., 2016; Morrison et al., 2017) and cows (Zapata et al., 2015).  The GLP-1 and -2 peptides 
are co-secreted in equal ratio (Ørskov et al., 1986), however the processing after secretion is 
different (Holst, 2007).   The half-life of GLP-1 is much shorter within the body and only 10-
15% of active peptide reaches circulation (Holst, 2007).  As a result the circulating 
concentrations may not measure in equal proportion in the blood but should result in a similar 
trend of secretion, however more research in dairy calves is needed to fully understand this.   
Interestingly, there was a tendency for OBE-fed calves to have higher prefeeding GLP-1 
concentrations in experiment 2.  In a previous experiment, we observed increases in circulating 
GLP-2 concentrations after feeding in response to OBE fed at a rate of 60 mg/kg of BW but there 
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were no differences in the prefeeding concentration of GLP-2 (Morrison et al., 2017).  It is 
unclear why we observed higher concentrations of GLP-1 for OBE fed calves but this would be 
promising if promotion of basal gut trophic actions related to GLP-1 and the co-secreted peptide, 
GLP-2 could be increased.  Theoretically, increased levels of GLP-2 could promote more trophic 
and regenerative properties for the intestinal epithelium (Burrin et al., 2000).  While these results 
indicated that OBE may have increased basal GLP-1 concentrations to a greater extent than 
CON, more research is needed in this area to fully understand the implications of the calf in 
terms of gut permeability and health.   
In this experiment we sought to have a more controlled occurrence of diarrhea and enteric 
challenge relative to a previous experiment conducted with OBE in preweaning dairy calves 
(Morrison et al., 2017).  Under those conditions we observed that OBE did not elicit 
improvements in permeability or gut function in calves with an average of 8 d of calves being 
classified as having scours.  It was unclear in that experiment if a longer time between the 
initiation of feeding and onset of enteric challenge would be more beneficial in eliciting positive 
improvements in gut permeability and health.  In the current experiment initial total protein was 
above the cutoff of 5.5 g/dL indicating that calves received enough colostrum to ensure passive 
transfer (McGurik, 2011).  Initial intestinal permeability before treatment administration was not 
different between treatments.  Intestinal permeability after birth has been indicated as a 
predisposing condition linked to diarrhea in calves in the first 21 d (Araujo et al., 2015).  
Comparatively, the initial intestinal permeability’s measured in this study was within ranges 
observed for health calves by Araujo et al. (2015).  Consequently, the number of days calves had 
scours was much less in the first 21 d, thus achieving the goal of reducing enteric challenge.   
While there was reduced incidence relative to the previous experiment calves still 
experienced an average of 2.29 to 2.53 d with scours for OBE and CON calves, respectively.  
Diarrhea and weaning challenges are associated with extensive alterations to the mechanistic 
control of barrier function and results in increased permeability and susceptibility to further 
bacterial invasion across the intestinal mucosa (Cameron and Perdue, 2005; Hu et al., 2013).  
During wk 2 there was a tendency for mannitol to be greater for calves fed OBE relative to CON.  
This is similar to piglets that were fed OBE and challenged with LPS, which showed increased 
mannitol, which also tended to reduce the ratio between markers (Liehr et al., 2017).  There was 
159 
 
no significant difference between treatments for lactulose/mannitol in the current experiment.  In 
the experiment with the piglets, the results indicated that OBE counteracted TNF-α mediated 
barrier disruption by rescuing mRNA levels of tight-junctional proteins in the ileum (Liehr et al., 
2017).  More research is needed to determine if this occurs in dairy calves during this time. 
During the week after weaning we did not observe any differences in intestinal 
permeability between treatments.  In piglets, weaning is associated with adverse changes to 
intestinal morphology, intestinal permeability, absorptive capacity, disaccharidase activity, and 
inflammation (Hampson, 1986; Le Huerou-Luron et al., 2002; Kelly et al., 1991; Pié et al., 2004; 
Hu et al., 2013).  Changes in intestinal morphology, absorptive capacity, and disaccharidase 
activity are associated with reduction in nutrient intake (Hampson, 1986; Le Huerou-Luron et al., 
2002; Kelly et al., 1991).  During the current experiment we did not observe decreases in feed 
intake and paired with the lack of difference in intestinal permeability it would appear that 
weaning did not have a significant negative impact to allow OBE to influence intestinal integrity 
in calves beyond that of CON.  Additionally, there were limited differences in body measures 
during the experiment.  Overall, this indicates that OBE did not have any additional effects on 
calf intake, growth, or permeability above that of CON.   
A relatively new, noninvasive technique has been developed to investigate changes in the 
GIT though the isolation of epithelial cells in the feces (Kamra et al., 2005; Donovan et al., 
2014).  Additionally, this method has been used to characterize changes in the GIT of calves 
undergoing a diarrhea event and the subsequent period of recovery (Rosa et al., 2018).  With the 
use of this technique RNA isolated from fecal samples can evaluate expression of specific genes 
related to inflammation in the GIT.  Expression of IL6 was not detected in the fecal samples from 
the current experiment.  Although not measured in this experiment circulating concentrations of 
IL-6 has been identified as a prognostic indicator for calf diarrhea and marker of early 
inflammation (Rincon, 2012; Fischer et al., 2016).  Furthermore, Rosa et al. (2018) observed 
increases in IL-6 in response to increased fecal scores, indicating an inflammatory response.  For 
the current experiment, the lack of IL6 expression could indicate that the inflammatory response 
was not activated, or was minimal at time of sampling.  While the onset of diarrhea in the calves 
was not controlled and relatively short between treatments it is possible that the severity of the 
inflammatory response was minimal or at a different time relative to fecal sampling.  
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Furthermore, there was no difference in the expression of TNFA between treatments.  In contrast, 
expression of the pro-inflammatory cytokine IL1B and MYD88 in the current experiment was 
decreased for calves fed OBE and expression of NFKB1 was increased.  Interestingly, a subacute 
chronic inflammatory model pigs resulted in inducing the expression of IL-1B but this response 
was attenuated by the supplementation of OBE (Liehr et al., 2017).  This was thought to be 
mediated though NF-κB, which is supported here with the decreased expression observed in 
OBE fed calves.  It is unclear how the increased expression by over 5 fold for NFKB1 might 
affect circulating concentrations of IL-1β if expression of IL1B and MYD88 was decreased in the 
current experiment.  While this is a small indication of the potential of OBE to reduce the 
inflammatory response to diarrheal challenges in calves we did not measure inflammatory 
cytokines to be able to compare at a systemic level.  Furthermore, we saw few improvements in 
intestinal permeability and health between treatments.  More research is needed to more clearly 
define the role that OBE supplementation could have on calf health and growth.     
CONCLUSIONS 
 A dose of 60 mg/kg of BW was identified as the optimal inclusion in dairy calves to 
promote the release of gut trophic hormones into circulation.  However, when fed to calves 
during the preweaning period OBE tended to increase prefeeding levels of GLP-1, this dose did 
not elicit improvements in permeability, intake or growth of the calves that were generally 
healthy in the preweaning period and did not experience any negative associations with the 
weaning period.  There was some indication that feeding OBE could reduce expression of genes 
related to the inflammatory response in GIT epithelial cells.  More work may be necessary to 
understand the potential benefits of supplementing OBE to dairy calves under different 
experimental settings.   
161 
 
TABLES AND FIGURES 
Table 7.1.  Target genes and their biological function in experiment 2.  
 *Jacometo, C. B., J. S. Osorio, M. Socha, M. N. Correa, F. Picciioli-Cappelli, E. Trevisi, and J. J.  Loor.  2015.  Maternal 
consumption of organic trace minerals alters calf systemic and neutrophil mRNA and microRNA indicators of inflammation and 
oxidative stress.  J. Dairy Sci.  98:7717-7729.  
Symbol Name Biological Function Source 
TLR2 Toll-like receptor 2 
Participates in the innate immune response to gram positive microbial 
agents * 
TLR4 Toll-like receptor 4 
Participates in the innate immune response to gram negative microbial 
agents 
* 
NFKB1 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 1 
Involved in many biological processes such as inflammation, 
immunity, differentiation, cell growth, tumorigenesis, and apoptosis 
* 
TNFA Tumor necrosis factor-α 
Involved in regulation of a wide spectrum of biological processes 
including cell proliferation, differentiation, apoptosis, lipid metabolism, 
and coagulation 
* 
IL1B Interleukin 1,β 
Mainly functions to mediate inflammatory response.  Also involved in 
cell proliferation, differentiation, and apoptosis 
* 
MYD88 
Myeloid differentiation primary 
response 88 
Acts as a connection to TLR and inteukins-1 receptors to activate the 
proinflammatory pathway 
* 
162 
 
 
Table 7.2.  Concentrations of glucagon-like peptide-1 (GLP-1) in plasma of dairy calves dosed with or without a bioactive extract 
from the olive (Olea europaea) in experiment 1. 
1Bioactive extract from the olive (Olea europaea) dosed in a gelatin capsule at varying levels 0, 60, 90, 120, and 180 mg/kg of BW.  
2Mean concentration, 15 to 120 min.  
3Delta = GLP-1 concentrations at 0 min (before dosing) - GLP-1 concentration 60 min (after dosing).    
 Treatments1  Contrast P-values 
Variable 0 60 90 120 180 SE Linear Quadratic Cubic 
GLP-12, pmol/L 37.4 52.6 46.8 46.0 45.8 5.2 0.43 0.18 0.24 
  0 min 66.4 69.1 61.8 72.6 69.8     
  15 min 38.2 46.2 44.1 51.4 40.8     
  30 min 30.2 46.8 45.4 44.3 38.2     
  60 min 55.9 77.8 62.0 58.0 76.0     
  90 min 35.1 40.2 36.4 37.9 34.5     
  120 min 27.5 52.2 46.8 38.1 39.6     
Delta3 -10.5 8.7 0.2 -14.6 6.2 6.0 0.33 0.93 0.007 
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Table 7.3.  Intakes of dry matter (DM), crude protein (CP), and metabolizable energy (ME) milk 
replacer, starter, water, and total intake of dairy calves fed a bioactive extract from the olive 
(Olea europaea) in milk replacer in the preweaning period (wk 1 to 7) and subsequent starter 
intake after supplementation (wk 8 to 9) in experiment 2. 
 Treatments  P-values 
Variable CON OBE SE Trt Time Trt × Time 
Pre-weaning (wk 1 to 6) 
  Milk Replacer       
    DM, g/d 912.5 913.5 3.0 0.62 <0.001 0.84 
    CP, g/d 265.9 266.2 3.6 0.61 <0.001 0.84 
    ME, kcal/d 3943.8 3948.1 6.0 0.61 <0.001 0.83 
  Starter       
    DM, g/d 237.5 209.6 51.2 0.31 <0.001 0.11 
    CP, g/d 61.7 54.9 5.1 0.35 <0.001 0.11 
   ME, kcal/d 804.4 709.8 176.2 0.31 <0.001 0.11 
  Total       
    DM, g/d 1149.6 1122.8 53.9 0.34 <0.001 0.11 
    CP, g/d 325.2 318.6 9.3 0.35 <0.001 0.11 
    ME, kcal/d 4746.9 4657.2 178.0 0.35 <0.001 0.11 
  Water, kg 3.19 3.48 0.21 0.34 <0.001 0.86 
Weaning (wk 7)       
  Milk Replacer       
    DM, g/d 486.2 486.1 0.4 0.46 - - 
    CP, g/d 141.7 141.7 1.9 0.39 - - 
    ME, kcal/d 2103.6 2106.4 210.5 0.59 - - 
  Starter       
    DM, g/d 1009.6 984.3 144.2 0.75 - - 
    CP, g/d 240.1 232.4 15.2 0.72 - - 
   ME, kcal/d 3415.6 3330.2 473.8 0.75 - - 
  Total       
    DM, g/d 1495.8 1470.5 144.6 0.75 - - 
    CP, g/d 390.3 383.4 44.8 0.72 - - 
    ME, kcal/d 5522.3 5436.7 478.9 0.75 - - 
  Water, kg 6.59 6.79 1.59 0.68 - - 
Post weaning (wk 8 to 9) 
  Starter       
    DM, g/d 2381.8 2258.8 59.3 0.14 <0.001 0.67 
    CP, g/d 574.4 543.1 15.1 0.15 <0.001 0.69 
    ME, kcal/d 8069.1 7654.8 200.4 0.15 <0.001 0.67 
  Water, kg 13.4 11.2 4.2 0.14 0.72 0.11 
1CON = control, OBE= bioactive extract from Olea europaea fed in milk replacer at 60 mg/kg of 
BW per day. 
 
164 
 
Table 7.4.  Body weight, ADG, gain:feed, and stature measurements of dairy calves fed a bioactive extract from the olive (Olea 
europaea) in milk replacer in the preweaning period (wk 1 to 7) and subsequent body weight and stature measurements after 
supplementation (wk 8 to 9) in experiment 2. 
 Treatments  P-values 
Variable CON OBE SE Trt Time Trt × Time 
Initial BW, kg 43.2 42.8 0.7 0.68 - - 
Weaning BW, kg (wk 7) 84.3 83.5 1.8 0.64 - - 
Mean BW, kg (1 to 7 wk) 66.3 66.0 1.7 0.69 <0.001 0.92 
ADG, g/d (1 to 7 wk) 830 823 43 0.80 <0.001 0.68 
Gain:feed, kg/kg 0.72 0.72 0.02 0.91 <0.001 0.40 
       
Withers height, cm 85.2 85.2 0.3 0.99 <0.001 0.31 
  ADG, cm/d 0.23 0.23 0.01 0.44 <0.001 0.57 
Hip height, cm 89.6 88.9 0.3 0.02 <0.001 0.04 
  ADG, cm/d 0.25 0.23 0.01 0.03 <0.001 0.05 
Heart girth, cm 90.2 89.9 0.8 0.54 <0.001 0.43 
  ADG, cm/d 0.4 0.4 0.02 0.31 <0.001 0.37 
Body length, cm 84.4 84.6 0.6 0.57 <0.001 0.04 
  ADG, cm/d 0.3 0.3 0.02 0.32 0.04 0.001 
Hip width, cm 23.7 23.7 0.24 0.54 <0.001 0.33 
  ADG, cm/d 0.08 0.08 0.01 0.15 0.25 0.58 
1CON = control, OBE= bioactive extract from Olea europaea fed in milk replacer at 60 mg/kg of BW per day. 
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Table 7.5.  Body weight, ADG, gain:feed, and stature measurements in the two weeks after weaning (wk 8 to 9) of dairy calves fed a 
bioactive extract from the olive (Olea europaea) in milk replacer in the preweaning period (wk 1 to 7) in experiment 2. 
 Treatments  P-values 
Variable CON OBE SE Trt Time Trt × Time 
Mean BW, kg  92.8 91.8 1.7 0.49 <0.001 0.77 
Final BW, kg (wk 9) 96.1 94.7 3.1 0.49 - - 
ADG, g/d (8 to 9 wk) 896 835 60 0.38 <0.001 0.83 
Gain:feed, kg/kg 0.38 0.36 0.02 0.56 0.04 0.91 
       
Withers height, cm 92.2 92.4 0.3 0.47 <0.001 0.73 
  ADG, cm/d 0.17 0.18 0.04 0.82 0.91 0.76 
Hip height, cm 96.8 96.4 0.3 0.19 <0.001 0.50 
  ADG, cm/d 0.16 0.18 0.02 0.32 0.53 0.91 
Heart girth, cm 102.4 101.6 0.8 0.16 <0.001 0.42 
  ADG, cm/d 0.38 0.36 0.02 0.38 0.05 0.68 
Body length, cm 95.0 94.2 0.4 0.16 0.001 0.42 
  ADG, cm/d 0.36 0.23 0.04 0.03 0.02 0.65 
Hip width, cm 25.8 25.9 0.5 0.34 0.001 0.62 
  ADG, cm/d 0.05 0.04 0.01 0.54 0.61 0.77 
1CON = control, OBE= bioactive extract from Olea europaea fed in milk replacer at 60 mg/kg of BW per day. 
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Table 7.6. The logistic model for scours1, respiratory, medication, and electrolyte occurrence by comparison of dairy calves fed a 
bioactive extract from the olive (Olea europaea) in milk replacer in the preweaning period (wk 1 to 7) in experiment 2. 
Variable Comparison2 Coefficient SEM Odds ratio3 95% CI P-Value 
Scours occurrence, wk 1 to 3 CON – OBE 0.1280 0.23 1.14 0.72-1.79 0.57 
Scours occurrence, wk 1 to 6 CON – OBE -0.0776 0.18 0.93 0.64-1.33 0.67 
Scours occurrence, wk 7 CON – OBE 0.4162 0.29 1.52 0.84-2.74 0.16 
Scours occurrence, wk 8 to 9 CON – OBE 0.1482 0.32 1.16 0.61-2.20 0.64 
Electrolyte, wk 1 to 3 CON – OBE 0.3266 0.30 1.38 0.76-2.53 0.28 
Medication for digestive issue, wk 1 to 3 CON – OBE 0.2025 0.55 1.22 0.41-3.63 0.71 
All medication, wk 1 to 3 CON – OBE -0.0775 0.36 0.93 0.45-1.89 0.83 
All medication, wk 1 to 7 CON – OBE -0.2735 0.30 0.76 0.42-1.37 0.36 
1Fecal scores were assigned on a 1 to 4 scale: 1= normal and well formed; 2 = soft but still holds form; 3 = loose without form; and 4 
= consistency of water. Calves with a fecal score > 2 were classified as having scours.   
1CON = control, OBE= bioactive extract from Olea europaea fed in milk replacer at 60 mg/kg of BW per day. 
2The OR indicates the probability of an event occurring for the first classification in the comparison to the second classification. If the 
OR is greater than one the first classification in the comparison is more likely to have either diarrhea or be medicated then the second 
classification by a factor of the difference above one.  If the OR is less than one the first classification has a lower probability of 
occurring then the second classification.  
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Table 7.7. The logistic model for days of scours, respiratory, medication, and electrolyte occurrence by comparison of treatments of 
dairy calves fed a bioactive extract from the olive (Olea europaea) in milk replacer in the preweaning period (wk 1 to 7) in experiment 
2.  
 Treatment   
Variable CON OBE SE P-Value 
Scours, d wk 1 to 3 2.53 2.29 0.84 0.57 
Electrolytes, d 0.72 0.55 1.22 0.24 
Medicated1, d wk 1 to 3 1.11 1.23 0.23 0.76 
Medicated1, d wk 1 to 7 1.78 2.19 0.31 0.40 
Medication for digestive issue, d wk 1 to 3 0.48 0.23 0.32 0.11 
Medication for digestive issue, d wk 1 to 7 0.88 0.88 0.52 0.99 
1CON = control, OBE= bioactive extract from Olea europaea fed in milk replacer at 60 mg/kg of BW per day. 
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Table 7.8.  Concentrations of blood metabolites (wk 2, 6, and 8) in serum sampled from dairy calves fed a bioactive extract from the 
olive (Olea europaea) in milk replacer in the preweaning period (wk 1 to 7) in experiment 2. 
 Treatment1  P-values 
Variable CON OBE SE Trt Time Trt × Time 
Creatinine, mg/dL 0.89 0.90 0.02 0.41 <0.001 0.55 
BUN, mg/dL 12.2 11.7 0.3 0.25 <0.001 0.41 
Total Protein, g/dL 5.3 5.2 0.08 0.36 <0.001 0.91 
Albumin, g/dL 2.9 2.9 0.03 0.87 <0.001 0.73 
Globulin, g/dL 2.4 2.3 0.09 0.34 <0.001 0.95 
Albumin/Globulin 1.2 1.3 0.05 0.27 0.002 0.86 
Ca, mg/dL 10.3 103 0.06 0.48 0.005 0.40 
P, mg/dL 8.2 7.9 0.12 0.10 <0.001 0.24 
Na, mmol/L 139.7 139.9 0.24 0.49 0.001 0.28 
K, mmol/L 4.84 4.79 0.04 0.35 <0.001 0.54 
Na/K 29.1 29.4 0.22 0.28 <0.001 0.36 
Cl, mmol/L 100.9 100.7 0.27 0.59 <0.001 0.47 
Glucose, mg/dL 111.5 110.0 3.09 0.55 <0.001 0.45 
Alkaline phosphorus, U/L 271.5 288.9 12.9 0.32 <0.001 0.36 
AST2, U/L 49.2 50.7 2.4 0.62 <0.001 0.70 
GGT2, U/L  29.2 22.7 4.1 0.27 <0.001 0.48 
Total bilirubin, mg/dL 0.22 0.20 0.01 0.41 <0.001 0.29 
CPK2, U/L 125.4 128.7 13.6 0.85 0.001 0.98 
Cholesterol, mg/dL 60.1 61.0 2.6 0.64 0.08 0.42 
GLDH2, U/L 44.9 46.6 6.5 0.85 <0.001 0.76 
Bicarbonate, mmol/L 24.8 25.0 0.6 0.41 <0.001 0.94 
Magnesium, mg/dL 1.99 1.99 0.02 0.98 <0.001 0.31 
Triglycerides, mg/dL 22.5 24.6 1.6 0.25 <0.001 0.87 
Anion gap 19.1 19.0 0.5 0.96 <0.001 0.01 
1CON = control, OBE= bioactive extract from Olea europaea fed in milk replacer at 60 mg/kg of BW per day. 
2 AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; CPK: creatine phosphokinase; GLDH: glutamate 
dehydrogenase activity;  
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Table 7.9.  Concentrations of glucagon-like peptide-1 (GLP-1) and permeability markers in plasma of dairy calves fed a bioactive 
extract from the olive (Olea europaea) in milk replacer in the preweaning period (wk 1 to 7) in experiment 2. 
 Treatment1  P-values 
Variable CON OBE SE Trt 
Initial total protein, g/dL 6.82 6.76 0.31 0.48 
GLP-12      
  Prefeeding, pmol/L 211.7 307.9 134.6 0.06 
  Postfeeding, pmol/L 204.0 185.1 76.7 0.71 
  Delta3 9.1 -106.0 74.4 0.11 
Adjusted GLP-14     
  Prefeeding, pmol/L 175.0 347.0 161.3 0.53 
  Postfeeding, pmol/L 190.5 181.6 70.3 0.94 
  Delta3 -2.7 -105.7 80.4 0.15 
Initial permeability     
  Mannitol4, μg/mL 1.83 1.82 0.15 0.97 
  Lactulose4, μg/mL 4.49 3.93 0.56 0.48 
  Lactulose/Mannitol4 2.32 2.22 0.13 0.59 
Permeability (wk 2)     
  Mannitol5, μg/mL 1.14 1.34 0.12 0.06 
  Lactulose5, μg/mL 3.67 4.03 0.70 0.44 
  Lactulose/Mannitol4 3.37 3.18 0.32 0.56 
Post weaning permeability (wk 8)     
  Mannitol5, μg/mL 1.87 1.79 0.14 0.61 
  Lactulose5, μg/mL 3.66 3.56 0.26 0.76 
  Lactulose/Mannitol4 1.97 2.00 0.08 0.68 
1CON = control, OBE= bioactive extract from Olea europaea fed in milk replacer at 60 mg/kg of BW per day. 
2GLP-1 sampled during wk 2 immediately before milk replacer feeding (prefeeding) and 60 min after milk replacer feeding 
(postfeeding).  
3Delta = postfeeding GLP-1 concentration – prefeeding GLP-1 concentration.   
4GLP-1 concentrations adjusted using mean milk replacer intake during the first 2 wk of study as covariate.   
5Mannitol, lactulose, and lactulose/D-mannitol measured wk 0, 2, and 6. 
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Table 7.10. Relative mRNA expression (log2 scale) of genes related to inflammatory response in 
experiment 2.  
Gene2 
Treatment1 
SEM3 P-value4 CON OBE 
TNFA -4.76 -4.49 0.59 0.74 
NFKB1 -4.62 -2.41 0.54 < 0.01 
TLR2 4.23 3.80 0.78 0.68 
TLR4 4.85 3.82 0.62 0.23 
MYD88 4.56 2.61 0.56 0.02 
IL1B 5.88 3.98 0.66 0.05 
1CON = control, OBE= bioactive extract from Olea europaea fed in milk replacer at 60 mg/kg of 
BW per day. 
2Gene Symbols: TNFA, Tumor necrosis factor alpha; NFKB1, Nuclear Factor of Kappa Light 
Polypeptide Gene Enhancer In B-Cells 1; TLR2, Toll Like Receptor 2; TLR4, Toll Like Receptor 
4; MYD88, Myeloid Differentiation Primary Response 88; IL1B, Interleukin 1 B. 
3Greatest SEM is shown 
4P-value for treatment 
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Figure 7.1. Milk replacer, starter and total dry matter intake and free water intake by dairy 
calves fed a bioactive extract from the olive (Olea europaea) in milk replacer in the preweaning 
period (wk 1 to 7) in experiment 2.  The treatments were CON (0 mg/kg of BW per day of Olea 
europaea; solid line) and OBE (60 mg/kg of BW per day of Olea europaea; dashed line).  Error 
bars represent SE of the least squares means.   Time points with asterisks (*) differ (P ≤ 0.05, 
Tukey adjusted).  
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Figure 7.2. Body weight by dairy calves fed a bioactive extract from the olive (Olea europaea) 
in milk replacer in the preweaning period (wk 1 to 7) in experiment 2.  The treatments were 
CON (0 mg/kg of BW per day of Olea europaea; solid line) and OBE (60 mg/kg of BW per day 
of Olea europaea; dashed line).  Error bars represent SE of the least squares means.   
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Figure 7.3. Hip Height by dairy calves fed a bioactive extract from the olive (Olea europaea) in 
milk replacer in the preweaning period (wk 1 to 7) in experiment 2.  The treatments were CON 
(0 mg/kg of BW per day of Olea europaea; solid line) and OBE (60 mg/kg of BW per day of 
Olea europaea; dashed line).  Error bars represent SE of the least squares means.   
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CHAPTER 8. SUMMARY, CONCLUSIONS, AND PERSPECTIVES 
 There continues to be a relatively high incidence of enteric challenge in preweaning dairy 
calf operations.  While it is commonly accepted that enteric challenges have negative 
implications for intake and growth during the preweaning period there are few estimates that 
have directly quantified differences between calves with diarrhea and their healthy counterparts.  
Growth and health of calves has been linked to longevity and lactation performance once heifers 
start milking so it remains an important objective to understand how early life events could 
impact future productivity and find ways to minimize the occurrence and severity.  Therefore, 
my first objective was to quantify how diarrhea in calves during the first 21 d after arrival affects 
water and feed intakes, growth, and efficiency.  A dataset of 313 calves from four experiments 
was developed to evaluate this objective (Chapter 3).   The results emphasized the continued 
prevalence and impact of enteric disease on preweaning dairy calves.  Young calves with 
diarrhea had reductions in feed intake, reduced body weight gain, and reduced efficiency.  My 
results also demonstrated that it is critical to provide diarrheic calves with supplemental 
electrolyte solutions in addition to normal milk or milk replacer intake, and ad libitum free water 
intake to help maintain fluid balance and overall total water intake.   
Glucagon-like peptide 2 (GLP-2) is a peptide released by the lower gut that has potent 
trophic and restorative effects on the intestinal epithelium. Reductions in voluntary feed intake 
when sick are common in most species.  Secretion of GLP-2 is mainly stimulated by delivery of 
nutrients.  My second objective was to understand how the concentration of GLP-2 in plasma 
was affected by feeding rate and either metabolizable or nonmetabolizable glucose (Chapter 4). 
In the experiment, 48 newborn calves were assigned to 12 treatments (n = 4) corresponding to 
the factorial combination of 4 milk feeding amounts [1.75, 1.32, 0.88, and 0.44% of body weight 
(BW) as dry matter (DM)] and 3 oral supplementation treatments (non-supplemented, glucose-
supplemented, and 3-O-methyl glucose-supplemented).  There was a saturating response of 
plasma GLP-2 to increasing feeding rates. The feeding rate at which 50% of the maximal GLP-2 
release occurred was estimated to be 0.53% of BW as DM or 30.3% of the maximum feeding 
rate (1.75% of BW as DM), whereas maximal secretion was estimated to be about 98.6 pmol/L. 
In turn, feeding 75, 50, or 25% of the maximal feeding rate (i.e., 1.75% BW as DM) resulted in 
plasma GLP-2 concentrations 87, 72, and 49% of that in fully fed calves, respectively. Neither 
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metabolizable nor non-metabolizable glucose supplementation affected GLP-2 secretion and no 
interaction with feed intake level was detected. 
With increased constraints on use of medically important antimicrobial drugs in feed for 
food-producing animals, it is more important to understand how gastrointestinal health is 
affected by disease so that alternative additives can be used to support health and growth of 
calves.  The last objectives of my dissertation were to determine if an extract from Olea 
europaea (OBE) is a natural TGR5 agonist that leads to increased GLP-2 secretion, and how it 
affects growth, overall health, and small intestine permeability in preruminant calves.  The first 
experiment (Chapters 5 and 6) to address this objective used 60 Holstein heifer calves assigned 
to 1 of 3 experimental treatments. Treatments were control (CON), standard milk replacer (MR) 
and ad libitum starter; CON plus OBE added into MR at 30 mg/kg of body weight per day 
(OBE30); and CON plus OBE added into MR at 60 mg/kg of body weight per day (OBE60).  
Compared with CON, administration of OBE60 increased the nutrient-induced response in GLP-
2 by about 1 fold and reduced MR intake during the second week of study. Throughout the 
study, however, all calves had compromised intestinal permeability and a high incidence of 
diarrhea. The GLP-2 response elicited by OBE60 did not improve intestinal permeability 
(measured by lactulose-to-d-mannitol ratio in serum) or incidence of diarrhea over the course of 
the preweaning period.  Additionally there was no improvement in the growth of calves with the 
addition of OBE.   
Next, two more experiments (Chapter 7) were conducted to further assess at what amount 
OBE could be used to promote maximal GLP-1 secretion above that stimulated by nutrient 
ingestion and to determine if that dose could improve intestinal permeability and reduce 
inflammation.  Glucagon-like peptide-1 is co-secreted with GLP-2, and so should be 
representative of GLP-2 while easier to analyze.  The first experiment was conducted as a 5 × 5 
Latin square design with 5 calves and 5 periods.  Five doses of OBE (0, 60, 90, 120, and 180 
mg/kg of BW) were randomly assigned to each calf during the five periods so that all treatment 
doses were represented in each period.  Blood was collected at 0, 15, 30, 60, 90, and 120 min 
relative to dosing to evaluate concentrations of GLP-1 in plasma. A dose of 60 mg/kg of BW was 
identified as the optimal inclusion in dairy calves to promote the release of gut trophic hormones 
into circulation and was used in experiment 2.  In the second experiment, 88 male Holstein 
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calves were enrolled in a randomized block design and randomly assigned to one of two 
treatment doses of OBE fed at a rate of 0 mg/kg of BW per day (CON) or 60 mg/kg of BW per 
day.  When fed to calves during the preweaning period OBE tended to increase prefeeding levels 
of GLP-1; however, this did not elicit improvements in permeability, intake, or growth of the 
calves that were generally healthy in the preweaning period and did not experience any negative 
associations with the weaning period.  There was some indication that feeding OBE could reduce 
expression of genes related to the inflammatory response in GIT epithelial cells.   
The data presented in Chapter 3 highlight the continued prevalence and negative impacts 
of diarrhea on preweaning calves.  Calves were classified as diarrheic or healthy over the course 
of the first 21 d after arrival.  This classification was very general as the calves were grouped 
into diarrheic if they had a fecal score > 2 for ≥ 3 consecutive days at any point during the first 
21 d after arrival.  While this dataset and analysis provides a good overview of effects of enteric 
challenge on calves it is only a first step in trying to quantify how a broad category of “enteric 
disease” impacts preweaning dairy calves. Ideally, the next steps would be to develop a more 
predictive model to determine if there were certain indicators indicating an enteric challenge is 
coming.  To do so, my data could be used to evaluate intake, growth, and efficiency in the days 
leading to a diarrheic event to determine if there were signs before the manifestation of a more 
clinical indication of disease (i.e., increased fecal score).  This is a challenging undertaking, as 
the onset and duration are dependent on many factors, including health status of the calf, 
environmental conditions, and pathogens associated with the enteric disease.  However, the 
importance of understanding the effects of enteric challenge on the calf is crucial to develop 
dietary strategies that could mitigate these negative impacts on dairy calf health and productivity.   
 Results from the experiments presented in this dissertation demonstrate that the ability to 
manipulate concentrations of gut trophic hormones is possible.  This finding is promising and 
supports the hypothesis that manipulation of gut trophic hormones could be used as a method to 
mitigate some of the negative associations of enteric challenges to dairy calves.  It was very clear 
from the experiment conducted in Chapter 4 that nutrient intake is the main stimulus of secretion 
of GLP-2, with limited to no changes in secretion in response to glucose or a non-metabolizable 
glucose analogue.  Uncertainty remains that the dose of glucose and metabolizable glucose 
analog was sufficient for the induction of further secretion of GLP-2 in addition to that of enteral 
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nutrients provided from milk replacer intake, even at the lower rates of intake.  It is possible that 
the sweet taste receptors that would respond to glucose were already saturated with the sugars 
provided from the milk replacer.  The dose of glucose used in the experiment was calculated 
from data obtained in mature sheep and so there could be differences between species or 
maturity.   
An important take-away is that more research is needed to define what concentration of 
GLP-2 needs to be achieved, but this may be challenging as variation between calves was high.  
Additionally, while the trophic actions of GLP-2 in the intestine are appealing, this is only one 
peptide in a broader system that serves to maintain and support growth of the gastrointestinal 
tract.  A more broad evaluation of other hormones and growth factors that are linked to intestinal 
growth could give a better indication of the actions that nutrients and additives have on the 
gastrointestinal tract epithelium and function.  Examples would include keratinocyte growth 
factor (KGF), endothelial nitric oxide synthase (eNOS), vasoactive intestinal polypeptide (VIP), 
insulin-like growth factors (IGFs), and the ErbB network.  Further information on gene 
expression and protein abundance of such compounds throughout the gastrointestinal tract and at 
different time points throughout the preweaning period of dairy calves also would be useful in 
determining targets for improved intestinal health during this time.     
 The three experiments that evaluated inclusion of OBE in the diets of preweaning calves 
showed minimal improvement or alleviation of diarrhea in the preweaning period.  The 
experiment described in Chapters 5 and 6 had a high incidence and a long duration of diarrhea 
across treatments.  We theorized that the gastrointestinal tract of the calves was already 
compromised before initiation of OBE treatment so there was limited opportunity to alleviate 
that challenge.  More research on the duration of feeding before enteric challenge or stress could 
be useful in determining how inclusion of OBE could be useful for preruminant calves.  For 
example, it may be useful to include OBE with colostrum or beginning in the feedings following 
colostrum to truly be able to promote responses in the gastrointestinal tract that would be 
beneficial to the calf.  Furthermore, in the experiments conducted with OBE we used spot 
sampling at different time points throughout the experiment that were preplanned during times 
we suspected calves to experience the greatest challenge.  While this is ideal from a consistency 
standpoint between calves and experiments, the sampling times did not necessarily align with the 
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times calves actually experienced enteric challenges.  If further research is conducted it may be 
of interest to have a more controlled experiment in which calves are fed OBE for a certain 
amount of time before being exposed to a single pathogen to induce enteric challenge at a 
uniform time for all calves.  This may aid in understanding how OBE could be used as a 
bioactive additive.   
 A final thought for this research is related to the measurement of GLP-1 and GLP-2.  
Interest in these two peptides is rooted in the trophic properties of GLP-2 in the small intestine.  
There is some difficulty with measuring the active form of these peptides in plasma.  Not only do 
they have a very short half-life but there is only one lab in the world who reliably measures GLP-
2 but several different methods to measure GLP-1 to varying success.  As mentioned above, we 
had focused our efforts on the effect of different strategies to promote GLP-2 in order to elicit 
benefits to calf health.  In the last two experiments we switched to analyzing GLP-1 because of 
ease of access to analytical procedures.  Theoretically, GLP-1 and GLP-2 are secreted in equal 
ratio.  However, there could be some limitations to assuming that both of these peptide hormone 
concentrations are being accurately reflected in circulation and that one peptide accurately 
represents changes in the other.  The first limitation is that these peptides are degraded 
differently.  Active GLP-1 has a shorter half-life compared to GLP-2.  Secondly, secretion of 
these peptides is generally thought to occur in response to nutrients; however, there is some 
reserach in meal-fed rats that indicates a cephalic response to anticipation of a meal.  This work 
has shown that concentrations of GLP-1 actually increase before a meal as a way to maintain 
homeostasis between meals, and then concentrations at time of nutrient delivery are decreased.  
This may explain some of the discrepancies between experiments in which we measured an 
increased GLP-2 concentration in response to feeding and increased GLP-1 concentration before 
feeding or dosing.  A more comprehensive approach to understanding how these peptides are 
working together is needed.  This might be accomplished by measuring both of these peptides for 
more intervals both before and after feeding.  It would be interesting to evaluate these changes 
throughout the preweaning period as calves go from fewer larger meals (milk feeding period) to 
more frequent smaller meals (with increased consumption of starter and solid feed).   
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 Overall, this line of research offers an intriguing and relatively unexplored opportunity to 
more fully understand the physiology of dairy calves and different methods that could promote 
intestinal health and function.   
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APPENDIX A. TIME COURSE CURVES FOR GLUCAGON-LIKE PEPTIDE-2 
CONCENTRATION IN RESPONSE TO FEED INTAKE AND GLUCOSE PROVISION 
FROM CHAPTER 4 
 The experimental design and methodology were described previously (Chapter 4).   
 
Figure A.1. Scatter plot of circulating glucagon-like peptide-2 (GLP-2) concentration in 
response to feeding rate (FR) at 15, 30, 60, 90, and 240 min relative to milk replacer feeding time 
of calves in experiment 1 in Chapter 4.   Feeding rate comprised 4 levels: 25 (■), 50 (♦), 75 (▲), 
and 100% (●) of a standard feeding level of 1.75% of BW as DM.  Feeding rate by time 
interaction P = 0.10. 
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Figure A.2. Scatter plot of circulating glucagon-like peptide-2 (GLP-2) concentration in 
response to supplement type at 15, 30, 60, 90, and 240 min relative to milk replacer feeding time 
of calves in experiment 1 in Chapter 4.  Control treatment (■) = commercial milk replacer 
without supplementation; glucose (♦) = commercial milk replacer plus glucose (220 mg/kg of 
BW daily); and 3-O-M-G (▲) = commercial milk replacer plus 3-O-methyl glucose (6 mg/kg of 
BW daily).  Supplement by time interaction P = 0.84. 
